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Thesis abstract  
Background 
Cancer survival in England is poorer than in other comparable countries. Older cancer 
patients generally have less evidence-based treatment, and poorer survival than younger 
patients. This is often attributed to the increasing presence of comorbidity with age. 
Concerns exist, particularly in England, that age-related differences in cancer outcomes arise 
because of clinical decision-making based on chronological age alone. This study aims to 
examine the impact of age on having optimal cancer management for colorectal cancer 
(CRC). 
Methods 
Using population-based cancer registration records of 139,457 CRC patients diagnosed in 
Denmark, England, Norway and Sweden during 2010-2012, I estimate and compare age-
standardised stage-specific three-year net survival, and the likelihood of receiving radical 
surgery by age and stage. Then, focusing on the 99,942 patients diagnosed in England, I 
quantify how far age-related differences in patient management are mediated by 
comorbidity and the diagnostic route, using causal mediation.   
Findings 
In comparison with Denmark, Norway and Sweden, CRC patients in England had lower three-
year net survival. There was an age gradient in the proportion treated at each stage of 
disease in England, which was not as evident in the other countries. Analyses focusing on 
patients without evidence of comorbidity in England and Denmark showed a similar trend. 
In England, the proportion of patients with evidence of receiving a full investigation and 
surgical treatment decreased with age. The age differential was partly mediated by the 
diagnostic route, but not by comorbidity.  
Interpretation 
These findings suggest that the CRC survival deficit in England can be attributed partly to 
under-management of older patients. Complex interactions between biological, attitudinal 
and contextual factors may be behind these findings. Raising the proportion of patients 
receiving optimal management to the levels observed in comparable countries would 
improve CRC outcomes, provided that adequate post-operative and long-term care are also 
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Chapter 1: Background  
1.1 Introduction 
Cancer patients in England have poorer outcomes than in other high-income countries.1-3 
Results from international comparisons of cancer survival have stimulated cancer policy in 
England, and other countries, with the aim of ‘closing the gap’ in cancer survival.4  
Significant efforts have been invested into understanding the origins of these disparities, 
especially between comparable high-income countries with universal health care coverage, 
such as Australia, Canada, Denmark, England, Norway and Sweden. Delays in diagnosis that 
lead to advanced stage disease, which is more difficult to treat and cure, as well as 
geographic and socioeconomic inequalities in access to care have been proposed as 
explanations of the international differences in cancer survival.2,3,5,6 Differences in stage 
distribution between countries partly explain international differences in cancer survival.6,7 
The survival deficit in England in comparison with other developed countries, however, 
seems to be driven by lower stage-specific survival. In a recent international population-
based comparison, colon and rectal cancer patients in England had lower survival at each 
Dukes stage than patients in Sweden and Norway (rectal cancer only), with the largest 
differences seen in patients in the age group 75-99 years.5 These differences in stage-specific 
survival suggest that cancer management varies between countries, and possibly more so 
for older patients. 
Cancer is currently the leading cause of death, ahead of cardiovascular disease, in several 
European countries, including Denmark, Norway and the United Kingdom,8 and it is a main 
contributor to disease burden in people aged 60 and over.9 It is estimated that by 2030, 76% 
of cancers in men and 70% in women will occur in people over the age of 65 years.10 
Nonetheless, older cancer patients frequently have fewer diagnostic and staging procedures 
and less evidence-based treatment than younger patients.9 There is substantial uncertainty 
on how best to manage cancer in older patients. They are under-represented in clinical trials, 
hence, the use and effectiveness of many clinical interventions in the older population is 
frequently not supported by scientific evidence.11,12 Adequate interventions in older patients 
are complicated by concomitant chronic conditions, frailty, and potentially deficient access 
to adequate care.9,10,13  
As the population ages, the proportion of people who are 65 years or older is growing. In the 
UK, the proportion of the population aged 65 years or older was 17.8% in 2015 and is 
projected to reach nearly a quarter of the population by 2045.14 This demographic trend 
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poses great challenges to health care systems, and in particular, for the provision of care of 
chronic conditions, such as cancer, to meet the needs of older people.9,10 
In this study, I examine the impact of increasing age on the likelihood of having optimal 
cancer management, in an international comparison (between Denmark, England, Norway 
and Sweden) and within England, focusing on colorectal cancer (CRC). I hypothesise that 
differences in the management of older patients may help explain the international 
differences in population-based cancer survival, beyond what would be explained by the 
presence of comorbidity. 
1.2 Colorectal cancer epidemiology 
Progression from pre-malignant lesions, adenomatous polyps, to cancer takes approximately 
ten to fifteen years, and is affected by both environmental and genetic factors that result in 
abnormal cell regulation and tumour growth.15 Potentially modifiable risk factors including 
physical inactivity, unhealthy diet, and smoking, which help to explain the association 
between low socioeconomic status and increased incidence of colorectal cancer.16,17 There is 
evidence indicating that potentially modifiable risk factors such as physical inactivity, 
consumption of red meat, processed meat, and folate are associated with colon cancer but 
not rectal cancer, and that genetic mutations vary between the two sub-sites.18,19 
Globally, colorectal cancer is the second most common cancer in women and the third most 
common cancer in men.20 It was the second most common cancer diagnosis in women and 
men in Denmark, UK, Norway and Sweden in 2012.20 Standardised incidence rates however 
vary between the countries, with higher CRC incidence in Denmark and Norway than in the 
UK and Sweden. In 2012, there were 45.9 diagnoses in men and 35.7 diagnoses in women 
per 100,000 persons in Denmark, with the corresponding figures of 42.6 and 35.8 in 
Norway.20 In contrast, the numbers were 36.8 in men and 24.5 in women in the UK, 32.2 and 
26.5 in Sweden, for the same calendar year.20 In Norway, the incidence of colorectal cancer 
has reportedly increased in men in recent years, particularly in lower socioeconomic groups, 
and probably in relation to increasing exposure to risk factors such as consumption of alcohol 
and processed meats.21 Using cancer incidence data for the period 2005-2014 (Denmark, 
Norway and Sweden) and 2004-2013 (UK), it was recently projected that age-standardised 
incidence rates (per 100,000 person-years) in 2018 were higher in Norway and Denmark than 
in the UK and Sweden.22 
13 
 
1.3 Diagnostic and staging investigation of colorectal cancer 
The aim of mass screening for colorectal cancer is to reduce incidence and mortality through 
diagnosis of asymptomatic – early stage – tumours and removal of pre-malignant lesions. 
Organised mass screening programmes have been introduced in many European countries in 
the last two decades, with large variation in terms of implementation and coverage.23 In 
Denmark, a feasibility pilot study in the Copenhagen county started in 2005 offering screening 
with biennial guaiac faecal occult blood test (gFOBT) to residents aged 50 to 74 years;24 the 
national screening programme was then rolled out in 2014.25 In England, the national Bowel 
Cancer Screening Programme (BCSP) was introduced in 2006, offering screening with biennial 
gFOBT to persons aged 60-69.26 A gradual extension of the eligibility age range to 74 years 
started in 2009.27 In 2013, the English BCSP introduced a new screening test: a one-off 
rectosigmoidoscopy at age 55 years.28 In 2018, the faecal immunochemical test (FIT) started 
to replace gFOBT in England because of its higher sensitivity and expected acceptance and 
uptake.29,30  In Norway, a regional pilot study started in 2012 offering screening (with either 
FIT, or flexible sigmoidoscopy) to residents of Østfold, Akershus and Buskerud counties aged 
50-74 years old. Currently, the Norwegian Directorate of Health is planning to start the 
national colorectal cancer screening programme in 2019, offering FIT or colonoscopy to 
residents aged  55 years.31 Similarly, a national bowel cancer screening programme is due to 
start in Sweden in 2019, offering FIT to residents aged 50 to 74 years,32 following regional 
screening programmes in Stockholm and Gotland counties.24 
Uptake of screening is highly variable and generally below target: 45.4% in the Copenhagen 
county, Denmark; 52.4% in England; and 65% in the Stockholm and Gotland counties in 
Sweden.24 Variation in uptake partly depends on the type of test used. Most screening 
programmes use non-invasive stool tests that identify small amounts of blood in stool 
samples. The faecal immunochemical test is associated with higher uptake as it involves one 
stool sample and no dietary restrictions, in comparison with the gFOBT that requires sampling 
of multiple bowel movements per screening and dietary restrictions due its poor-to-
moderate sensitivity.33 Screening with invasive imaging techniques such as colonoscopy 
generally have even lower uptake than non-invasive tests.24 Deprivation and age gradients in 
screening uptake for colorectal cancer have been described, with older patients and those of 
lower socioeconomic status less likely to participate.34,35 
Besides screening, the pathway from suspicion of cancer to a colorectal cancer diagnosis may 
be through primary care, referral from other health care specialists, or through an emergency 
admission. With the publication of the first National Cancer Plan in England in 2000, cancer-
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specific referral routes were introduced along with waiting time targets to avoid delays in 
cancer diagnosis. The two-week wait referral route demands rapid referral of patients with 
suspected cancer to secondary care.4 Patients diagnosed through an emergency presentation 
generally have poorer cancer outcomes than those diagnosed through other routes.36-38 
Comparable measures to avoid delays in cancer diagnosis have been introduced in several 
other countries. In Denmark, a law setting up a maximum wait of two weeks between a 
cancer diagnosis and treatment was introduced in 2001.39 Additional measures were 
introduced in 2007 including a maximum wait of two days between GP referral and specialist 
appointment, and public reporting of waiting times throughout the cancer patient pathway.39 
Rapid referral routes were introduced in Norway and Sweden in 2016, reportedly influenced 
by the Danish experience.40 
Once in secondary care, patients may have more than one investigation to confirm or exclude 
a colorectal cancer diagnosis. According to current clinical guidelines in England, colonoscopy 
should be offered to all patients with suspected colorectal cancer, unless contraindicated due 
to major comorbidities, in which case flexible sigmoidoscopy followed by a barium enema, or 
computed tomographic colonography should be performed.41 Patients with confirmed 
colorectal cancer should be offered clinical investigations for staging, including computed 
tomography (CT) scans of chest, abdomen and pelvis. Patients with suspected rectal cancer, 
should additionally be offered Magnetic Resonance Imaging (MRI) of the primary tumour, 
and further trans-anal ultrasound if deemed amenable to local excision through MRI, or if 
MRI is contraindicated.41 The European Registration of Cancer Care (EURECCA) 
multidisciplinary consensus conference on tumours of the colon and rectum found large 
consensus about the elective imaging work-up to diagnose and stage colon cancer in several 
European countries (including Denmark, England, Norway and Sweden among others) in their 
first meeting in 2012.42 For rectal cancer, there was large consensus for most imaging tests, 
except for the use of digital rectal examination and endo-rectal ultrasound following MRI.42 
Determining disease extension is important to determine patient eligibility for specific 
treatment options, with either curative or palliative intent. The International Union for 
Cancer Control’s TNM classification of malignant tumours categorises colorectal tumours 
according to the extension of the disease, based on three components: primary tumour (T), 
regional lymph nodes (N) and distant metastasis (M).43 Two classifications are defined for 
each tumour: a pre-treatment clinical classification drawn from imaging tests, biopsy or 
endoscopy, and/or physical examination; and a pathological classification, following 
histopathological assessment of the primary tumour, regional lymph nodes, and of distant 
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metastases. Different combinations of the T, N and M components (pathological and/or 
clinical) are used to define categories of summary stage.  
1.4 Overview of treatment of colorectal cancer 
Treatment options are mostly determined by the extension of the disease. Potentially 
curative treatment of colorectal tumours generally involves surgery with or without 
additional therapies. The aim of surgery for colorectal cancer is to remove the tumour and 
its lymphatic drainage.  
The colon and rectum have different location, blood supply, lymphatic drainage and 
innervation, therefore they have different treatment and outcomes.19 Total or partial 
colectomy, or removal of the colon, with its associated blood supply and lymphatic drainage 
has been the standard surgery for colon cancer for decades. 
The location of rectal tumours within a confined space, the pelvic cavity, means that a 
complete surgical removal is a challenging task. Historically, results of rectal cancer surgery 
have been poor in terms of residual disease and recurrence.44,45  In view of the high 
recurrence rates, in the early 20th century, English surgeon William Miles devised an 
extensive surgical procedure (named abdominoperineal resection, APR) to remove the 
rectum, rectosigmoid, along with their lymphatic drainage and blood supply, mesorectum 
(fatty tissue surrounding the rectum), plus the anus and levator ani muscles, to cover the 
upward, downward, and lateral spread of rectal tumours. Though oncologic outcomes were 
improved, perioperative mortality and associated morbidity was high, and the procedure 
was generally deemed too risky for patients older than 60 years or with concomitant 
conditions.45 With advances in medical technologies such as anaesthesia and blood 
transfusion, APR eventually became the standard care for rectal cancer, and most later 
surgical developments in rectal cancer focused on developing less radical procedures, 
preserving sphincter function, while maintaining oncologic outcomes (e.g. Hartmann’s 
procedure and [low] anterior resection).45  By the late 1970s however, recurrence rates were 
still high at around 30%,46 and it was recognised that circumferential margins were likely to 
be compromised with a blunt excision of the mesorectum by hand.45,46  The concept of total 
mesorectal excision (TME) was introduced by English surgeon Richard (Bill) Heald working at 
Basingstoke District Hospital in the late 1970s.47 He postulated that high recurrence rates 
were a result of leaving mesorectal residue rather than extension outside the mesorectum.48 
TME is based on the embryological development of the bowel, and entails sharp dissection 
under direct vision in the embryological plane (between the visceral fascia covering the 
mesorectum and the parietal pelvic fascia lining the retroperitoneum) to remove the tumour 
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and mesorectum en bloc.45,46,49 Recurrence rates decreased sharply with TME, to 4% at 5 
years postoperatively, over a 13-year period.50 Heald’s experience was reproduced in other 
institutions51 and in the mid-1990s, TME was introduced in Scandinavian countries and in 
The Netherlands by workshops, tutoring and video demonstrations.49 Although the 
technique was developed in the UK, it was adapted earlier in the Scandinavian countries than 
in England.6 Currently, TME is the gold-standard surgical technique for rectal cancer, 
however, it remains a challenging and demanding procedure that requires a high degree of 
specialisation and skill.49 
The TME principle of dissection in the embryological plane and intact removal of the bowel 
and surrounding mesenterium (mesocolon) was later applied to colon cancer (denoted 
complete mesocolic excision, CME) by Hohenberger and colleagues in Germany with good 
outcomes in terms of reduced recurrence rates (from 6.5% to 3.5%) and 5-year survival (from 
82.1 to 89.1%).52 The use of CME for colon tumours is more variable than TME for rectal 
cancer. 
The use of additional therapies for non-metastatic rectal tumours is determined by the risk 
of local recurrence. Since before the adoption of TME, preoperative radiation has been part 
of the standard treatment of locally-advanced rectal tumours in most European 
countries,41,42,53,54  however, practice varies between and within countries.42 In Norway, 
preoperative chemo-radiotherapy with delayed surgery is the norm, whereas in Sweden the 
standard is to have a short course of radiotherapy preoperatively.55 The use of radiotherapy 
for rectal cancer is highly variable within England.56 Currently, there is an ongoing debate on 
whether the benefit of (neo)adjuvant therapy is relevant for most CRC patients, in view of 
the advances in surgical resection techniques in the last decades, namely TME and CME.57 
Adjuvant chemotherapy is generally recommended for stage III/IV colon cancers.42 
1.5 Measures of health status 
An important determinant of cancer treatment, along with disease extension, is the patient’s 
overall health status and concomitant, pre-existent chronic conditions (comorbidity)58. The 
term ‘multimorbidity’ refers to the existence of two or more chronic conditions.58 Several 
summary measures of comorbidity and multimorbidity have been proposed, validated and 
used in epidemiological research.59 The commonly used Charlson Comorbidity Index (CCI) 
ranks specific chronic conditions based on their associated risk of death;60,61 specific 
conditions are given weights based on age-standardised relative risks of death at one year in 
hospitalised patients with selected conditions, then added to obtain a composite score.61 This 
assumes that the relationship between concomitant conditions is additive instead of 
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multiplicative (i.e. there is no synergy between them), and that the risk of death associated 
with the indexed conditions remains valid with current clinical practice. 
In surgical settings, several indices or scales are used to stratify patients’ ability to tolerate 
surgery (operative risk). The American Society of Anaesthesiologists physical status 
classification system (ASA) was introduced in the early 1940’s to stratify the physical state of 
patients in the preoperative period for statistical analyses (from no organic pathology to 
emergency surgery in patients with extreme systemic disorders that are a threat to life 
regardless of the type of treatment).62 In the 1941 publication, Meyer Sakland proposed the 
six classes of physical state, acknowledging that this was one of the many factors to be 
considered to assess operative risk (including the planned surgical procedure, skills of the 
surgeon, postoperative care, and the patient’s history with anaesthesia).62 It is however 
frequently used for grading the preoperative health of surgical patients, and as a ‘predictor’ 
of risk of surgical complications and outcomes, because of its simplicity and its reported 
association with surgical outcomes.63,64 The ASA system has been criticised for its low 
discriminatory power, and low inter-observer consistency,65,66 and there is varying opinion on 
its value to risk-stratify patients in the preoperative period.67  
Other risk prediction indices have been developed specifically for the preoperative setting. 
The physiological and operative severity score for the enumeration of mortality and 
morbidity (POSSUM) was developed for the preoperative assessment of patients to plan and 
standardise the quality (and level) of care in the UK.68 It uses 12 physiological variables 
(including systolic blood pressure, pulse, electrocardiogram and serum levels of sodium and 
potassium, among others) to predict 30-day mortality and morbidity after surgery. It was later 
revised and modified (and named Portsmouth POSSUM or P-POSSUM) to make better 
predictions of in-hospital mortality.69 Although it was developed for surgical audit in a UK 
setting, it has been found to be a good risk predictor in some settings,70 though not in 
others.71 
Specific to cancer, ‘performance status’ scales are used in clinical settings to assess the 
general well-being and degree of independence of cancer patients, and to help determine 
eligibility for (and tolerance to) specific treatments.72,73 There are several scoring systems, 
with the most frequently used being the Karnofsky performance score (KPS, which has 11 
levels ranging from 0 to 100, with the highest indicating no evidence of disease, and the 
lowest death),74 and the Eastern Cooperative Oncology Group (ECOG) score, also called WHO 
or Zubrod score (with five levels from 0 to 4, with the highest indicating death and the lowest 
used for asymptomatic patients).75 Both KPS and ECOG scales were developed to monitor 
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patients’ ability to carry out normal activities and self-care during clinical trials for 
chemotherapeutic drugs,74,75 and currently they are also used to assess operative risk.76 The 
scores are not based on a standard questionnaire but on the clinician’s impression about the 
autonomy of the patient, making them easy to use without detailed questioning.76 Some 
authors argue, however, that performance status scales lack sensitivity for the older cancer 
population, especially those with multimorbidity and or functional deficits.77,78  
Besides multimorbidity, older people may also develop frailty, defined as an age-associated 
clinical syndrome characterised by a decline in function in several physiologic systems, 
causing vulnerability to adverse health outcomes.79-81 In 2001, Linda Fried and colleagues 
proposed a frailty phenotype as a standardised definition of frailty and demonstrated its 
predictive validity for adverse outcomes in two US cohorts from the Cardiovascular Health 
Study.81 The characteristic included in the frailty phenotype include unintentional weight loss, 
muscle mass loss, weakness (measured as grip strength), exhaustion (self-report), slowness 
(walking speed), and low activity (kilocalories per week). Three or more of those 
characteristics would identify a frail patient.81 Several other operational definitions of frailty 
have been proposed, including the clinical frailty scale from the Canadian Study of Health and 
Aging (which uses 70 variables to define seven levels of the scale, from very fit to severely 
frail).82 The concept of frailty has recently expanded from its origins in epidemiological 
research into clinical practice, where it has the added benefit (additional to identifying ‘high 
risk patients) that it allows the identification of patients whose physical decline is still 
reversible.80,83  
Frailty (and multimorbidity) can lead to disability or dependency in carrying out essential 
tasks for self-care and for living independently.79 Disability is thus partly determined by the 
wider environment, because it is about an individual being able to carry out tasks that are 
expected within a physical and sociocultural environment (at home, work, etc.).84 The same 
limitation in function may have different levels of disability depending on the expectation of 
others (such as family members and service providers), and on the physical environment 
(barriers or assistance for physical access, for instance). Disability is generally assessed with 
questionnaires of activities of daily living (ADL, assessing ability to bathe, dress, ambulate, 
and use the toilet) or instrumental ADL (IADL, ability to perform domestic tasks, such as 
housework, cooking and shopping).85  
Because older patients are at risk of having multimorbidity, frailty, and/or disability, 
comprehensive geriatric assessment (CGA) techniques have been suggested as better 
multidimensional tools to plan and deliver medical, rehabilitative and psychosocial care.86 In 
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the oncology setting, CGA has been used to monitor and predict side effects from 
chemotherapy, and mortality. More recently, the international Preoperative Assessment of 
Cancer in the Elderly (PACE) project produced a CGA tool focused on the surgical cancer 
patient. PACE incorporates several tools used for surgical risk assessment (including ECOG 
performance status, ASA, P-POSSUM, ADL, mini mental state (MMS), and Satariano’s 
modified index of comorbidities, among others).78 Aspects relating to frailty and disability (PS 
and ADL) were particularly associated with 30-day morbidity.78 A 2018 review of the literature 
reporting the use of CGA for prediction of postoperative complications in gastrointestinal 
cancers found six studies (two from Norway, and one each from Korea, Poland, US, and 
Singapore). The meta-analysis showed that CCI score of three or higher, polypharmacy 
(defined as five drugs per day or more), and ADL dependency were important predictors of 
postoperative complications.87 One of the Norwegian studies compared the predictive value 
of elements of different CGA and ECOG performance status in a cohort of colorectal cancer 
patients, and found that severe comorbidity, dependency (IADL), depression and 
malnutrition were the most important predictors of postoperative complications and early 
mortality.88 
Despite the recent availability of multidisciplinary tools to assess the health status of patients 
and their suitability for (cancer) treatment, these are not widely used in clinical practice. The 
ASA classification and performance status scale are the tools more easily and frequently used 
in clinical practice, and the Charlson Comorbidity Index is one most frequently used in 
epidemiologic research, despite their known disadvantages. The presence of comorbidity, 
frailty and/or disability may determine the options for cancer treatment and affect cancer 
outcomes in the short and longer term.89 Suboptimal management of cancer in older patients 
is usually attributed to their observed health status and associated risks, which may outweigh 
potential benefits of procedures indicated by clinical guidelines.59,90 Although less intensive 
cancer treatment in older patients may sometimes be justifiable, there are concerns that, 
particularly in England, age-related disparities in cancer care and outcomes also arise because 
of clinical decision-making based on chronological age rather than biological age.13,34,91 
1.5 Cancer management in older patients  
Suboptimal management of chronic conditions in older patients has been extensively 
described in the literature.89,92,93 Previous studies have found that older cancer patients may 
be under-treated, even if chronological age alone is not a contraindication for treatment.12,92-
95 Even those patients with resectable disease seem to be less likely to be treated than 
younger patients.96  
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There are many physiological changes in relation to age, such as atrophy of muscle cells in 
the cardiovascular, respiratory and musculoskeletal systems, reduced function of liver and 
kidneys, neuronal loss, among others.97 These factors may affect body functioning and 
tolerance to stressors, including disease and clinical interventions to control them.  
Additionally, older patients tend to have more concomitant chronic conditions than younger 
people, and it is generally presumed that poor cancer outcomes in older patients relate to 
their comorbidities and how these influence cancer management and outcomes.59,93  
Besides comorbidity, older patients have higher prevalence of cognitive impairment, 
depression, decreased mobility and may also lack social support.98,99 Patients with cognitive 
impairment are more likely to under-report pain.12 Beliefs that “good patients don’t 
complain” may be more prevalent in older patients than in younger ones.12  
Furthermore, there is significant uncertainty about the benefit of medical procedures for 
diagnosing, staging and treating cancer in older patients. Despite the need for scientific 
evidence to justify medical interventions in older cancer patients, they are generally 
excluded from clinical trials. This is usually justified by the frequent presence of 
multimorbidity in older patients that may compromise the generalisability of the findings, 
but it has the effect of reducing the evidence-base for the management of older patients. 
This may be impeding older patients from getting adequate cancer care because in order to 
justify the risks, the benefits must outweigh them, and the evidence of this benefit is often 
lacking. In general, clinical guidelines tend to focus on single illnesses, and health services 
are overall organised around younger patients who present one disorder or a limited episode 
of illness.98  
Suboptimal management of cancer in older patients may be guided by best clinical intentions 
to protect people from unnecessary interventions that may worsen their quality of life with 
little impact on survival; or because postoperative care may be inadequate for those 
requiring additional support, who tend to be old. Health professionals may be less confident 
in treating older patients and less willing to offer aggressive treatment to patients with 
insufficient social support.13  
Whatever the cause, there are concerns that the needs of older cancer patients are not being 
met, and that chronological age is informing clinical decision-making rather than biological 
age.10,13,91,92,100 There is some debate as to whether the suboptimal management of older 
cancer patients is due to age-differentiated behaviour or age discrimination/ageism.101,102 
Discrimination may refer to the “unjust of prejudicial treatment of different categories of 
people”, or to the “recognition and understanding of the difference between one thing and 
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another”.103 Arguably, the second form of discrimination is inherent and needed in clinical 
practice.104 
‘Ageism’, a term first used by US psychiatrist Robert Butler, is a process of discrimination and 
negative stereotyping against people because of their chronological age.105 Ageism and age 
discrimination are often used interchangeably, but some make the distinction between 
ageism as the attitude (stereotypes and presumptions) which may lead to a set of actions, 
which are known as age discrimination. Pessimistic attitudes towards older patients in the 
clinical setting may be held by healthcare professionals and patients themselves. Negative 
views of ageing held by patients and their carers may have a negative impact on their health, 
as it is likely to impact their behaviours, such as healthy eating, smoking, drinking, and health-
seeking behaviour.92,102 A recent study found that perceiving life expectancy to be longer was 
associated with higher participation in bowel cancer screening.106  Health professionals may 
make assumptions about patients’ potential tolerance of treatment and their preferences, 
and there is a danger of under-treating healthy older patients who have a long life 
expectancy and who may benefit from cancer treatment.  
1.7 Study Aim 
The aim of this study is to examine the impact of increasing age on the likelihood of having 
optimal management of colorectal cancer, and on cancer outcomes. 
To address the question “Are older patients in England under-managed in comparison with 
older patients in other countries, and in comparison with younger patients in England?”, 
different endpoints in the pathway of management of colorectal cancer patients are 
examined in each of the objectives. 
A comparison of cancer management and survival between Denmark, England, Norway and 
Sweden is undertaken because these countries have similar wealth and coverage of their 
health systems, and because they have high-quality cancer registries with comparable 
available data on patient characteristics, cancer management, and outcomes at population 
level. 
1.8 Objectives 
1) To estimate and compare stage-specific net survival between Denmark, England, 
Norway and Sweden. 
2) To determine and compare the effect of age on receiving surgical treatment for 
colorectal cancer in Denmark, Norway and Sweden, and to quantify the proportion 
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of under-treatment that could be avoided if patients in England were managed as in 
the best-performing country.  
3) To explore the role of comorbidity in explaining international differences in surgical 
management of colorectal cancer, focusing on Denmark and England. 
4) To examine the effect of age on receiving a complete staging investigation for 
colorectal cancer and to explore how this relationship is mediated by comorbidity 
and the diagnostic route in England. 
5) To examine the effect of age on receiving optimal treatment for colorectal cancer 
and explore how this relationship is mediated by comorbidity and the diagnostic 
route in England. 
1.9 Theoretical framework and outline of thesis 
Understanding whether some patients may benefit from more aggressive management is 
imperative for improving cancer outcomes. In this study, I explore age inequalities in cancer 
management as potential determinants of colorectal cancer outcomes. I address the main 
research question through an international comparison of stage-specific survival and surgical 
treatment of colorectal cancer patients by age and, when possible, level of comorbidity; 
followed by a closer examination of the age inequalities in CRC management within England. 
Lastly, I provide a contextual interpretation of the quantitative findings. 
To compare the clinical characteristics of patients by age and country, I develop and apply 
several algorithms to derive information on the relevant clinical characteristics and 
endpoints (stage at diagnosis, completeness of staging investigation, and potentially curative 
surgery), in a standardised and harmonised manner. These are described, along with other 
materials and methods, in Chapter 2. 
Chapters 3 and 4 encompass the main quantitative analyses carried out for this thesis. In 
general, these analyses focus on individual-level biological characteristics as determinants of 
individual-level health outcomes, while making statistical adjustments for socioeconomic 
and contextual variables. The statistical analyses presented in these chapters are, hence, 
mainly guided by the biomedical theory of disease distribution.107 Specifically, in Chapter 3, 
I compare the management and survival of colorectal cancer patients between Denmark, 
England, Norway and Sweden, addressing objectives 1, 2 and 3. In Chapter 4, I address 
objectives 4 and 5, by examining some of the potential underlying mechanisms behind the 
age inequalities in colorectal cancer management within England.  
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In Chapter 5, I present a summary of the main findings; followed by a contextual 
interpretation and implications of this work, reflecting on the potential benefit of 
‘alternative’ epidemiologic theories of disease distribution to understand and potentially 




Chapter 2: Overview of methods 
2.1 Data sources 
Information on all colorectal cancer patients diagnosed in England between 2010 and 2012 
was extracted from national population-based cancer registration (NCR) records. Individual 
tumour NCR records of patients diagnosed in England were linked to the National Bowel 
Cancer Audit (NBOCA)108 data, Hospital Episode Statistics (HES)109 in-patient and out-patient 
records, Cancer Waiting Times Monitoring Data Set (CWT)110 and to the Routes to Diagnosis 
(RtD) dataset. Individual NCR records of tumours diagnosed in Denmark were linked to the 
Danish Colorectal Cancer Group (DCCG.dk) database for additional clinical information.111 
Norwegian NCR data are routinely linked to the Norwegian Colorectal Cancer Registry 
(NCCR), a specialised registry that contains detailed clinical information on all CRC patients 
nationwide.112 The Swedish Colorectal Cancer Registry provided clinical data on patients 
diagnosed with colorectal adenocarcinoma in Sweden;113 its coverage for the study period 
was over 98%.114 
2.1.1 Specialised colorectal cancer registries  
Rectal cancer has historically been associated with high recurrence rates, morbidity and poor 
survival. After the introduction of TME as the gold-standard surgical technique to remove 
rectal cancer, clinicians in several countries established clinical databases to monitor and 
audit surgical outcomes of rectal cancer patients.  
In Denmark, the Danish Colorectal Cancer Group of the Danish Surgical Society (DCCG.dk) 
established a national database in 1994 aiming to improve the quality of diagnosis and 
treatment of patients with rectal cancer.111 Since 2001 this database has also included all 
patients diagnosed with colon cancer.111 The DCCG.dk database includes all adult patients 
diagnosed with colorectal adenocarcinomas referred to a surgical department in Denmark. 
Following smaller clinical audits of bowel cancer patients in England,115 the Association of 
Coloproctology of Great Britain and Ireland (ACPGBI) initiated the National Bowel Cancer 
Audit (NBOCA) project in 2003 as a joint initiative with the National Clinical Audit Support 
Programme (NCASP).116 It aims to measure the quality of care and survival of patients with 
colorectal cancer in England and Wales, and it is currently delivered jointly by the ACPGBI, 
the Royal College of Surgeons Clinical Effectiveness Unit, and NHS Digital.117  
The Norwegian Rectal Cancer project was initiated in 1993 aiming to improve rectal cancer 
outcomes, by introducing TME surgery, and establishing a registry for quality control: the 
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Norwegian Rectal Cancer Registry (NRCR).112 In 2007, the NRCR was broadened to include 
colon cancer patients, forming the Norwegian Colorectal Cancer Registry (NCCR).112 
The Swedish Rectal Cancer Registry started in 1995 to monitor outcomes of all patients with 
rectal adenocarcinoma in Sweden.118 From 2007, the coverage of the registry was widened 
to include patients diagnosed with colon adenocarcinoma, forming the Swedish ColoRectal 
Cancer Registry (SCRCR).119 
The data collected by these specialised registries or clinical audits are regularly analysed and 
fed back to health care providers, and contribute to the standardisation and quality 
assurance of care.1,120  
2.1.2 Additional data sources for England 
Given that the coverage of the NBOCA dataset was not 100% complete during the study 
period (86% in 2011-2012),121 English NCR records were also linked to additional data sources 
to reduce missing information on the main clinical variables. The Hospital Episode Statistics 
is an administrative dataset that records information on all clinical procedures, performed in 
NHS Hospitals, it contains information on outpatient, inpatient and emergency admissions.  
The Cancer Waiting Times Monitoring Data Set records information on patients who are 
referred to secondary care for suspicion of cancer, and who are offered treatment within the 
NHS.122 It is used to monitor cancer waiting times targets from referral in primary care to 
specialist evaluation, from referral to treatment, and from decision to treat to treatment 
receipt.  
2.2 Ethical and data access approvals 
Access and use of the English datasets for this study is covered by the Health Research 
Authority ethical (13/LO/0610) and statutory (PIAG 1-05(c)/2007) approvals to the LSHTM 
Cancer Survival Group. For the international comparison, this study is covered by approvals 
from the UK Health Research Authority (reference ECC 3-04(i)/2011), the National Health 
Service Research Ethics Service (11/LO/0331), and the London School of Hygiene & Tropical 
Medicine (LSHTM, 12171). These approvals were reviewed and accepted by the LHSTM 
Research Governance Committee in August, 2018 as appropriate for this Research Degree 
Project. Additional local approvals were sought for the international data sources: a Data 
Processing Agreement with the Danish Cancer Society and approval from the Danish Data 
Protection Agency was established for using the DCCG.dk data; a Data Disclosure Agreement 
with the Cancer Registry of Norway for using the Norwegian data; and ethical approval from 
the Regional Ethical Committee in Uppsala for the Swedish data. 
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2.3 Variable definitions 
Information on date of birth, date of diagnosis, last day of follow-up, and vital status was 
extracted from national population-based cancer registry records. The main exposure 
variable age was calculated as the difference between the date of cancer diagnosis and the 
date of birth. Different age categories and age as a continuous variable were explored and 
used for specific analyses (detailed in the Results section). 
Socioeconomic status of patients diagnosed in England was represented by the income 
domain of the Index of Multiple Deprivation123 of the Lower Layer Super Output Area (LSOA) 
of residence (~1,500 inhabitants), categorised into five categories of deprivation according to 
the quintiles of the national distribution of the LSOA-level deprivation scores. 
Information on comorbidity recorded in the six years previous to the colorectal cancer 
diagnosis was derived from HES records for English cancer patients. A detailed description of 
the algorithm for obtaining comorbidity information from HES records has been described 
by Maringe and colleagues.124 The individual diagnoses included were ischaemic heart 
disease, heart failure, stroke, peripheral vascular disease, peptic ulcer, chronic kidney 
disease, chronic obstructive pulmonary disease, chronic liver disease, diabetes mellitus, 
dementia, para/hemiplegia, human immunodeficiency virus infection, morbid obesity and 
previous cancer diagnoses. Ideally, the information in the comorbidity variable should reflect 
the overall health status of patients, that is, both in relation to their cancer (how cancer 
affects different systems and organs) and in relation to their pre-existing chronic conditions.  
Information on comorbidity for patients diagnosed in Denmark was readily available in the 
DCCG.dk database, as the Charlson Comorbidity Index. This variable was derived by DCCG.dk 
staff using diagnoses made in the 10 years previous the colorectal cancer diagnosis and 
excluding those made in the three months before the cancer diagnosis. Information on 
individual disease diagnoses and durations was not available. Information on comorbidity 
was not available from the Norwegian and Swedish data sources included in this study, 
therefore these countries were not included in the analysis by comorbidity status (Section 
3.3). 
Information on route to diagnosis of patients diagnosed in England was extracted from the 
Routes to Diagnosis (RtD) dataset. This dataset includes a variable that assigns each tumour 
one of several predefined routes to diagnosis using the algorithm developed and described 
by Elliss-Brookes and colleagues.37 
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2.3.1 Stage at diagnosis 
A hierarchical algorithm was developed and applied for these analysis, updating and 
extending a previous stage algorithm125 to derive information on disease extension, defined 
by the Union for International Cancer Control (UICC) TNM classification of malignant 
tumours,43 from multiple data sources. In summary, each tumour is assigned a single TNM 
summary stage from individual pathological and clinical T, N and M components. The 
algorithm gives priority to pathological confirmation of the tumour, lymph node extension, 
and distant metastases (if positive), over clinical TNM components. Stage was categorised as 
missing when there was not sufficient information from individual T, N and M components 
to derive summary stage. 
The description of the algorithm and its application to colorectal and lung tumours was 
published in the British Journal of Cancer in 2016.126 This work was also presented as a poster 
at the PHE Cancer Data and Outcomes conference in Manchester, June, 2016; and at the UICC 
World Cancer Congress, Paris, 2016. The stage algorithm was applied to all the datasets used 
for the analyses presented in Chapters 3 and 4. 
 
 
RESEARCH PAPER COVER SHEET 
 
Please note that a cover sheet must be completed for each research paper included within a thesis. 
 
 
SECTION A – Student Details 
 
Student ID Number 376763 Title Ms 
First Name(s) Sara 
Surname/Family Name Benitez Majano 
Thesis Title 
Exploring age inequalities in the management and survival of 
colorectal cancer patients 
Primary Supervisor Dr Sarah Walters 
 
If the Research Paper has previously been published please complete Section B, if not please move 
to Section C. 
 
 
SECTION B – Paper already published 
 
Where was the work published? British Journal of Cancer 
When was the work published? June, 2016 
If the work was published prior to 
registration for your research degree, 
give a brief rationale for its inclusion 
      
Have you retained the copyright for the 
work?* 
Yes 
Was the work subject 





*If yes, please attach evidence of retention. If no, or if the work is being included in its published format, 




SECTION C – Prepared for publication, but not yet published 
 
Where is the work intended to be 
published? 
      
Please list the paper’s authors in the 
intended authorship order: 
      
Stage of publication Choose an item. 
 
 
Page 2 of 2 
SECTION D – Multi-authored work 
 
For multi-authored work, give full details of 
your role in the research included in the 
paper and in the preparation of the paper. 
(Attach a further sheet if necessary) 
I was the lead author of this paper. I planned the study, 
developed the algorithm presented in the paper, carried 
out the analysis, and prepared the draft of the paper. Co-
authors provided feedback and input on the 






Student Signature       




Supervisor Signature       
Date       
 
Deriving stage at diagnosis from multiple
population-based sources: colorectal and lung
cancer in England
S Benitez-Majano*,1, H Fowler1, C Maringe1, C Di Girolamo1 and B Rachet1
1Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
Background: Stage at diagnosis is a strong predictor of cancer survival. Differences in stage distributions and stage-specific
management help explain geographic differences in cancer outcomes. Stage information is thus essential to improve policies for
cancer control. Despite recent progress, stage information is often incomplete. Data collection methods and definition of stage
categories are rarely reported. These inconsistencies may result in assigning conflicting stage for single tumours and confound the
interpretation of international comparisons and temporal trends of stage-specific cancer outcomes. We propose an algorithm that
uses multiple routine, population-based data sources to obtain the most complete and reliable stage information possible.
Methods: Our hierarchical approach derives a single stage category per tumour prioritising information deemed of best quality
from multiple data sets and various individual components of tumour stage. It incorporates rules from the Union for International
Cancer Control TNM classification of malignant tumours. The algorithm is illustrated for colorectal and lung cancer in England. We
linked the cancer-specific Clinical Audit data (collected from clinical multi-disciplinary teams) to national cancer registry data. We
prioritise stage variables from the Clinical Audit and added information from the registry when needed. We compared stage
distribution and stage-specific net survival using two sets of definitions of summary stage with contrasting levels of assumptions
for dealing with missing individual TNM components. This exercise extends a previous algorithm we developed for international
comparisons of stage-specific survival.
Results: Between 2008 and 2012, 163 915 primary colorectal cancer cases and 168 158 primary lung cancer cases were diagnosed
in adults in England. Using the most restrictive definition of summary stage (valid information on all individual TNM components),
colorectal cancer stage completeness was 56.6% (from 33.8% in 2008 to 85.2% in 2012). Lung cancer stage completeness was
76.6% (from 57.3% in 2008 to 91.4% in 2012). Stage distribution differed between strategies to define summary stage. Stage-
specific survival was consistent with published reports.
Conclusions: We offer a robust strategy to harmonise the derivation of stage that can be adapted for other cancers and data
sources in different countries. The general approach of prioritising good-quality information, reporting sources of individual TNM
variables, and reporting of assumptions for dealing with missing data is applicable to any population-based cancer research using
stage. Moreover, our research highlights the need for further transparency in the way stage categories are defined and reported,
acknowledging the limitations, and potential discrepancies of using readily available stage variables.
Stage at diagnosis is a key predictor of cancer survival (Richards,
2009). Differences in stage are believed to be one of the main
drivers of disparities in cancer survival between and within regions
(Sant et al, 2003). England is known to lag behind in cancer
survival in comparison to other comparably wealthy countries with
a universal health system (Coleman et al, 2011). Part of this
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survival differential is presumably due to a poorer stage
distribution of cancer cases in England (Sant et al, 2003; Walters
et al, 2013b). In the past couple of decades, many resources have
been invested in improving cancer outcomes through identifying
and treating cancer at an earlier stage (Richards, 2009; Department
of Health, 2011).
Research examining national and international temporal and
geographical patterns in cancer outcomes is usually based on
population-based cancer registry data, which have historically
lacked information on stage. Further granularity of information is
required to understand in depth the effect of stage on cancer
outcomes at the population level and to monitor and evaluate
cancer policy and changes in clinical practice. Recent efforts by
Public Health England (PHE) and the National Cancer Registra-
tion Service have driven an improvement in availability of stage
information for cancers diagnosed in England (McPhail et al,
2015). The national aim is for at least 70% of cancer patients to be
staged at diagnosis (Health and Social Care Information Centre,
2015).
Clinical or surgical quality assurance programmes, also called
clinical audits, have been developed as instruments to ensure
clinical quality standards of health-care providers (van Gijn et al,
2010). Clinical audits contain detailed clinical data, including
information on diagnostic investigations, stage at diagnosis, and
treatment for cancer (van Gijn et al, 2012). Besides helping clinical
specialists improve their practice, clinical audits offer a rich,
complementary source of clinical data for population-based cancer
research.
Comparability of stage information from different sources has
been a controversial issue, especially when making international or
temporal comparisons, as clinical protocols, data collection
methods, coding practices, and tumour classification systems
may vary between geographies and time periods (Walters et al,
2013a). Inconsistencies may also occur between different sources of
information from the same country.
We describe an algorithm to derive stage at diagnosis from
different sources, based on a series of hierarchical rules applied on
both the data sources and the individual stage variables from the
TNM classification (Sobin et al, 2009). This extends the algorithm
proposed and used by Walters et al (2013a) for the International
Cancer Benchmarking Partnership module 1 study. The algorithm
is illustrated for colorectal and lung cancer.
MATERIALS AND METHODS
Data sources. The National Cancer Registry data provides
information on date of birth, sex, vital status, date of death,
tumour site, and morphology (Office for National Statistics, 2015).
The Cancer Analysis System (CAS) is a national database
administered by the National Cancer Intelligence Network of PHE.
It combines the National Cancer Registry data with data from
other sources (Health and Social Care Information Centre, 2015)
and holds information on main tumour features, socio-demo-
graphic characteristics, stage, and treatment dates.
The National Clinical Audit Programme comprises multiple
clinical audits to monitor and evaluate health-care practice on
specific conditions, benchmark performance, and inform patients
and the general public of current standards of care in different
medical specialties (Healthcare Quality Improvement Partnership,
2015). Cancer clinical audits contain information on patient
referral, diagnostic investigations, pretreatment staging, treatment,
pathology evaluations, posttreatment follow-up, and outcomes.
Information is collected at the hospital level and its accuracy and
completeness should, in principle, be ensured by relevant clinicians
before submission to the Audit (Scott et al, 2014). The National
Bowel Cancer Audit Project (NBOCAP) was developed to collate
detailed clinical bowel cancer data by the Association of
Coloproctology of Great Britain in 2001 (Health and Social Care
Information Centre, 2014). The Lung Cancer Audit Database
(LUCADA) was developed by the Royal College of Physicians
Intercollegiate Lung Cancer Group in 2002 and started collecting
lung cancer data nationally in 2005 (Royal College of Physicians,
2015). Figure 1 summarises the sources of information for the stage
algorithm.
Data linkage. Individual colorectal and lung cancer records from
the ONS National Cancer Registry data were linked to the CAS
records of the same cancers diagnosed between 2008 and 2012. It
followed a two-part strategy, linking records at the patient level
using an eight-level hierarchy based on the availability of
information on NHS number, date of birth, sex, and postcode
and linking records at the tumour level by tumour site and
diagnosis date. Of the 163 915 colorectal cancer cases (ICD-10
C18-C19) in the ONS National Cancer Registry data diagnosed in
England during the study period, 158 953 (96.97%) linked to a CAS
record and 121 707 (74.25%) linked to an NBOCAP record. For
lung cancer (ICD-10 C33-C34), there were 168 158 tumours
diagnosed in England during the study period. Of these, 167 236
(99.45%) linked to a CAS record and 131 540 (78.22%) linked to a
LUCADA record.
The staging algorithm. The algorithm is based on rules of the
Union for International Cancer Control TNM classification of
malignant tumours. The TNM classification was developed in the
1950s as an international standard for classifying malignant
tumours by anatomical extent (Sobin et al, 2009). It aims to
provide an unambiguous grouping of cancer cases for clinicians to
make standardised and consistent decisions for adequate disease
management.
The anatomical extent of disease is based on the assessment of
three components: the extent of the primary tumour (T), the
presence and extent of metastases to regional lymph nodes (N),
and the presence of distant metastases (M). For each tumour, two
classifications are defined: a pretreatment clinical classification (c),
drawn from physical examination, imaging tests, endoscopy,
or biopsy; and a pathological classification (p), after histopatho-
logical assessment of the primary tumour, removal and assess-
ment of lymph nodes, and microscopic evaluation of distant
metastases.
The TNM classification goes through periodic prospective and
retrospective evaluations that lead to the development and
publication of improved editions. The Fifth and Sixth Editions
were published in 1997 and 2002, respectively (Sobin and
Wittekind, 1997, 2002), followed by the current Seventh Edition,
in effect since 2010 (Sobin et al, 2009). Possibly the biggest change
between the latest editions was the elimination of the category Mx,
previously used to denote that distant metastases could not be
assessed (Sobin et al, 2009). This category is now considered
inappropriate as clinical assessment of metastases may be based
solely on physical examination (cM). Pathological Mx (pMx) may
be misinterpreted and overused by pathologists when they have
access to histological material to assess pT and pN, but not for pM,
a frequent situation after surgery for resection of the primary
tumour (Sobin and Compton, 2010). The deletion of this category
encourages the use of M0 when metastasis cannot be proven and
should facilitate the completeness of stage grouping.
Hierarchies of data sources and stage variables. A hierarchy of
data sources was established for different types of information to
avoid inconsistencies, given that information could potentially
come from a maximum of three data sets. The ONS National
Cancer Registration data was our preferred data set for main
person and basic tumour characteristics such as date of birth, vital
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status, deprivation quintile, topography, and morphology of the
primary tumour. This decision was based on their established
quality-control processes to verify this information and to be
consistent with official national cancer statistics (Office for
National Statistics, 2015). Clinical audits were the preferred source
for detailed clinical data such as pretreatment diagnostic
investigations, dates and results of medical interventions, and
staging resulting from these. Staging information from CAS was
used if missing or invalid from the clinical audit.
The algorithm can be divided into two parts for descriptive
purposes. The first part entails deriving individual T, N, and M
components from all available sources of pathological and clinical
stage information. Once individual T, N, and M components have
been ascertained, the second part of the algorithm applies TNM
definitions for stage grouping, to obtain the overall grouped TNM
stage (I, II, III, IV). Two different strategies for deriving TNM stage
grouping are described depending on the acceptable level of
missing information from individual T, N, and M components.
Deriving individual T, N, and M components. We used a set of
rules to treat potentially discordant information from different
sources to derive overall individual T, N, and M components from
different types of variables in the data sets following TNM
classification rules.
The pathological TNM classification uses information from
clinical TNM and complements it using additional information
from pathological evaluation (Sobin et al, 2009). Pathological TNM
should therefore be the most complete source of staging
information, at least for T and N. In our data sets, there was
information for pathological and clinical individual T, N, and M
components from the clinical audits and CAS plus staging
information from additional variables (Table 1). We gave priority
to the pathological variables over clinical ones for T and N, but cM
was prioritised over pM (Walters et al, 2013a). Although distant
metastases are not generally evaluated during surgery for resection
of the primary tumour (Sobin and Compton, 2010; Walters et al,
2013a), pathological confirmation of metastases, from a biopsy, for
example, was given priority over a negative or inconclusive result
from a clinical/imaging test.
Our algorithm allowed results from medical tests and diagnostic
procedures to inform individual clinical T, N, and M components
when missing or with a value of zero. Similarly, records of the
presence of metastases in specific organs or of regional lymph node
involvement were used to inform cM or pN, respectively.
Information in these additional variables was used as evidence of
local, regional, and/or distant extension of disease when positive
but did not rule out their presence. For example, if there was
evidence of distant metastases from one of these additional
variables, this replaced the value of cM to cM1; however, if there
was no evidence of metastasis in that variable, it did not change the
value of cM to cM0, allowing the algorithm to keep looking for
information in subsequent variables.
In addition to the clinical and pathological T, N, and M
components, CAS reports a third type of staging information that
may come from either pathological or clinical data and may use the
highest value of a particular component for a given tumour or be
directly flagged by the registry. This ‘integrated’ stage information
was used only when exhausting all other possible sources because
its algorithm was not fully documented.
We used an additional step for determining the M component
to account for the fact that, although the categories Mx and pM0
do not exist in the Seventh Edition of the TNM classification, their
use is still common practice: If M was still missing after looking in
all potential sources, and there was indirect evidence of a clinical
examination, that is information on both clinical T and N, M was




















Figure 1. Sources of data for deriving stage for colorectal and lung cancer, England, 2008–2012. *Main tumour characteristics include ICD-10
topography codes, histology, behaviour, and date of diagnosis. Abbreviations: CAS¼Cancer Analysis System; CT¼ computarised tomography
scan; MRI¼magnetic resonance imaging; ONS¼Office for National Statistics Cancer Registration Dataset.
Tumour stage at the population level BRITISH JOURNAL OF CANCER
www.bjcancer.com | DOI:10.1038/bjc.2016.177 393
component was populated at a specific step of the algorithm, there
was generally no need to look further for information of that
particular component in subsequent steps of lower priority.
Deriving the grouped TNM stage. After ascertaining individual –
and unique – T, N, and M values to each tumour, the second part
of the algorithm followed TNM classification definitions to
categorise different combinations of T, N, and M values into
TNM stage groupings. This part of the algorithm starts by
examining M. Generally, for most cancer sites, including colorectal
and lung, a positive M value effectively represents the maximum
value of TNM stage grouping, stage IV, independently of the values
of N and T. Similarly, once a positive M has been excluded,
and there is a positive N, the algorithm assigns a TNM stage III to
the tumour, independently of the value of T. The algorithm
then evaluates subsequent subcategories in a descending order
(stages II and I).
To manage the missing information within N and/or M, we
applied two different strategies to derive overall stage based on the
algorithm for deriving stage described by Walters et al (2013a). The
most conservative of the two approaches, the restrictive strategy, is
stricter in the sense that all three components need to be present to
derive the grouped stage. In contrast, the non-restrictive strategy
allows for the interpretation of missing information as an absence
of metastases to the lymph nodes (N) or to distant organs (M).
Additionally, after exhausting all possibilities of deriving the
grouped TNM stage from individual T, N, and M components, the
algorithm moves on to using the pathological and clinical
summary stage information. The restrictive strategy differs in that
we ignore the grouped stage variables, given that we cannot verify
individual T, N, and M components from these.
The staging algorithm applied to colorectal cancer. Both CAS
and NBOCAP use the Fifth Edition of the TNM classification
(Sobin and Wittekind, 1997), following guidance from the Royal
College of Pathologists (Health and Social Care Information
Centre, 2014). The definition of node involvement changed in later
editions, specifically in that evaluation of satellite mesenteric
Table 1. Sources of valid T, N, and M components: completeness of variables and contribution to final staging











pT K 32 648 (19.9) 32 017 (19.5)a 15 427 (9.2) 15 427 (9.2)
Serosal involvement or perforation K 5209 (3.2) 710 (0.4) NA NA
pT K 77 997 (47.6) 52 761 (32.2) 14 933 (8.9) 5970 (3.6)
cT K 48 204 (29.4) 16 113 (9.8) 107 171 (63.7) 89 265 (53.1)
Result from MRI K 22 056 (13.5) 2295 (1.4) NA NA
cT K 5773 (3.5) 754 (0.5) 7952 (4.7) 1217 (0.7)
iT K 104 047 (63.5) 11 358 (6.9) 91 917 (54.7) 11 437 (6.8)
Missing T component 47 907 (29.2) 44 842 (26.7)
N component
pN K 32 666 (19.9) 32 518 (19.8)a 15 177 (9.0) 15 177 (9.0)
Count of positive lymph nodes K 14 523 (8.9) 310 (0.2) NA NA
pN K 74 212 (45.3) 49 351 (30.1) 15 180 (9.0) 6914 (4.1)
Count of positive lymph nodes K 35 695 (21.8) 4656 (2.8) 3511 (2.1) 841 (0.5)
cN K 50 108 (30.6) 16 141 (9.9) 107 300 (63.8) 88 336 (52.5)
Result from MRI K 20 387 (12.4) 1319 (0.8) NA NA
cN K 6576 (4.0) 1261 (0.8) 8085 (4.8) 1274 (0.8)
iN K 101 453 (61.9) 9574 (5.8) 91 693 (54.5) 11 349 (6.7)
Missing N component 48 785 (29.8) 44 267 (26.3)
M component
cM K 51 542 (31.4) 50 548 (30.8)a 107 057 (63.7) 107 057 (63.7)
Distant metastasis K 17 890 (10.9) 8727 (5.3) NA NA
Result from liver CT K 75 714 (46.2) 1064 (0.6) NA NA
cM K 13 212 (8.1) 6548 (4.0) 8987 (5.3) 1894 (1.1)
pM K 10 333 (6.3) 3248 (2.0) 10 845 (6.4) 648 (0.4)
pM K 10 936 (6.7) 4170 (2.5) 9675 (5.8) 2944 (1.8)
iM K 67 948 (41.5) 18 800 (11.5) 92 930 (55.3) 14 197 (8.4)
Clinical examination 3294 (2.0) 3056 (1.8)
Missing M component 67 516 (41.2) 38 362 (22.8)
Summary stageb
pStage K 30 239 (18.4)c 2206 (1.3)c 16 946 (10.1) 20 (o0.01)
cStage K 80 036 (48.8)c 1098 (0.7)c 105 410 (62.7) 485 (0.3)
pStage K 4351 (2.7) 38 (o0.01) 2117 (1.3) 41 (o0.01)
cStage K 508 (0.3) 5 (o0.01) 679 (0.4) 7 (o0.01)
iStage K 57 596 (35.1) 1189 (0.7) 85 267 (50.7) 1520 (0.9)
Stage K 108 105 (66.0)d 4003 (2.4)d NA NA
Total 163 915 168 158
Abbreviations: CAS¼Cancer Analysis System; M¼metastases; MRI¼magnetic resonance imaging; N¼ lymph nodes; NA¼ not available; T¼ tumour. Colorectal and lung cancer diagnoses in
England, 2008–2012. Prefixes: p: pathological; c: clinical; i: integrated (origin may be pathological, clinical, highest value, or simply flagged by the registry).
aSome zero values for this variable are replaced by positive values in the next step of the algorithm, where the contribution to final staging is made. Therefore, completeness of this variable
does not equal its contribution to final staging.
bSummary stage variables contribute to non-restrictive strategy only.
cDukes stage from Audit.
dDukes stage from CAS.
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tumour deposits use a size criterion in the Fifth Edition, while the
Sixth and Seventh Editions use a shape criterion to determine the
presence of mesenteric lymph node involvement (Doyle and
Bateman, 2012). Subdivisions of stage categories have been added,
and definitions of T4a and T4b have been reversed in the Seventh
Edition (Sobin et al, 2009). Except for the lymph node definition
change, none of the changes affect definitions of overall stage
grouping categories.
NBOCAP data allowed for single tumours to have several
treatment records. These records may hold conflicting information
on pathological T, N, and M components, presumably measured at
different points in the treatment journey. Therefore, the first part
of the algorithm applied to colorectal cancer was to establish a
hierarchy of NBOCAP treatment records based on their closeness
to diagnosis date. As a general rule, only records with treatment
procedures dated within 30 days before or after the date of
diagnosis were eligible to contribute with information on
pathological T, N, and M components. This was to avoid assigning
values of TNM associated with restaging and/or disease progres-
sion to what we define as stage at diagnosis. Of these records with
procedures dated between the ±30-day window from diagnosis,
the closest one to the date of diagnosis would be given priority over
information contained in subsequent treatment records, assuming
it contained a valid code for that variable. In cases where multiple
records of one tumour had the same procedure dates, the one with
lowest values of individual T, N, and M components would be
given priority, following a general rule of the TNM classification
(Sobin et al, 2009, p. 9). Information in subsequent treatment
records would only be used if such information was missing in the
previous one. Information on individual clinical T, N, and M
components from NBOCAP was the same in all treatment records
of any single tumour, as in CAS. Additional variables with
information on colorectal cancer-specific staging are listed in
Table 1. The full procedure to derive individual T, N, and M
components of stage for colorectal cancer is detailed in
Supplementary Appendix Figures S1–S3.
The second part of the algorithm for deriving overall stage
grouping using the non-restrictive strategy used additional
information from the colorectal cancer-specific Dukes classifica-
tion. As the Dukes classification is not directly equivalent to
specific combinations of individual T, N, and M components,
TNM summary stage variables from CAS were given priority over
Dukes staging, in the same order as individual T, N, and M
variables (pathological, followed by clinical and integrated). The
second part of the colorectal cancer stage algorithm is summarised
in Figures 2 and 3.
The staging algorithm applied to lung cancer. The first part of
the algorithm remains as described above, except that there were
no additional variables to inform individual T, N, and M
components in LUCADA (See Supplementary Appendix Figures
S6–S8).
The main challenge in adapting the algorithm to lung cancer
was the substantive modifications between the Sixth and Seventh
Editions of the TNM classification (Goldstraw et al, 2007):
definitions of some individual components of T and M as well as
of some categories of the stage grouping have changed (Mirsadraee
et al, 2012). We derived TNM stage grouping following definitions
of the Sixth and Seventh Editions of the TNM classification
separately. Most of these changes do not affect the overall TNM
stage grouping, therefore we chose to apply definitions of the
current Seventh Edition of TNM classification for the whole study
period (see Supplementary Appendix Figures S4 and S5).
Statistical analyses. We estimated age-standardised 5-year net
survival, stratified by stage, including a missing stage category, for
patients diagnosed in England between 2008 and 2012 and
followed up until end of 2013. Net survival represents survival
with cancer as the only potential cause of death by factoring out
mortality from other causes (expected mortality) (Pohar Perme
et al, 2012). Within the relative survival setting in which causes of
death are not available, the expected mortality was provided by life
tables from the England general population, namely, life tables by
age, sex, calendar year, and deprivation (London School of Hygiene
& Tropical Medicine, 2015). Net survival was estimated with the
non-parametric Pohar-Perme estimator (Pohar Perme et al, 2012)
implemented in the Stata program stns (Clerc-Urmès et al, 2014).
We used the complete approach for survival analysis, as used for
national cancer survival statistics (Office for National Statistics,
2015). We used the International Cancer Survival Standard weights
for age standardisation, which categorises age into five groups (15–
44, 45–54, 55–64, 65–74, and 75–99 years of age) (Corazziari et al,
2004). We compared 5-year net survival between both versions of
the staging algorithm (restrictive and non-restrictive) for each
cancer.
RESULTS
The proportion of cases with valid information on individual T and
N components was comparable between cancer sites (Table 1).
Completeness of valid information on the M component varied
significantly between colorectal and lung cancer (41.2% vs 22.8%
missing M component, respectively Table 1). Of the 163 915
primary malignant colorectal tumours, 92 778 (56.6%) had valid
stage using the restrictive strategy and 137 429 (83.8%) using the
non-restrictive strategy. Of the 168 158 primary lung cancer cases,
128 866 (76.6%) had stage information with the restrictive strategy,
vs 135 666 (80.7%) with the non-restrictive strategy. Completeness
of derived stage improved over time for both cancer sites, as did
the difference in stage completeness between the restrictive and
non-restrictive strategies (Table 2).
Distribution of stage differed between strategies for colorectal
cancer (Table 2). Assuming equivalence between values of zero and
missing for N and M, as in the non-restrictive strategy, decreased
dramatically the overall missingness of TNM stage grouping for
colorectal cancer and affected the overall stage distribution. For
instance, 25 431 (27.4% of data with observed stage) tumours were
classified as stage III using the restrictive strategy and increased to
41 537 (30.2% of data with observed stage) using the non-
restrictive strategy, mainly owing to the assumption of equivalence
between missing and zero value of M in the first part of the
algorithm. This difference was less pronounced for lung cancer,
because of better completeness of the individual M component
(Table 1). Lung cancer stage distribution was comparable between
strategies (Table 2).
Using summary stage, variables in the non-restrictive strategy
did not considerably improve the completeness of stage for either
cancer site, indicating that most cases had fairly complete T, N, and
M information before reaching this step or had all stage variables
missing.
Age-standardised 1-year net survival for colorectal cancer was
significantly lower using the non-restrictive strategy for all stages,
particularly for the missing stage category. Differences in lung
cancer survival between the two strategies were negligible (Table 3;
Supplementary Appendix Figure S9). These figures reflect the
differences between both strategies and how incomplete the
individual stage components are.
DISCUSSION
This paper describes an algorithm to derive stage from
multiple data sources. Recording of stage is now one of the
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Clinical Commissioning Group Outcome Indicators in England.
However, it is rarely reported how this information is collected and
then integrated into stage categories. We aim to adopt a standard
approach to derive stage from multiple sources using a series of
hierarchical rules. We have adapted it to specific cancer sites to
illustrate its generalisability and highlight some data and cancer-
specific issues.
In our example, the use of TNM Fifth Edition for colorectal
cancer is justified to facilitate comparability of temporal trends
(Royal College of Pathologists, 2014). There is a perceived increase
in interobserver variability when assigning lymph node status
using the shape criterion of the Seventh TNM Edition, rather than
the size criterion of the Fifth Edition (Doyle and Bateman, 2012;
Royal College of Pathologists, 2014). In England, the RPC
recognises that some multidisciplinary teams – from which
Clinical Audit stage data may be collected – use the Seventh
Edition of TNM to stage colorectal cancers and that it might be
requested in particular cases, such as those enrolled in clinical
trials. There was poor individual information of the TNM edition
used for staging colorectal cancer in the data sets we used. Given
that there were some codes that are valid in TNM Seventh but not
in TNM Fifth, we remain uncertain that all cases were staged using
the Fifth Edition of TNM. There is conflicting evidence on the
effect of using different editions of the TNM classification on the
final staging (Nagtegaal et al, 2011; Doyle and Bateman, 2012).
Nonetheless, comparing categories using different TNM editions
may lead to stage migration, complicating comparisons of stage-
specific outcomes. In contrast, the lung cancer data sets, in
particular the Clinical Audit data, consistently reported an
individual indicator of the edition of TNM used.
Distribution of colorectal cancer stage and stage-specific
survival differed between strategies to define summary stage.
Survival was lower for all stage categories using the non-restrictive
strategy. Imputing all cases with missing M and/or N to a value of
zero, as in the non-restrictive strategy, relies on very strong
assumptions and may lead to misclassification, biased stage-
specific survival estimates, and overly narrow variances. The
missing stage categories contain a mixture of various stages,
even though on average their prognosis is poorer than
observed stage. The real stage distribution within the missing
categories is different between strategies, as is their survival. The















































Figure 2. Deriving stage for colorectal cancer using the restrictive strategy, England, 2008–2012. Abbreviations: T¼ tumour; N¼ lymph nodes;
M¼distant metastases.
BRITISH JOURNAL OF CANCER Tumour stage at the population level
396 www.bjcancer.com | DOI:10.1038/bjc.2016.177
cancer. This is because there was more complete information on
individual M component for lung (77.2%) than for colorectal
cancer (58.8%). The restrictive approach is more conservative and
keeps open, when necessary, the possibility of using specific
approaches to deal with missing data, such as multiple imputation
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Figure 3. Deriving stage for colorectal cancer using the non-restrictive strategy, England, 2008–2012. Abbreviations: CAS¼Cancer Analysis
System; cDukes¼ clinical Dukes staging; cStage¼ clinical TNM stage; iStage¼ integrated TNM stage; M¼distant metastases; N¼ lymph nodes;
NBOCAP¼National Bowel Cancer Project; pDukes¼pathological Dukes staging; pStage¼pathological TNM stage; T¼ tumour.
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A particular limitation arises when applying the algorithm for
staging tumours receiving neoadjuvant therapy. Pathological
stage components are collected after neoadjuvant treatment,
thus downgrading may occur. This issue may be addressed by
making specific rules to deal with such tumours. This was not
possible in our data given that information on neoadjuvant
therapy is missing in the vast majority of cases from all available
sources. Differences in aggressiveness of diagnostic investigation
may also affect the comparability of stage-specific outcomes
(Allemani et al, 2013).
We acknowledge potential limitations and have discussed the
data issues and our assumptions. We encountered several issues in
relation to coding of stage variables, inconsistencies in use of
editions of TNM classification, conflicting stage information for
single tumours, and a high proportion of missing data. We believe
these may arise in other settings and data sets and have tried to
address them in a transparent way, useful for other users of cancer
staging information.
We have applied the algorithm to two cancer sites in a single
country but aim for the hierarchical rules to be adaptable for
other cancer sites and data sources in different countries, as the
issue of inconsistently defined and reported stage categories is
widespread in the current population-based cancer research
(Ciccolallo et al, 2005; Walters et al, 2013a). The outcome will
depend heavily on the quality of the specific data source but the
general approach of prioritising information of highest quality,
reporting sources of individual TNM variables, and reporting of
assumptions when dealing with missing or inconsistent data is
relevant to any cancer research using stage information.
Descriptive results such as reported in Tables 1 and 2 are helpful
















Missing stage 6996 (22.1) 6408 (19.8) 5114 (15.7) 4777 (14.3) 3191 (9.4) 26 486 (16.2)
Observed stage 24 630 (77.9) 25 939 (80.2) 27 518 (84.3) 28 708 (85.7) 30 634 (90.6) 137 429 (83.8)
I 3774 (15.3) 4159 (16.0) 4602 (16.7) 5043 (17.6) 5803 (18.9) 23 381 (17.0)
II 7631 (31.0) 7612 (29.3) 7764 (28.2) 7944 (27.7) 8195 (26.8) 39 146 (28.5)
III 7890 (32.0) 8212 (31.7) 8495 (30.9) 8508 (29.6) 8432 (27.5) 41 537 (30.2)
IV 5335 (21.7) 5956 (23.0) 6657 (24.2) 7213 (25.1) 8204 (26.8) 33 365 (24.3)
Restrictive strategy
Missing stage 20 948 (66.2) 19 360 (59.9) 15 071 (46.2) 10 749 (32.1) 5009 (14.8) 71 137 (43.4)
Observed stage 10 678 (33.8) 12 987 (40.1) 17 561 (53.8) 22 736 (67.9) 28 816 (85.2) 92 778 (56.6)
I 1046 (9.8) 1434 (11.0) 2333 (13.3) 3637 (16.0) 5117 (17.8) 13 567 (14.6)
II 2175 (20.4) 2684 (20.7) 4169 (23.7) 5883 (25.9) 7645 (26.5) 22 556 (24.3)
III 2759 (25.8) 3455 (26.6) 4839 (27.6) 6408 (28.2) 7970 (27.7) 25 431 (27.4)
IV 4698 (44.0) 5414 (41.7) 6220 (35.4) 6808 (29.9) 8084 (28.1) 31 224 (33.7)
Total 31 626 32 347 32 632 33 485 33 825 163 915
Lung cancer
Non-restrictive strategy
Missing stage 11 498 (35.9) 8242 (25.0) 5622 (16.8) 3938 (11.4) 2441 (6.9) 31 741 (18.9)
Observed stage 20 509 (64.1) 24 765 (75.0) 27 846 (83.2) 30 463 (88.6) 32 834 (93.1) 136 417 (81.1)
I 2888 (14.1) 3560 (14.4) 3713 (13.3) 4092 (13.4) 4871 (14.8) 19 124 (14.0)
II 1303 (6.4) 1661 (6.7) 2221 (8.0) 2509 (8.2) 2764 (8.4) 10 458 (7.7)
III 6338 (30.9) 7204 (29.1) 7030 (25.2) 7211 (23.7) 7623 (23.2) 35 406 (26.0)
IV 9980 (48.7) 12 340 (49.8) 14 882 (53.4) 16 651 (54.7) 17 576 (53.5) 71 429 (52.4)
Restrictive strategy
Missing stage 13 661 (42.7) 10 143 (30.7) 7321 (21.9) 5121 (14.9) 3046 (8.6) 39 292 (23.4)
Observed stage 18 346 (57.3) 22 864 (69.3) 26 147 (78.1) 29 280 (85.1) 32 229 (91.4) 128 866 (76.6)
I 2223 (12.1) 2952 (12.9) 3237 (12.4) 3781 (12.9) 4703 (14.6) 16 896 (13.1)
II 1060 (5.8) 1455 (6.4) 2030 (7.8) 2383 (8.1) 2696 (8.4) 9624 (7.5)
III 5357 (29.2) 6434 (28.1) 6531 (25.0) 6894 (23.5) 7437 (23.1) 32 653 (25.3)
IV 9706 (52.9) 12 023 (52.6) 14 349 (54.9) 16 222 (55.4) 17 393 (54.0) 69 693 (54.1)
Total 32 007 33 007 33 468 34 401 35 275 168 158
Note: %*: Percentages for stages I to IV represent the proportion of observed stage data, excluding observations with missing stage. Colorectal and lung cancer diagnoses in England, 2008–2012.
Table 3. Age-standardised estimates of 1- and 5-year net





Stage NS (CI) NS (CI)
Colorectal cancer
One-year net survival
I 0.979 (0.976, 0.981) 0.982 (0.978, 0.985)
II 0.936 (0.933, 0.939) 0.949 (0.945, 0.952)
III 0.880 (0.877, 0.883) 0.898 (0.893, 0.902)
IV 0.495 (0.489, 0.501) 0.510 (0.504, 0.515)
Missing 0.605 (0.599, 0.612) 0.777 (0.774, 0.780)
Five-year net survival
I 0.952 (0.944, 0.960) 0.957 (0.945, 0.969)
II 0.849 (0.843, 0.855) 0.861 (0.852, 0.871)
III 0.638 (0.632, 0.645) 0.665 (0.655, 0.674)
IV 0.152 (0.146, 0.157) 0.158 (0.152, 0.164)
Missing 0.414 (0.406, 0.423) 0.619 (0.614, 0.624)
Lung cancer
One-year net survival
I 0.843 (0.837, 0.848) 0.852 (0.846, 0.858)
II 0.685 (0.675, 0.695) 0.693 (0.683, 0.704)
III 0.431 (0.425, 0.437) 0.439 (0.433, 0.445)
IV 0.182 (0.179, 0.185) 0.183 (0.180, 0.186)
Missing 0.256 (0.250, 0.262) 0.298 (0.293, 0.303)
Five-year net survival
I 0.542 (0.531, 0.554) 0.541 (0.529, 0.554)
II 0.325 (0.310, 0.340) 0.325 (0.309, 0.341)
III 0.099 (0.094, 0.104) 0.100 (0.095, 0.105)
IV 0.025 (0.024, 0.027) 0.026 (0.024, 0.028)
Missing 0.093 (0.088, 0.098) 0.125 (0.120, 0.130)
Abbreviations: CI, confidence interval; NS, net survival. Diagnoses in England, 2008–2012.
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in understanding the origins of summary stage and the reasons
for shifts in stage distributions.
Validity of the information contained in cancer records
remains a general issue. We believe it should be mandatory to
have a relevant clinician at the health-care provider level
ensuring that data collected are complete and truly reflect the
information clinical decisions are based on. For each cancer
case, it should be clear what classification was used to
assign stage variables. As skilled clinicians are needed to
collect and use stage information to make adequate medical
decisions, there is also the need of people with standardised
skills for recording and compiling of clinical information
from medical records. The National Health System should
make an effort to train and support such a workforce. Complete
and accurate stage information is essential to assess cancer
control policy and to understand inequalities in cancer
management and cancer survival, at both national and interna-
tional levels. We encourage cancer registries and health-care
providers to clearly document the process for deriving stage
grouping and reporting any data quality checks to validate this
information. This information should be readily available for
researchers.
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Pohar Perme M, Stare J, Estève J (2012) On estimation in relative survival.
Biometrics 68(1): 113–120.
Richards MA (2009) The size of the prize for earlier diagnosis of cancer in
England. Br J Cancer 101(Suppl 2): S125–S129.
Royal College of Pathologists (2014) Dataset for Colorectal Cancer
Histopathology Reports. The Royal College of Pathologists: London, UK.
Royal College of Physicians (2015) National Lung Cancer Audit. Available
at https://www.rcplondon.ac.uk/projects/national-lung-cancer-audit
(last accessed 29 October 2015).
Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW,
Coleman MP, Grosclaude P, Martinez C, Bell J, Youngson J, Berrino F.
Group EW (2003) Stage at diagnosis is a key explanation of differences in
breast cancer survival across Europe. Int J Cancer 106(3): 416–422.
Scott N, Hill J, Kelly S, Fearnhead N, Kuryba A, Walker K, van der Meulen J,
Greenaway G, Meace C, Bunn E (2014) National Bowel Cancer Audit
Report 2014. Health and Social Care Information Centre: Leeds, UK.
Sobin LH, Compton CC (2010) TNM seventh edition: what’s new, what’s
changed. Cancer 116(22): 5336–5339.
Sobin LH, Gospodarowicz M, Wittekind C (eds) (2009) TNM Classification of
Malignant Tumours. John Wiley & Sons: New York, USA.
Sobin LH, Wittekind C (eds) (1997) TNM Classification of Malignant
Tumours. John Wiley & Sons: New York, USA.
Sobin LH, Wittekind C (eds) (2002) TNM Classification of Malignant
Tumours. Wiley-Liss: New York, USA.
van Gijn W, van de Velde CJ. members of the Ec (2010) Improving quality of
cancer care through surgical audit. Eur J Surg Oncol 36(Suppl 1): S23–S26.
Tumour stage at the population level BRITISH JOURNAL OF CANCER
www.bjcancer.com | DOI:10.1038/bjc.2016.177 399
van Gijn W, van den Broek CB, Mroczkowski P, Dziki A, Romano G, Pavalkis
D, Wouters MW, Møller B, Wibe A, Påhlman L, Harling H, Smith JJ,
Penninckx F, Ortiz H, Valentini V, van de Velde CJ (2012) The
EURECCA project: data items scored by European colorectal cancer audit
registries. Eur J Surg Oncol 38(6): 467–471.
Walters S, Maringe C, Butler J, Brierley JD, Rachet B, Coleman MP (2013a)
Comparability of stage data in cancer registries in six countries: lessons
from the International Cancer Benchmarking Partnership. Int J Cancer
132: 676–685.
Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, Bergström S,
Hanna L, Jakobsen E, Kölbeck K, Sundstrøm S, Engholm G, Gavin A,
Gjerstorff ML, Hatcher J, Børge Johannesen T, Linklater KM, McGahan CE,
Steward J, Tracey E, Turner D, Richards MA, Rachet B. ICBP Module 1
Working Group (2013b) Lung cancer survival and stage at diagnosis in
Australia, Canada, Denmark, Norway, Sweden and the United Kingdom:
a population-based study, 2004–2007. Thorax 68: 551–564.
White IR, Royston P, Wood AM (2011) Multiple imputation using
chained equations: Issues and guidance for practice. Stat Med 30(4):
377–399.
This work is licensed under the Creative Commons
Attribution 4.0 International License. To view a
copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Tumour stage at the population level





Web-Appendix Figure 1. Deriving T component of TNM stage for colorectal cancer, England, 2008-2012. ...................... 2 
Web-Appendix Figure 2. Deriving N component of TNM stage for colorectal cancer, England, 2008-2012. ..................... 3 
Web-Appendix Figure 3. Deriving M component of TNM stage for colorectal cancer, England, 2008-2012. .................... 4 
Web-Appendix Figure 4. Deriving TNM stage for lung cancer using the restrictive strategy, England, 2008-2012. .......... 5 
Web-Appendix Figure 5. Deriving TNM stage for lung cancer using the non-restrictive strategy, England, 2008-2012. ... 6 
Web-Appendix Figure 6. Deriving T component of TNM stage for lung cancer, England, 2008-2012. ............................... 7 
Web-Appendix Figure 7. Deriving N component of TNM stage for lung cancer, England, 2008-2012. .............................. 8 
Web-Appendix Figure 8. Deriving M component of TNM stage for lung cancer, England, 2008-2012. ............................. 9 
Web-Appendix Figure 9. Age standardised net survival by TNM stage, England 2008-2012 ........................................... 10 













































Web-Appendix Figure 9. Age standardised net survival by TNM stage, England 2008-2012 
 
Notes: 
T: Tumour component of TNM stage 
NBOCAP: National Bowel Cancer Project 
pT: Pathological T 
%: Percent 
+: Positive 
≠: Not equal to 
.: Missing 
CAS: Cancer Analysis System 
cT: Clinical T 
MRI: Magnetic Resonance Imaging 
iT: Integrated T 
N: Lymph nodes component of TNM stage 
pN: Pathological N 
≥: Greater than or equal to 
cN: Clinical N 
iN: Integrated N 
M: Distant Metastases component of TNM stage 
cM: Clinical M 
CT: Computerised Tomography scan 
pM: Pathological M 
iM: Integrated M 
pStage: Pathological TNM Stage 
cStage: Clinical TNM Stage 
iStage: Integrated TNM Stage 




2.3.2 Additional information on stage 
With recent improvements in the availability of stage information in population-based data 
sources, the first research paper of this thesis focuses on setting and updating general 
hierarchical rules to derive stage information in a transparent and reproducible manner for 
research purposes. In summary, the stage algorithm presented in the BJC paper (Section 
2.3.1) has two dimensions. The first one provides some general rules to maximise the staging 
information available from multiple data sources, and potentially multiple records per 
patient. The second dimension of the stage algorithm focuses on deriving a single TNM 
summary stage. 
In the case of CRC diagnoses in England, during the study period (2010-2012), stage 
information was available from the NBOCA dataset and from the national cancer registry 
(CAS, Cancer Analysis System). NBOCA allowed multiple records per patient, each of them 
corresponding to an individual “treatment record”. There might be conflicting information 
on individual pathological T, N, and M components in different treatment records of the 
same patient, as these could have been measured at different points during the treatment 
journey, for instance, before and after radiotherapy. To avoid assigning TNM values 
associated with restaging and/or disease progression, the first rule of the stage algorithm is 
to focus on information from treatment records with procedures dated within ±30 days from 
the cancer diagnosis date. In the case of multiple treatment records within the ±30-day 
window, priority is given to the stage information in the record closest to the date of 
diagnosis. In the case of multiple treatment records with the same treatment date, priority 
is given to the record with the lower (valid) value of pathological T (or N, when the value of 
T is the same between records with the same date, and so on), following a general rule 
specified in the 7th Edition of the TNM Classification.43 This series of rules ensures that the 
same order of records is used consistently, and minimises the potential effect of re-staging 
of tumours.  
To derive a single TNM summary stage, the stage algorithm gives priority to pathological over 
clinical information, except for the M component, where clinical evidence of distant 
metastases, cM1, supersedes the absence of pathological evidence of metastases, pM0. The 
paper describes two strategies to derive TNM summary stage, namely the ‘restrictive’ and 
‘non-restrictive strategy’. In essence, the difference between the two strategies is the 
handling of missing information on the M component of TNM stage. The ‘restrictive’ strategy 
makes no assumption of missing M information, while the ‘non-restrictive’ strategy assumes 
that missing information on M indicates absence of metastases, or M0. The restrictive 
51 
 
strategy therefore results in a higher proportion of missing information than with the non-
restrictive strategy. The choice of strategy may influence stage-specific survival, as M status 
is a strong determinant of cancer outcomes. In the example presented in the BJC 
publication,126 stage-specific 5-year survival is slightly poorer for colorectal and lung cancer 
patients in each of the (I-IV) stage categories using the non-restrictive strategy than with the 
restrictive strategy. For fair comparisons, the same strategy for deriving stage needs to be 
used across populations. 
The choice of strategy to derive summary TNM stage depends on the research question, 
choice of analysis, and on the procedure to handle missing information. Different to previous 
editions, the 7th edition of TNM does not include the Mx category indicating undetermined 
M status.43 This is to avoid inconsistencies in the use and interpretation of the Mx category, 
and the “unintended consequence of preventing stage grouping by cancer registries”.127 
Instead, the TNM 7th edition recommends using the M0 category when there is no evidence 
of metastatic disease. This results in no missing information on M, because patients are 
considered M0 unless proven otherwise (by clinical examination for clinical M, and/or 
pathological confirmation for pathological M).127 The ‘non-restrictive’ strategy of the stage 
algorithm effectively introduces this TNM 7th edition rule, regardless of the actual edition 
used at the cancer registry: it assigns M0 to patients without pathological (pM1) nor clinical 
evidence of metastases (cM1).  This is important, especially for international comparisons of 
cancer outcomes, because registries may adhere to different editions of the TNM 
Classification. For instance, following recommendations from the Royal College of 
Pathologists, English registries follow the 5th edition of TNM, while other registries, such as 
those in Norway, adhere to the 7th edition of TNM. In order to harmonise the definition of 
stage, and improve the comparability of stage-specific results, I used the ‘non-restrictive’ 
strategy to derive stage in all datasets included in the international comparison of CRC 
treatment and survival presented in Section 3.  Results are shown for the missing stage 
categories of each country in the web-appendix of the Lancet Oncology publication.128 
Cautious interpretation is needed when comparing cancer outcomes in the stage category 
because the reasons for having stage missing (or the ‘missingness mechanisms’) likely differ 
between the countries, and so the characteristics of patients in this category.  
For the England-specific analyses presented in Section 4, I used the ‘restrictive’ strategy to 
derive stage, thus making no assumptions about missing M information. This was to avoid 
using two different strategies to deal with missing data, as I used single stochastic imputation 
with chained equations to handle missing information on stage (and on the diagnostic route). 
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This strategy assumes that the missingness mechanism is missing at random, meaning that 
there may be systematic differences between the observed and the missing values, but that 
these differences may be explained by other observed variables.129 This is a sensible 
assumption when focusing on the English data. The other variables included in the multiple 
imputation models for stage included treatment status, completeness of diagnostic and 
staging investigations, the Nelson-Aalen indicator (of the cumulative hazard rate of death), 
age, sex and deprivation quintile. 
It is worth recognising that the completeness and quality of stage information in the English 
registries has substantially improved over time.130 With increasing efforts to improve the 
completeness of stage in cancer registration, the case-mix and characteristics of patients 
who remain in the missing stage category likely change, as well as their survival. Even with 
best efforts to collect and register, a (hopefully small) proportion of patients will remain 
unstaged: because they were too ill to be investigated and/or died soon after diagnosis. 
These patients will have poorer prognosis than those who are missing stage because of 
‘administrative’ reasons (patients who were staged in the clinical setting, but whose stage 
information is not recorded in cancer registration because of administrative issues). As 
‘administrative’ reasons of missing stage information become less prevalent due to efforts 
to improve registration, the comparability of the missing stage category between countries 
with a small proportion of patients with missing stage likely improves.  
2.3.3 Diagnostic and staging investigations 
Another algorithm was developed for this project to obtain information on staging 
investigations from HES and NBOCA records. The HES dataset contains information on in-
patient and out-patient diagnoses and medical procedures performed within the National 
Health System. A single patient may have multiple observations, one for each hospital 
episode, and multiple diagnoses and procedures per episode. The OPCS Classification of 
Interventions and Procedures 4.7, an NHS Fundamental Information Standard for the 
classification of interventions and procedures performed in NHS hospitals in England is used 
to classify medical procedures.  
OPCS-4.7 is used to code the relevant procedures in HES records, using NHS guidance on data 
collection for diagnostic waiting times, and covering all imaging and endoscopic tests 
recommended for investigating colorectal tumours by current English clinical guidelines.131 
Individual hospital episodes with any of the OPCS-4.7 codes for each of the staging 
procedures performed in the three months prior to and/or after the cancer diagnosis were 
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first flagged. In cases where there were multiple OPCS-4.7 codes for the same procedure, 
priority was given to codes that were considered more specific than others, and to those 
performed closest to the date of the cancer diagnosis. This information summarised into 
several variables each staging procedure recommended by clinical guidelines (chest 
tomography, abdominal tomography, pelvic tomography, pelvic magnetic resonance 
imaging, colonoscopy, and CT colonography).41 Information on staging investigations derived 
from the HES data was then complemented with information from NBOCA. 
2.3.4 Potentially curative surgery 
For patients diagnosed in England, information on surgical treatment procedure and date of 
surgery was derived from HES and NBOCA records, following an algorithm similar to the one 
for deriving information on staging investigation. OPCS-4.7 codes for cancer-directed 
surgeries that are generally used with potential curative intent were identified using the 
OPCS-4.7 full list of codes.132 Codes for cancer-directed diagnostic, palliative and/or non-
resectional symptom-alleviating procedures, such as colonoscopy without resection, 
colostomy, and colonic stents were excluded. The final list of valid OPCS codes included all 
those listed in the Lancet Oncology Commission on Global Cancer Surgery 2015 publication 
and classed as surgical procedures needed to treat colorectal cancer.133 Additionally, I 
included some less specific codes for certain procedures (such as H10.9, Unspecified excision 
of sigmoid colon). Relevant procedures performed within one month before and nine 
months after the colorectal diagnosis were identified. This time window allows the 
identification of relevant surgical procedures performed before the official date of diagnosis, 
(which could be, for instance, the date of the pathology report, which would be dated after 
the surgical procedure). Additionally, the time window allows the identification of delayed 
surgical procedures following neoadjuvant chemo-radiotherapy therapy, which may have 
been in use in some hospitals during the study period.134 The information on surgical 
procedures was then summarised into several variables by extent of resection and/or 
topography (e.g.: total proctocolectomy, total colectomy, anterior resection, 
rectosigmoidectomy, hemicolectomy, local excision, etc.). Of these categories, the most 
extensive procedure was chosen. Local excisions were considered radical for stage I tumours 
only. Information on surgical treatment was extracted from NBOCA when no information 
was available in HES records.  
For patients diagnosed in Denmark, Norway and Sweden, information on surgical procedures 
and the date they were performed was extracted from National Colorectal Cancer Registries 
following the same criteria above with regards to time from diagnosis, and valid procedures.  
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2.3.5 Chemotherapy and Radiotherapy 
Information on chemotherapy and radiotherapy status were derived from NBOCAP and CWT 
records when available for patients diagnosed in England.  
For patients diagnosed in Denmark, Norway and Sweden, information on chemotherapy, 
radiotherapy and dates was extracted from the National Colorectal Cancer Registries 
following the same criteria above with regards to time from diagnosis, and valid procedures.  
2.4 Overview of statistical methods 
2.4.1 Causal assumptions and direct acyclic graphs 
To study age inequalities in cancer management, I have made assumptions about the 
relationships between the different factors explored as determinants of the outcome(s): 
- A person’s age at presentation, the main exposure of all analyses included in 
this thesis, affects the likelihood of having comorbidity, of being diagnosed following 
an emergency presentation, as well as the likelihood of having a complete diagnostic 
and staging investigation, of having resectional surgery, and ultimately affects that 
person’s chances of surviving.  
- A person’s comorbidity status, affects the likelihood of being diagnosed 
through an emergency presentation, having a complete investigation, receiving 
treatment, and surviving. 
- A person’s diagnostic route (emergency or not) affects their chances of being 
fully investigated, being treated for their cancer, and surviving.  
- Receiving resectional surgery determines a person’s survival. 
- All the relationships above are confounded by patients’ socioeconomic 
status and sex. 
- Additionally, the relationship between comorbidity, diagnostic route, 
completeness of the investigation, treatment status, and survival may be 
confounded by system factors, such as the quality of care provided in hospitals. 
- The effect of age on different factors may reflect other mechanisms, such as 
attitudinal factors  




Figure 2.1:  Assumed causal relationship between age and colorectal cancer outcomes 
Age affects survival directly and by several mechanisms (mediators), including health status, the diagnostic route 
(emergency presentation or not), completeness of the staging investigation and by resectional surgery status. 
Age is assumed to affect the other health outcomes directly, too (health status, diagnostic route, investigation 
and surgery). Variables sex and deprivation are assumed to potentially confound all the relationships. 
 
Directed acyclic graphs (DAGs) are a useful tool to illustrate the assumed causal relationships 
between the variables considered in the analysis. A DAG is a graphical model that uses 
unidirectional arrows to represent the prior knowledge that we have regarding the 
relationships between the variables before the analysis.135 DAGs have theoretical and 
mathematical underpinnings, but without parametric assumptions.136 Although DAGs do not 
make assumptions about the distribution of the variables or shapes of the associations, they 
contain assumptions about causal relations. For instance, the absence of an arrow between 
two variables represents the assumption of no direct link between those two variables.136 
The presence of an arrow between two variables is however not deterministic; it implies that 
we are not making an assumption of independence between the variables. 
DAGs facilitate the identification of different types of variables, which is informative for the 
analysis plan and variable adjustment.137 For instance in figure 2.1, deprivation is a 
confounder of the relationship between age at presentation (main exposure) and the 
ultimate endpoint (or outcome) survival; or deprivation affects age at presentation and 
survival, and is not in the causal pathway between those two variables. The variable ‘health 
status’ is a mediator of the relationship between age and survival because it is associated 
with both, and lies in the causal pathway between them. 
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2.4.2 Net survival 
For the first objective, the international comparison of stage-specific net survival, I estimated 
and compared net survival between Denmark, England, Norway and Sweden up to 3 years 
after diagnosis, using the complete approach.138 Net survival represents survival that would 
be seen if cancer were the only potential cause of death. It therefore excludes the force of 
mortality due to other causes.  Net survival can be estimated in the relative survival setting 
and the cause-specific setting. The cause-specific setting requires information on the 
underlying causes of death, so non-cancer causes are censored in the analysis.139 Reliable 
information on causes of death is not generally available in cancer registry records, therefore 
the relative survival setting is preferred. In the relative survival setting, information on non-
cancer mortality hazard is provided by life tables for the general population (by country, sex, 
age in complete years, calendar year, and deprivation information if available). For the 
survival analyses presented in this thesis, I used life tables prepared by the Cancer Survival 
Group, London School of Hygiene and Tropical Medicine.140  
In both settings, survival estimation can be biased by informative censoring. Informative 
censoring occurs when patients are censored (they stop being at risk of experiencing the 
outcome) in a non-random manner, and their mortality hazard is different from that of 
patients who remain at risk. Informative censoring is likely because older cancer patients are 
more likely to die due to non-cancer causes in comparison to younger patients, thus to be 
censored, but they are also more likely to die of cancer than younger patients (who tend to 
remain in the risk set).139  The Pohar-Perme estimator of net survival takes into account this 
informative censoring, thus providing unbiased estimation of net survival.141 
Net survival, is useful for international comparisons of survival, because it effectively 
accounts for differences in the background mortality between populations. To obtain age-
standardised stage-specific net survival by country, I used a multivariate modelling approach 
to estimate the excess mortality hazard due to colorectal cancer and predicted survival by 
country, disease stage and age group (defined by the International Cancer Survival Standard 
population for age-standardisation)142 using the strcs Stata command.143  A weighted average 
of these age-group specific estimates provided age-standardised net survival estimates to 
account for differences in the age distribution of patients between the countries. 
Additionally, I used a non-parametric approach (Pohar-Perme)141  to estimate net survival for 
all stages combined in the international comparison, and stage-specific survival in England 
to validate the algorithm to derive stage, using the stns Stata command.144 
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2.4.3 Regression models and predictions 
For the first part of the second objective, I estimated the probability of receiving radical 
surgery using multivariate logistic regression models. Models were developed for each 
disease stage and initially included country, age, and sex. I kept the main effects of these 
exposure variables and important interactions between country and age a priori, and added 
other interactions on the basis of the likelihood ratio test.  
To quantify the proportion of under-treatment that could be avoided if patients in England 
were managed as in the best-performing country (second part of objective 2), I used a 
standardisation technique, applying the coefficient of the best performing country (from the 
logistic regression models described above) to the other countries, to assess the hypothetical 
change in the probability of receiving radical surgery if patients had been treated as in the 
best performing country, given their observed characteristics.  
For the third objective, I explored the role of comorbidity in explaining the probability of 
receiving radical surgery using similar multivariate logistic regression models to those used 
for the second objectives, additionally including a comorbidity variable, and/or stratifying by 
comorbidity level (defined by categories of the Charlson Comorbidity Index). Additionally, I 
estimated the rate of decrease in the probability of receiving radical surgery by age for each 
stage and country included in this sub-analysis, by comparing the slopes of the country-
specific probability functions (derivatives). 
2.4.4 Mediation analysis 
For objectives 4 and 5, I used causal mediation analysis to examine the mechanisms by which 
age determines the likelihood of receiving an incomplete diagnostic and staging investigation 
and treatment for colon and rectal cancer in England. The general objective of mediation 
analysis is to split the total effect of an exposure on an outcome into mediated (indirect) and 
not mediated (direct) effects.145 For example, in the analysis for objective 4, age at 
presentation (the main exposure) may influence the completeness of staging investigations 
(outcome) directly, and/or indirectly through comorbidity (mediator): comorbidity is 
determined by age, and the completeness of staging investigations is determined by the 
comorbidity level. 
Traditional approaches to carry out mediation analysis are prone to biased results,145-147 but 
recent methodologic advances have shown how to examine the decomposition of total 
effect into indirect and direct effects, even within complex scenarios like this.146 
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The causal mediation setting relies on the counterfactual framework in which several 
hypothetical scenarios of interest are compared. In these ‘alternative worlds’, researchers 
‘intervene’ on (or change the level of) the exposure and mediator(s) in the whole study 
population and contrast all the potential outcomes with of different levels of exposure and 
mediator(s), conditional on the confounders.  
A simplified example to describe the process for identifying direct and indirect effects for 
objective 5 (examining the effect of age on receiving optimal CRC surgical, and explore how 
this relationship is mediated by comorbidity and the diagnostic route in England): Let age be 
the main exposure variable (with levels old/young), comorbidity (with levels Yes/No) be the 
mediator, and treatment (with levels Yes/No) be the outcome. For obtaining direct causal 
effects, we compare the outcome of interest (treatment) between two scenarios: one in 
which everyone is old and another in which everyone is young, and in both, comorbidity is 
assumed to be distributed as if everyone was young. Comparably, the indirect effects are 
estimated comparing another set of scenarios in which everyone is old, but their comorbidity 
distribution is either as observed among the old or as if observed among the young. In other 
words, we ask two legitimate questions: 
1. Which treatment would be given, in comparison to the young, if the old 
had the comorbidity of the young? – direct effect of age 
2. Which treatment would be given, in comparison to the old with no 
comorbidity, to the old with comorbidity? – effect of age mediated by comorbidity 
 
In the analyses, I consider whether the health status of patients (given by their comorbidity 
level and underlying disease stage), and/or their diagnostic route are mechanisms that 
explain age differences in the completeness of diagnostic investigation (objective 4), and in 
receiving radical surgery for colorectal cancer (objective 5) using a parametric g-computation 
procedure, as described by Daniel and colleagues.148 
 I used Stata software (releases  14 or 15) for all statistical analyses.149,150 
The next two Chapters (3 and 4) cover the main quantitative analyses applying the methods 
described in this Chapter to research questions addressing the specific objectives of this 
project.   
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Chapter 3: International comparison of survival and stage-
specific surgical treatment of colorectal cancer patients 
3.1 Introduction 
Population-based cancer survival is an important measure of the effectiveness of healthcare 
systems in managing cancer.151 International comparisons of population-based cancer 
survival have historically shown that patients in England (and the UK) have poorer survival 
than patients in other European2,152,153 and other high-income countries with universal access 
to healthcare.3,154 This survival deficit has driven cancer policy in England since the 
publication of the first National Cancer Plan in 2000, which aimed to improve cancer survival 
in England to match that of the best-performing countries.4  
Proposed causes of the survival differences include advanced stage at diagnosis, delays 
between onset of symptoms and diagnosis, and treatment.155 Reported deficits in stage-
specific colorectal cancer indicate that suboptimal cancer management in England may also 
have a role in explaining poorer cancer survival in England.5 Evidence also suggests that the 
international differences in colorectal cancer survival may be wider in the older age group.5  
Previous work from the International Cancer Benchmarking Partnership (ICBP) found poorer 
stage distribution of colorectal tumours in Denmark, and poorer stage-specific survival in 
England, suggesting deficits in early diagnosis in Denmark and in treatment in England.5 
Recent reports have shown that cancer survival in Denmark is improving and is now closer 
to that seen in Norway and Sweden; whereas cancer survival in England, though improved, 
still lags behind.1,156 In both countries, cancer policy has focused on early diagnosis initiatives. 
Denmark and England introduced expedited referral routes in the early 2000s to avoid delay 
in diagnosis and improve cancer outcomes. In England, cancer waiting time targets were 
introduced, for instance, from primary care referral to treatment receipt. Waiting time 
targets, however, do not consider the type of treatment received. The waiting time target 
between referral and treatment receipt is equally met when undergoing resectional surgery, 
or receiving pain control. Although important, timing to (diagnosis and) treatment is not the 
only determinant of cancer outcomes.   
I hypothesise that differential management of older cancer patients may be another 
contributing factor to the ‘survival gap’ between England and better performing countries. 
To examine this, first, I present a recent comparison of colorectal cancer survival in England, 
Denmark, Norway and Sweden for all patients and by disease stage, using data from national, 
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population-based colorectal cancer registries in each of the countries. Then, I compare the 
proportion (and probability) of patients receiving potentially curative treatment, specifically 
surgery to remove the primary tumour, by age and stage. Finally, to account for differences 
in comorbidity and its associated operative risk, I present a sub-analysis exploring the role of 
comorbidity in determining treatment receipt in a comparison between Denmark and 
England. 
3.2 Surgical treatment and survival from colorectal cancer in Denmark, England, 
Norway, and Sweden 
This section addresses objectives 1 and 2 of this research degree project: To estimate and 
compare stage-specific net survival between Denmark, England, Norway and Sweden; and 
to determine and compare the effect of age on receiving surgical treatment for colorectal 
cancer in Denmark, Norway and Sweden, quantifying the proportion of under-treatment that 
could be avoided if patients in England were managed as in the best-performing country.  
The research for this section has been reported in the paper entitled “Surgical treatment and 
survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-
based study”, which was published in the peer-review journal The Lancet Oncology in 
December, 2018.128 The findings were also presented at the Union for International Cancer 
Control World Cancer Congress, Kuala Lumpur, 2018. Earlier findings were presented at the 
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Summary
Background Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable 
high-income countries. We used data from national colorectal cancer registries to assess whether differences in the 
proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer 
survival.
Methods In this population-based study, we collected data from all patients aged 18–99 years diagnosed with primary, 
invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, 
from national colo rectal cancer registries. We estimated age-standardised net survival using multivariable modelling, 
and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression 
to predict the resectional surgery status patients would have had if they had been treated as in the best performing 
country, given their individual characteristics.
Findings We extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in 
Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England 
(63·9%, 95% CI 63·5–64·3) and Denmark (65·7%, 64·7–66·8) than in Norway (69·5%, 68·4–70·5) and Sweden (72·1%, 
71·2–73·0). Rectal cancer survival was lower in England (69·7%, 69·1–70·3) than in the other three countries (Denmark 
72·5%, 71·1–74·0; Sweden 74·1%, 72·7–75·4; and Norway 75·0%, 73·1–76·8). We found no significant differences in 
survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and 
stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0–87·6; stage III rectal 
cancer 75·5%, 74·2–76·7; and stage IV colon cancer 20·5%, 19·9–21·1) than in Norway (94·1%, 91·5–96·0; 83·4%, 
80·1–86·1; and 33·0%, 31·0–35·1) and Sweden (92·9%, 90·8–94·6; 80·6%, 78·2–82·7; and 23·7%, 22·0–25·3). 3-year 
survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal 
cancer 91·2%, 88·8–93·1; and stage IV colon cancer 23·5%, 21·9–25·1). The total proportion of patients treated with 
resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for 
colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This 
range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 
4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), 
and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of 
the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other 
three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given 
their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal 
cancer in England (increasing from 70·3% to 88·2%).
Interpretation Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than 
in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences 
in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might 
partly explain these differences in international colorectal cancer survival.
Funding Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348).
Copyright 2018 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Colorectal cancer is among the three most common 
cancer diagnoses and causes of cancer death in women 
and men in Denmark, Norway, Sweden, and the UK.1 
The deficit in survival from colorectal cancer seen in 
Denmark and England compared with that of Norway and 
Sweden2–4 might be explained partly by differences in 
disease stage distribution, arising from delays in 
diagnosis.5 The variations in stage-specific survival also 
suggest differences in treatment.5
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The primary treatment for colorectal cancer is surgical 
removal of the main tumour or tumours and affected 
tissues. Total mesorectal excision became the standard 
surgery for rectal cancer in Denmark, Norway, and 
Sweden in the mid-1990s6–8 and some years later in 
England.9 This technique entails the removal of the rec-
tum and surrounding tissues, including lymph nodes and 
fascia,10 and requires particular surgical training and skills 
to secure good results. The surgical principle of resection 
in the embryological plane, which is used in mesorectal 
excision, was later applied to colon cancer surgery, with 
favourable results in terms of recurrences and survival.11,12
Preoperative (neo-adjuvant) or postoperative (adjuvant) 
radiotherapy or chemotherapy can be used to reduce the 
risk of recurrence and treat micrometastases.13,14 The 
decision to treat patients with colorectal cancer with 
neo-adjuvant or adjuvant therapy depends on the extent 
of disease and risk of recurrence. In general, clinical 
guide lines do not recommend additional therapy for 
early-stage colon tumours or rectal tumours treated with 
surgery with adequate resection margins.13–15 The use of 
neo-adjuvant or adjuvant therapy for stage II or III 
tumours is variable between—and within16—countries, 
particularly for rectal tumours.17
We used population-based data from national color-
ectal cancer registries to estimate stage-specific and 
age-standardised net survival at 3 years of patients 
diagnosed with colorectal cancer in Denmark, England, 
Norway, and Sweden, and to compare the proportions of 
patients receiving resectional surgery in those countries 
by patient and tumour characteristics.
Methods
Study design and data sources
In this population-based study, we included all patients 
aged 18–99 years diagnosed with primary, invasive 
colorectal adenocarcinomas from Jan 1, 2010, to 
Dec 31, 2012. Patients diagnosed by their death 
certification alone and patients with records with invalid 
date sequences were excluded.18 In Denmark, England, 
and Norway, we extracted data from population-based 
national cancer registries. By linking individual patient 
records in Denmark to the Danish Colorectal Cancer 
Group database,19 additional clinical information was 
available for 11 746 (90·7%) patients registered with 
colorectal adenocarcino mas in the Danish National 
Cancer Registry. Similarly, 97 185 (99·7%) English 
national cancer registry records for patients with 
colorectal cancer were linked to at least one of the 
National Bowel Cancer Audit data, Hospital Episode 
Statistics inpatient and outpatient records, and the 
Cancer Waiting Times Monitoring Data Set. Norwegian 
national cancer registry data are routinely linked to 
the Norwegian Colorectal Cancer Registry, a specialised 
registry that contains detailed clinical infor mation on all 
patients with colorectal cancer nationwide.8 The Swedish 
Research in context
Evidence before this study
To identify previous population-based international 
comparisons of colorectal cancer survival and treatment, 
we searched PubMed for articles published between 
Jan 1, 1980, and Jan 31, 2018, using the terms 
“population-based”, “cancer”, “survival”, “treatment”, 
“international”, “colorectal OR colon OR rectum”, without 
language restrictions. We manually searched the 95 references 
retrieved. In total, 22 articles assessed colorectal cancer 
outcomes in at least one of the countries included in our study. 
Additionally, we examined secondary references, national and 
international clinical guidelines, and other national reports for 
information on colorectal cancer management. Previous 
research showed that colorectal cancer survival was lower in 
England and Denmark than in other high-income countries 
with similar health-care coverage. The deficit in survival was 
partly explained by a more advanced stage distribution in 
Denmark and, potentially, by suboptimal care in England. 
Analysts who did this research pointed to the need for research 
into differences in stage-specific treatment between these 
countries.
Added value of this study
We used national population-based clinical data to compare 
stage-specific survival of patients diagnosed with primary 
colorectal adenocarcinoma in Denmark, England, Norway, 
and Sweden between 2010 and 2012, and to assess whether 
the international survival differences could be explained by 
differences in patient care. We considered stage-specific survival 
differences in relation to the proportion of patients who 
received resectional surgery. We showed that net survival up to 
3 years after colon cancer was substantially lower in England 
and Denmark than in Norway and Sweden, and survival from 
rectal cancer was lower in England than in the other three 
countries. International differences were wider for patients with 
more advanced disease stage. The probability of receiving 
resectional surgery paralleled the survival outcomes, with 
patients in England substantially less likely to receive 
resectional surgery than in the other three countries. We also 
found a steep declining age gradient in the probability of 
receiving resectional surgery in England, which was less 
noticeable or not evident in the other countries.
Implications of all the available evidence
These findings have important policy implications, showing 
that the colorectal cancer survival deficit in England can be 
attributed partly to shortfalls in treatment. Patients older than 
75 years, in particular, are less likely to receive surgery than 
patients with the same characteristics in Denmark, Norway, and 
Sweden. We highlight the need for more patient data on 
comorbidities, frailty, and additional therapies to understand 
these differences better.
For more on the Danish 
Colorectal Cancer Group see 
http://www.DCCG.dk 
For the National Bowel Cancer 
Audit see https://www.nboca.
org.uk/
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Colorectal Cancer Registry provided clinical data on 
patients with colorectal cancer in Sweden;7 its coverage 
for the study period was near complete.20 Definitions of 
clinical variables (site, stage, or treatment) were agreed 
with in-country clinicians and specialised cancer registry 
staff to reconcile differences in coding between the 
various data sources. The data specifications were agreed 
in advance with other countries through a prespecified 
data protocol. Some further discussions with clinicians 
and registry staff were held to understand and reconcile 
differences in coding and clinical practices in those 
countries.
 All patients included in this study were followed up 
from time of diagnosis until death or until Dec 31, 2014, 
whichever occurred first. Last vital status was assessed by 
linking data to national death registry records.
Procedures
Colon cancer was defined by topographical codes C18.0–
C19.9 and rectal cancer by codes C20.0–C20.9 of the 
International Classification of Diseases for Oncology, 
3rd edition.21 Tumours located 15 cm or less from the 
anal verge were considered rectal cancers. Tumours with 
morphological codes for non-adenocarcinoma were 
excluded from analyses.
We applied consistent quality control measures to all 
records (appendix pp 1–2).18 In cases of multiple tumours 
diagnosed at the same site within 6 months of each other, 
we retained the date of diagnosis of the first tumour; 
where stage and type of surgery were inconsistent 
between records (n=327, 0·23%), we selected the most 
advanced stage and most extensive surgery. For all 
patients with record of more than one surgery, we 
selected the most extensive surgery.
Disease extent (stage), as defined by the Union for 
International Cancer Control TNM classification of 
malignant tumours, was characterised by applying a 
hierarchical algorithm previously described.22 Priority 
was given to pathological confirmation of tumour, lymph 
node extension, and distant metastases (if positive), over 
clinical TNM components. During 2010–12, Denmark 
and England used the 5th edition of TNM in their 
colorectal cancer registries, whereas the 7th edition was 
used in Norway and Sweden. There is broad comparability 
between the main stage categories among these TNM 
editions.22
We defined resectional surgery as the surgical removal of 
the primary tumour, irrespective of the intent and outcome 
of surgery, done within 9 months of diagnosis. Information 
regarding surgery for each patient was extracted from the 
specialised registry data for Denmark, Norway, and 
Sweden. For England, we derived this information from 
Hospital Episode Statistics and National Bowel Cancer 
Audit records, by identifying relevant codes from the 
Classification of Intervention and Procedures of the Office 
of Population Censuses and Surveys (OPCS), version 4.7 
(OPCS 4.7),23 a standard classification of procedures done 
in National Health Service (NHS) hospitals in England. 
Local excisions were considered radical for stage I tumours 
alone. Non-resectional procedures that were purely 
diagnostic or symptom-alleviating (eg, stoma) were not 
considered as resectional surgery. In Denmark and 
England, surgical status was categorised as missing when 
patients were registered in the national cancer registry but 
were not recorded in the specialised colorectal cancer 
registry (or in Hospital Episode Statistics for England). We 
calculated the potential range of the proportion of patients 
that might have had resectional surgery in Denmark and 
England, first assuming that all patients with missing data 
were treated and then assuming that they were all 
untreated. We then estimated upper and lower limits of 
the probable distribution of resectional surgery in each of 
these countries.
Information regarding radiotherapy and planned 
chemo therapy within 6 months of diagnosis was extracted 
from colorectal cancer registry data in Denmark, Norway, 
and Sweden, and from National Bowel Cancer Audit and 
Cancer Waiting Times records in England.
We hold approvals from the UK Health Research 
Authority (reference ECC 3–04(i)/2011), the National 
Health Service Research Ethics Service (11/LO/0331), and 
the London School of Hygiene & Tropical Medicine 
(LSHTM, 12171). We have a data proces sing agreement 
with the Danish Cancer Society and approval from the 
Danish Data Protection Agency to use data from the 
Danish Colorectal Cancer Group; a data disclosure 
agreement with the Cancer Registry of Norway to use the 
Norwegian data; and ethical approval from the Regional 
Ethical Committee in Uppsala to use the Swedish data. 
Data preparation and analyses were done at the London 
School of Hygiene & Tropical Medicine. Data were 
extracted and transferred with a standard data structure 
protocol and file transmission procedure, in line with the 
CONCORD programme for the global surveillance of 
cancer survival.24
Outcomes
Our primary aim was to assess the estimated age-
standardised net survival up to 3 years after diagnosis by 
country and disease stage and the estimated probability of 
patients receiving resectional surgery by stage and age in 
each country. We also estimated the hypothetical change in 
the probability of receiving resectional surgery that patients 
would have had if they had been treated as in the best 
performing country, given their individual characteristics.
Statistical analysis
We compared the demographic and clinical character-
istics of patients with colorectal cancer diagnosed in 
Denmark, England, Norway, and Sweden, including 
patients’ age, sex, and disease stage. We estimated net 
survival up to 3 years after diagnosis by country and 
disease stage, using the complete approach.25 Net survival 
controls for the hazard of death from other causes 
See Online for appendix
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(background mortality) and is suitable for use in inter-
national comparisons of survival because background 
mortality differs between countries. In the absence of 
reliable information on the cause of death, the 
background mortality hazard was provided by life tables 
for the general population defined by country, sex, single 
year of age, and year.26 We used a multivariable modelling 
approach to estimate the excess mortality hazard (ie, due 
to colorectal cancer) and predict net survival. Survival 
models were stratified by country and disease stage. We 
used a model selection strategy to test for non-linearity 
and time dependence of the effects of sex and age on the 
excess mortality hazard and their interactions.27 Survival 
was predicted by age group, defined by the International 
Cancer Survival Standard. We used International Cancer 
Survival Standard weights to produce a weighted average 
of the survival estimates (age-standardisation), to allow 
for differences between countries in the age distribution 
of the population of patients with cancer.28 We used the 
Stata command strcs to fit flexible parametric survival 
models on the log-hazard scale.29
We used multivariate logistic regression models to 
compare the probability of receiving resectional surgery 
between countries. Models were developed for each 
disease stage and initially included country, age, and sex. 
We started with a full, saturated model that included 
main effects and all potential interactions. The main 
effects and important interactions between country and 
age were kept a priori, and we considered other inter-
actions on the basis of the likelihood ratio test. Non-
linearity was assessed by comparing the model with age 
as a categorical variable against a model with age as a 
continuous variable. If categorical age was chosen, the 
non-linear effect of age was modelled by use of a 
restricted cubic spline variable. Subsequently, we applied 
the model coefficients of the best performing country to 
individuals from the other countries, to assess the 
hypothetical change in the probability of receiving 
resectional surgery if patients had been treated as in the 
best performing country, given their observed character-
istics. We used Stata 15 software for all statistical 
analyses.30
Colon tumours Rectal tumours
Denmark England Norway Sweden Denmark England Norway Sweden
Mean age, years (SD) 71·9 (11·3) 72·4 (12·0) 72·6 (11·9) 72·7 (11·5) 69·5 (11·5) 70·0 (12·2) 69·9 (12·2) 70·3 (11·9)
Age group, years
18–54 660 (7·7%) 5700 (8·2%) 656 (7·9%) 863 (7·3%) 481 (11·0%) 3109 (11·3%) 346 (11·1%) 626 (10·8%)
55–64 1480 (17·3%) 11 818 (16·9%) 1345 (16·1%) 1796 (15·2%) 935 (21·3%) 5936 (21·5%) 679 (21·8%) 1102 (19·0%)
65–74 2841 (33·2%) 20 403 (29·2%) 2441 (29·3%) 3653 (31·0%) 1502 (34·2%) 8359 (30·3%) 946 (30·4%) 1900 (32·8%)
75–84 2567 (30·0%) 21 942 (31·4%) 2670 (32·0%) 3907 (33·1%) 1107 (25·2%) 7289 (26·4%) 809 (26·0%) 1580 (27·3%)
85–99 1019 (11·9%) 10 004 (14·3%) 1227 (14·7%) 1567 (13·3%) 366 (8·3%) 2906 (10·5%) 331 (10·6%) 589 (10·2%)
Sex
Men 4160 (48·6%) 37 279 (53·4%) 4087 (49·0%) 5875 (49·8%) 2670 (60·8%) 17 700 (64·1%) 1836 (59·0%) 3421 (59·0%)
Women 4407 (51·4%) 32 588 (46·6%) 4252 (51·0%) 5911 (50·2%) 1721 (39·2%) 9899 (35·9%) 1275 (41·0%) 2376 (41·0%)
Disease stage at diagnosis*
Stage I 839 (10·7%) 7413 (12·8%) 972 (13·0%) 1462 (13·0%) 793 (20·7%) 5674 (24·4%) 705 (26·0%) 1247 (23·3%)
Stage II 2723 (34·7%) 17 524 (30·3%) 2482 (33·2%) 3648 (32·5%) 1032 (27·0%) 5014 (21·6%) 659 (24·3%) 1264 (23·6%)
Stage III 2036 (25·9%) 17 258 (29·8%) 1931 (25·9%) 3436 (30·6%) 1062 (27·8%) 7520 (32·4%) 645 (23·8%) 1551 (29·0%)
Stage IV 2256 (28·7%) 15 679 (27·1%) 2081 (27·9%) 2670 (23·8%) 935 (24·5%) 5026 (21·6%) 699 (25·8%) 1294 (24·2%)
Unknown stage 713 (8·3%) 11 993 (17·2%) 873 (10·5%) 570 (4·8%) 569 (13·0%) 4365 (15·8%) 403 (13·0%) 441 (7·6%)
Received resectional 
surgery†
6040 (70·5%) 47 803 (68·4%) 6023 (72·2%) 9582 (81·3%) 2982 (67·9%) 16 544 (59·9%) 2064 (66·3%) 4106 (70·8%)
Received radiotherapy‡ 134 (1·6%) 2097 (3·0%) 109 (1·3%) 54 (0·5%) 1182 (26·9%) 11 299 (40·9%) 1321 (42·5%) 2935 (50·6%)
Received 
chemotherapy‡§
3272 (38·2%) 18 640 (26·7%) 1654 (19·8%) 2525 (21·4%) 2060 (46·9%) 8484 (30·7%) 931 (29·9%) 1404 (24·2%)
Unknown treatment 
status¶
949 (11·1%) 214 (0·3%) 0 (0·0%) 0 (0·0%) 263 (6·0%) 67 (0·2%) 0 (0·0%) 0 (0·0%)
Total 8567 (100%) 69 867 (100%) 8339 (100%) 11 786 (100%) 4391 (100%) 27 599 (100%) 3111 (100%) 5797 (100%)
Data are n (%), unless otherwise specified. *Proportions of total number of patients with known stage. †Defined as surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and 
palliative procedures. ‡Received within 6 months of diagnosis; sources and completeness of information on chemotherapy or radiotherapy varied greatly between countries, with a high proportion of missing 
information in England. §Planned chemotherapy in Norway and Sweden. ¶Proportion of patients not registered in specialised colorectal cancer registries (or Hospital Episode Statistics, Cancer Waiting Times 
Monitoring Data Set for England). 
Table 1: Characteristics of patients diagnosed with colorectal adenocarcinoma, 2010–12
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Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the manuscript. The corresponding author had full access 
to all the data in the study, and the final responsibility for 
the decision to submit for publication.
Results
We included information from 139 457 patients diagnosed 
with colorectal adenocarcinoma in England, Denmark, 
Norway, and Sweden in our analyses. The distribution by 
topographical site varied slightly between countries. 
The age distri bution of patients was similar between 
countries, with patients with rectal cancer being younger 
than patients with colon cancer overall (table 1). Median 
follow-up was similar between countries (table 2). 
Disease stage was known for 11 676 (90·1%) of 
12 958 patients in Denmark, 81 108 (83·2%) of 97 466 in 
England, 10 174 (88·9%) of 11 450 in Norway, and 16 572 
(94·3%) of 17 583 in Sweden. In patients with known 
disease stage, the proportion diagnosed with stage I–III 
colon cancer was higher in Sweden than in England, 
Colon tumours Rectal tumours
Denmark England Norway Sweden Denmark England Norway Sweden
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Table 2: Age-standardised net survival of patients diagnosed with colorectal adenocarcinoma, 2010–12
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Norway, and Denmark; for rectal cancer, the proportion 
diagnosed with stage I–III rectal cancer was higher in 
England than in Sweden, Denmark, and Norway (table 1).
3-year age-standardised net survival from colon cancer 
was higher in Sweden and Norway than in Denmark and 
England. Rectal cancer survival was consistently higher 
than that for colon tumours in the study countries. 3-year 
survival from rectal cancer was generally similar between 
Denmark, Norway, and Sweden, and lower in England 
(table 2).
Net survival decreased with the increase in disease 
stage (table 2, figure 1). Age-standardised 3-year survival 
for stage I tumours was higher than 95% in all countries 
for both colon and rectal cancers. 3-year survival for 
patients with stage II tumours was about 90% or higher 
in all countries, although survival for patients with rectal 
or colon cancer in England and colon cancer in Denmark 
was notably lower than for patients in Sweden or Norway. 
Although generally higher than 75%, survival for patients 
with stage III colon and rectal cancer was lower in 
England than in Norway and Sweden up to 3 years after 
diagnosis, and in Denmark 1 year after diagnosis. 
Survival from stage IV colon cancer was consistently 
lowest in England and highest in Norway, reaching 
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Figure 1: Age-standardised stage-specific survival for colon (A) and rectal (B) adenocarcinoma diagnosed in 2010–12
Shaded areas represent 95% CI of survival estimates.
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20·5% for England and 33·0% for Norway at 3 years. For 
stage IV rectal cancer, survival was lowest in Sweden and 
England (26·7% in Sweden and 27·1% in England) and 
highest in Norway (38·5%) at 3 years (figure 1).
The overall proportion of patients who received 
resectional surgery was higher for colon than for rectal 
cancer in all countries (table 1). We could not establish 
the surgical status of some patients in Denmark because 
they were not registered in the Danish Colorectal Cancer 
Group database (949 [11·1%] of 8567 patients with colon 
cancer and 263 [6·0%] of 4391 patients with rectal 
cancer). Patients with colorectal cancer who were not 
registered in the Danish Colorectal Cancer Group 
database were more likely to have advanced stage disease 
or missing stage information and be slightly older than 
patients registered in the database. Data on surgery were 
unavailable for 0·3% of patients with colorectal cancer in 
England because their national cancer registry records 
could not be linked to the additional databases (Hospital 
Episode Statistics, National Bowel Cancer Audit, or 
Cancer Waiting Times). We report here analyses of the 
patients with known surgical status. The proportion of 
patients receiving resectional surgery was highest in 
Sweden and lowest in England, for both types of cancer 
(table 1).
The proportion of patients treated with resectional 
surgery was lower in individuals aged 75 years or older 
than in younger patients in each country, and 
international differences in resectional surgery use 
widened with increasing age of patients (table 3). The 
share of patients aged 75 years or older with colon cancer 
with evidence of resectional surgery varied from 
19 078 (59·7%) of 31 946 patients in England to 4429 
(80·9%) of 5474 in Sweden. In patients aged 75 years or 
older with rectal cancer, the share of those with 
resectional surgery varied from 4663 (45·7%) of 10 195 
patients in England to 1342 (61·9%) of 2169 in Sweden. 
Sweden had the highest proportion of patients treated 
with resectional surgery for colon cancer, for each age 
group. For rectal cancer, Norway and Sweden had the 
highest proportions of resectional surgery for all but the 
youngest age group, where Denmark had the highest 
proportion of patients treated. England had the lowest 
proportion of patients treated with resectional surgery 
for rectal cancer in all age groups and for colon cancer in 
the two oldest age groups (table 3).
To account for differences in disease stage distribution, 
we examined the proportion of patients treated by stage 
and age group (figure 2). The proportion of patients with 
colon cancer with evidence of resectional surgery for 
each stage and age group was mostly similar between the 
four countries for stages I and II and in patients aged 
75 years or younger. A higher proportion of patients 
younger than 85 years with stage I colon cancer in 
England had resectional surgery than in other countries. 
However, we observed a steep decline in the proportion 
of patients that had surgical treatment in the older age 
categories in England for each disease stage and for both 
types of cancer, which was not evident in the other 
countries (figure 2). For instance, a higher proportion of 
patients received resectional surgery for stage I colon 
tumours in the 75–84 age group than in the 85 and older 
age group in all countries, but the absolute difference 
between these age groups was 18·0% in England 
Colon tumours Rectal tumours
Denmark England Norway Sweden Denmark England Norway Sweden
Age group, years
18–54 463 (70·2%) 4233 (74·3%) 495 (75·5%) 712 (82·5%) 371 (77·1%) 2065 (66·4%) 248 (71·7%) 465 (74·3%)
55–64 1091 (73·7%) 8951 (75·7%) 990 (73·6%) 1442 (80·3%) 705 (75·4%) 4083 (68·8%) 499 (73·5%) 860 (78·0%)
65–74 2077 (73·1%) 15 541 (76·2%) 1844 (75·5%) 2999 (82·1%) 1072 (71·4%) 5733 (68·6%) 664 (70·2%) 1439 (75·7%)
75–84 1818 (70·8%) 14 834 (67·6%) 1974 (73·9%) 3255 (83·3%) 698 (63·1%) 3962 (54·4%) 510 (63·0%) 1090 (69·0%)
85–99 591 (58·0%) 4244 (42·4%) 720 (58·7%) 1174 (74·9%) 136 (37·2%) 701 (24·1%) 143 (43·2%) 252 (42·8%)
Sex
Men 2917 (70·1%) 25 649 (68·8%) 2925 (71·6%) 4711 (80·2%) 1843 (69·0%) 10 820 (61·1%) 1239 (67·5%) 2427 (70·9%)
Women 3123 (70·9%) 22 154 (68·0%) 3098 (72·9%) 4871 (82·4%) 1139 (66·2%) 5724 (57·8%) 825 (64·7%) 1679 (70·7%)
Disease stage at diagnosis
Stage I 752 (89·6%) 6916 (93·3%) 836 (86·0%) 1328 (90·8%) 741 (93·4%) 5100 (89·9%) 605 (85·8%) 1122 (90·0%)
Stage II 2528 (92·8%) 16 438 (93·8%) 2189 (88·2%) 3541 (97·1%) 928 (89·9%) 3958 (78·9%) 556 (84·4%) 1145 (90·6%)
Stage III 1849 (90·8%) 15 555 (90·1%) 1688 (87·4%) 3282 (95·5%) 900 (84·7%) 5289 (70·3%) 539 (83·6%) 1361 (87·7%)
Stage IV 882 (39·1%) 6263 (39·9%) 1158 (55·6%) 1356 (50·8%) 307 (32·8%) 1293 (25·7%) 331 (47·4%) 376 (29·1%)
Unknown stage 29 (4·1%) 2631 (21·9%) 152 (17·4%) 75 (13·2%) 106 (18·6%) 904 (20·7%) 33 (8·2%) 102 (23·1%)
Total 6040 (70·5%) 47 803 (68·4%) 6023 (72·2%) 9582 (81·3%) 2982 (67·9%) 16 544 (59·9%) 2064 (66·3%) 4106 (70·8%)
Data are n (%). Resectional surgery defined as surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and palliative procedures.
Table 3: Proportion of patients diagnosed with colorectal adenocarcinoma in 2010–12 that received resectional surgery by age, sex, and disease stage
Articles
www.thelancet.com/oncology   Vol 20   January 2019 81
compared with 2·9–5·5% in the other countries. A 
similar pattern was noted in the other disease stage 
categories. The proportion of patients with colon cancer 
aged 85 years and older with evidence of resectional 
surgery was consistently highest in Sweden for each 
disease stage as compared with the other three countries.
Age at diagnosis (years)Age at diagnosis (years)






































































































































































A Colon: stage I
B Rectal: stage I
Colon: stage II




























































Figure 2: Proportion of patients who underwent resectional surgery for colon (A) and rectal (B) adenocarcinoma by disease stage at diagnosis and age group, 
for diagnoses 2010–12
Error bars are 95% CI. Resectional surgery is defined as surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and palliative 
procedures. Information on surgical status was available for all patients in Norway and Sweden. Information on surgery was missing for some patients in Denmark 
and for a small proportion of patients in England: light grey areas represent the proportion of patients with unknown surgical status by stage and age group; overall 
height of the bars shows the proportion of patients that would receive surgery if all patients with missing treatment data had surgical treatment.
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Among patients younger than 85 years with rectal 
cancer who were diagnosed with stage I or II disease, we 
observed no significant differences in the likelihood of 
















































































































































Colon: stage III Colon: stage IV
Rectum: stage II
Rectum: stage III Rectum: stage IV
Figure 3: Predicted probability of receiving resectional surgery by patient characteristics (age and sex) and 
tumour characteristics (stage at diagnosis)
Error bars are 95% CI. Resectional surgery is defined as surgery to remove the primary tumour within 9 months of 
diagnosis, excluding diagnostic and palliative procedures. *Predicted probabilities of patients receiving 
resectional surgery by applying the coefficients of the Swedish logistic model to the cohorts of patients in each 
country, on the basis of the country-specific distributions of patient characteristics. Light grey areas at the top of 
the bars for Denmark and England represent the proportion of patients with unknown surgical status by stage 
and age group. The overall height of the bars shows the proportion we would observe if all patients with missing 
treatment data had received surgery.
being treated with resectional surgery in any of the four 
countries. However, for patients with rectal cancer 
diagnosed with stage III–IV disease, the proportion 
treated was lower in England than in the other countries 
in our study, particularly in the oldest age groups 
(figure 2). We observed an age gradient in the proportion 
of patients receiving resectional surgery with all rectal 
cancer stages in Denmark, England, and Sweden, with 
lower proportions among patients aged 85 years or older 
than among younger patients. The age gradient was 
steeper in England than in other countries. For instance, 
between patients aged 75–84 years and those aged 
85 years or older, the absolute difference in the proportion 
of patients who received resectional surgery for stage III 
rectal tumours was 29·6% in England, 20·9% in Sweden, 
and 12·8% in Denmark. We found no age gradient in the 
proportion of patients treated for rectal cancer in Norway, 
except for patients with stage IV cancer.
To assess the validity of our findings and check whether 
the age differences in the likelihood of patients receiving 
resectional surgery were driven by differences in the 
management of patients diagnosed at aged 90 years or 
older, we repeated the analyses with exclusion of this 
patient group. The patterns we observed persisted in this 
reanalysis (appendix pp 3, 6–7).
Overall, Sweden had the highest survival for colon and 
rectal cancer and the highest proportion of patients 
receiving resectional surgery, compared with those of the 
other countries (although outcomes in Norway were 
generally similar, or better in specific strata, to those in 
Sweden). To highlight any groups of patients who might 
be at a disadvantage in the likelihood of receiving 
resectional surgery compared with patients in other 
countries, we applied the coefficients for Sweden to data 
from the other three countries and interpreted it as the 
probability of a patient receiving resectional surgery if 
they had been treated as in Sweden, given their observed 
age, sex, and disease stage. The number of events per 
parameter was above the recommended threshold of ten 
in all categories,31 at 100 events per parameter for our 
most complex model in the category with fewest events 
(stage IV rectal cancer).
In this hypothetical scenario, changes in the proportion 
of patients with stage I colon or rectal cancer receiving 
resectional surgery would be minor (figure 3). In 
England, Denmark, and Norway there would be a higher 
proportion treated among patients with stage II and III 
colon and rectal cancer, if treated as in Sweden. Overall, 
the largest improvements in the proportion of patients 
receiving resectional surgery would be seen in patients 
with stage II (from 78·9% to 90·7%) or III (from 70·3% 
to 88·2%) rectal cancer in England. The proportion of 
patients receiving resectional surgery for stage IV colon 
cancer in Denmark and England would increase (from 
39·1% to 51·1% in Denmark and from 40·0% to 49·8% 
in England)—whereas in Norway, the proportion would 
decrease (from 55·6% to 49·9%) if patients had been 
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treated as in Sweden. The hypothetical decrease in the 
proportion of stage IV patients receiving surgery in 
Norway would be even larger for rectal cancer (from 
47·4% to 28·8%).
Patients with missing disease stage were slightly older 
than the mean age for each country and cancer type (range 
75·3–77·3 years for colon cancer and 74·5–75·4 years for 
rectal cancer). The proportion of patients with colon cancer 
without known disease stage who had evidence of having 
resectional surgery was lower than that of any known stage 
category in each country and higher in England than in the 
other three countries (table 3). The proportion of patients 
with rectal cancer without known disease stage who had 
evidence of having resectional surgery was higher in 
Sweden than in the other three countries. Survival of 
patients with colorectal cancer without known disease 
stage was higher in Sweden than in Denmark, England, 
and Norway. Additionally, survival of these patients was 
higher than that of patients with known stage III disease 
and lower than that of patients with known stage IV 
disease, in all four countries (table 2).
Discussion
In this study, to understand the mechanisms underlying 
international differences in cancer outcomes, we com-
pared the characteristics of patients diagnosed with 
colorectal adenocarcinoma in Denmark, England, Norway, 
and Sweden. We provide updated figures of up to 3-year 
net survival in these countries, and our results support 
previous findings of lower survival for patients in England 
and, to a lesser degree, in Denmark, than in Sweden or 
Norway.2–5 Our results also support findings that Denmark 
seems to be closing the survival gap with Sweden and 
Norway, particularly for rectal cancer.4,6,24 In the stage-
specific analyses, we noted no significant differences 
between countries in survival for patients diagnosed with 
early stage (I or II) colorectal adenocarcinomas, but wider 
international survival differences in patients with more 
advanced disease stages (III or IV). Additional information 
on treatment, available from specialised colorectal cancer 
registries, helped us to understand these survival 
differences better.
Cancer survival is largely determined by receipt of 
potentially curative treatment, which, in the case of 
colorectal cancer, is primarily surgery. Treatment options 
mainly depend on disease stage and the underlying 
health status of patients, which is determined by their 
comorbidities, frailty, and age.
Clinical guidelines for cancer treatment aim to stan-
dardise and assure adequate cancer care for a population. 
The amount of detail in the national clinical guidelines 
regarding colorectal cancer management varied, with 
recom mendations from England being generally less 
specific than guidelines from Denmark, Norway, and 
Sweden.14,15,32,33 Nonetheless, indications for surgery were 
largely consistent between these countries, especially for 
rectal tumours. Treatment guidelines for colon cancer in 
Denmark, Norway, and Sweden explicitly recommend the 
removal of the part of the bowel that contains the tumour 
and its mesentery (and en-bloc resection, if the visceral 
fascia is compromised because of ingrowth of the tumour 
into neighbouring organs).13,14,32 By contrast, English 
guidelines recognise mesorectal excision as the standard 
surgery for most rectal tumours but do not explicitly 
recommend the corresponding procedure (dissection in 
the embryological plane) for colon tumours.15
None of the guidelines for the countries in our study 
mentions age as an exclusion criterion for receiving 
surgical treatment. However, we found stark differences 
between countries in the proportion of patients aged 
75 years or older who received resectional surgery. Older 
patients (aged 75 years or older with stage II–IV rectal 
cancer or stage IV colon cancer and aged 85 years or 
older for the other stages of rectal and colon cancer) in 
England had a lower probability of receiving resectional 
surgery than patients of a similar age with similar disease 
extension in the other three countries, and a lower 
probability than younger patients in England. Countries 
with better survival—Norway and Sweden—had a higher 
proportion of older patients receiving resectional surgery 
than that in England for most stages of disease. England 
had the steepest negative age gradient in the proportion 
of patients receiving resectional surgery and had a 
survival deficit in comparison with the other three 
countries, particularly for rectal cancer. These patterns 
persisted even after we excluded patients aged 90 years or 
older from the analyses. Conversely, we noted a higher 
proportion of patients younger than 85 years who were 
diagnosed with stage I or II tumours who had evidence 
of resectional surgery in England than in the other three 
countries. Of the countries studied, only England had a 
colorectal cancer screening programme with national 
coverage during the study period.34 The diagnosis and 
treatment of asymptomatic disease through screening 
might explain the high proportion of patients surgically 
treated for early stage disease in the eligible age group in 
England. In the other countries in our study, screening 
was not imple mented at national level during the study 
period34 and could not have affected the disease stage 
distribution or population-based survival.
Although less aggressive treatment for older patients 
might sometimes be justified because of comorbidity or 
frailty, concerns have been raised that some of the 
disparities in age-related cancer care in England arise 
because of clinical decision making on the basis of 
chronological age.35 A 2011 report36 showed lower resection 
rates in older patients with cancer in England during 
2004–06 than those of younger patients, with less than 
2% of patients aged 80 years or older having a major 
resection surgery for six of 13 cancers examined.
Although an increase in the proportion of patients 
receiving resectional surgery does not necessarily trans-
late into better short-term survival because aggressive 
treatment might be associated with high short-term 
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mortality, our findings suggest that international 
differences in survival are, at least in part, determined by 
differences in patient selection practices for surgical 
treatment. Choices in management of older patients 
with colorectal cancer might greatly affect population-
based survival because the mean age at diagnosis is 
about 70 years.37
Patients in countries with a greater proportion of 
patients treated with surgery and better short-term
survival might also have more access to laparoscopic 
surgery or better postoperative care than in the other 
countries. Although there is conflicting evidence about 
the long-term benefit of a laparoscopic versus an open 
surgical approach for rectal cancer,38,39 laparoscopic 
surgery is associated with lower perioperative mortality 
and fewer complications than open surgery.40,41 
In Denmark, the increasing use of laparoscopic surgery 
for colorectal cancer has been associated with a reduction 
in perioperative mortality rates.42 Differences between 
countries in the use of this approach might explain some 
of the differences in the proportion of patients receiving 
surgical treatment and, potentially, in survival. However, 
we were not able to account for this information in our 
analysis because not all datasets had sufficiently complete 
data for this question.
Our study has some limitations. We were able to do 
this international comparison of detailed clinical chara-
cteristics and outcomes for patients with colorectal cancer 
because of the existence of specialised colorectal cancer 
registries. These include core variables that have pre-
viously been examined for comparability and validated—
in these and other European colorectal cancer registries.43 
However, some residual data quality issues might affect 
the comparability of results. Our analyses accounted for 
age, sex, and disease stage, but comparable information 
on comorbidities—an important determi nant of treat-
ment—was not available in all countries. Furthermore, 
comorbidity measures might not reveal a patient’s overall 
health status. Performance status scales, which are 
commonly used to assess patients’ general condition 
(such as their degree of independence) and eligibility for 
specific treatments,44 might not be ideal for older patients 
with cancer, especially those with mul tiple comorbidities.45 
Although comprehensive geriatric assessment scales 
have been proposed and validated,45 they are rarely used, 
documented, or routinely collected.46 Nevertheless, at the 
population level, the burden of cardiovascular disease—
the most common contra indication for surgery—is 
similar in the four countries included in our study.47 
Population-based all-cause mortality and life expectancy 
in older ages are also similar in these four countries 
(appendix p 4), supporting the validity of the findings in 
our study.
The overall proportion of patients with unknown 
disease stage is notably higher in England than in 
Denmark, Norway, and Sweden. The reasons for stage 
information to be missing are likely to differ according to 
how high or low the proportion of unknown stage is and, 
therefore, probably differ between countries. Patients 
with unknown disease stage had a lower probability of 
receiving resectional surgery than patients with known 
stage, and had similar survival to that of patients with 
advanced disease stages. Therefore, our complete-case 
analysis might overestimate stage-specific survival and 
the proportion of patients receiving resectional surgery 
in England, and provides a conservative estimate of the 
disparities between England and the other three countries 
in our study.
In Denmark, 9·3% of patients were not registered in the 
Danish Colorectal Cancer Group database and thus, their 
treatment status remained undetermined. By contrast 
with the Danish National Cancer Registry, the Danish 
Colorectal Cancer Group database only includes adults 
with a first-time diagnosis of colorectal adenocarcinoma 
treated in Danish public hospitals who were in contact 
with a surgical department.19 Therefore, we calculated a 
potential range of the proportion of patients that might 
have had resectional surgery and estimated upper and 
lower limits of the probable distribution of resectional 
surgery in Denmark. Because of the Danish Colorectal 
Cancer Group database’s exclusion criteria and the stage 
distribution of patients without a Danish Colorectal 
Cancer Group database record, it is probable that a 
substantial number of these patients did not undergo 
resectional surgery. Assuming that none of these patients 
received resectional surgery, the proportion of patients 
with rectal cancer who received resectional surgery was 
still higher in Denmark than in England and similar to 
that in Sweden for most combinations of age and disease 
stage. Nevertheless, these missing data might have 
masked some age and stage trends in the likelihood of 
patients undergoing resectional surgery, especially for 
colon cancer.
We were not able to ascertain treatment intent, residual 
disease status, venous invasion status, or postoperative 
complications in patients who received resectional 
surgery. We expect that the prognosis of patients who 
underwent resectional surgery but had residual disease or 
any postoperative complication was poorer than those 
without residual disease. Systematic differences in the 
distribution of such patients between these four countries, 
or differences in their perioperative management, might 
affect the between-country comparability of these results. 
Further more, patients with non-resectable tumours in 
better-performing countries might be more likely to be 
offered other treatment (such as treatment to prolong life 
or make tumours amenable to resection) than patients 
in worse-performing countries. For example, clinical 
guidelines in Norway and Sweden describe the 
importance of neo-adjuvant or conversion treatment of 
metastatic tumours to render them resectable,13,14 whereas 
guidelines in England prioritise symptom control and 
state that initial systemic treatment followed by surgery 
should be considered only if both primary and metastatic 
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tumours are judged to be resectable.15 Moreover, in 
countries that frequently use neo-adjuvant therapy with 
delayed surgery for rectal cancer, the resulting down-
staging could cause an under estimation of the differences 
in stage-specific survival when these countries are 
compared with settings where neo-adjuvant treatment is 
more variable or followed by immediate surgery.
The completeness and granularity of the data collected 
by the colorectal cancer registries regarding chemo-
therapy and radiotherapy varied greatly during the study 
period—from complete registration of radiotherapy 
protocols in Norway and Sweden to a high proportion of 
missing information in England. These inconsistencies 
meant that including radiotherapy and chemotherapy in 
our analyses was not possible (appendix p 5). Adjuvant 
chemotherapy is associated with improved outcomes in 
stage III colon cancer and is used universally, but for 
stage II colon cancer and rectal cancer (in general) its 
value and therefore its use have been more variable.48–50 
Neo-adjuvant radiotherapy decreases recur rence rates, 
but evidence for its effect on survival is conflicting and 
so use also varies within countries16,51 and between 
countries.17 The use of targeted therapy in com bination 
with chemotherapy might help to make tumours 
amenable to resection in some patients with metastatic or 
locally advanced disease,52 but no survival benefit has 
been shown for this combination.53 For patients with 
metastatic disease treated with non-curative intent, 
optimal use of systemic therapy contributes to longer 
survival.52,54 Variability between countries in the use of 
these additional therapies, and other differences in 
oncological care beyond surgery, might also contribute to 
the observed differences in survival.
Despite the limitations of the data included in our study, 
we have identified important international differences in 
the distribution of resectional surgery by age and disease 
stage. The main data quality issue (the higher proportion 
of patients with unknown disease stage in England) is 
likely to have led to a conservative estimate of the 
differences found in stage-specific survival outcomes in 
England compared with those of other countries. We 
noted that differences in survival between patients with 
colorectal cancer treated in England, Denmark, Norway, 
and Sweden tended to increase with time after diagnosis, 
and it is possible that these differences between countries 
would widen with longer follow-up.
Changes in practice during and after the study period 
are likely to affect future trends. Over the past two or three 
decades, colorectal cancer outcomes have improved in all 
the countries compared in our study.3,24,55 The centralisation 
and specialisation of colorectal cancer surgery have been 
suggested as important drivers of this improvement.4 A 
2012 Cochrane review56 found a clear association between 
operative mortality and 5-year survival with hospital and 
surgeon caseload and specialisation. Specialisation of 
surgeons has led to more widespread and aggressive 
treatment of metastatic disease, with increased use of 
chemotherapy and resection of metastases. However, it is 
likely that centralisation and specialisation vary between 
the four countries in our study, and these changes in 
practice are also likely to affect patient survival differently 
in these countries.4,6
Expedited referral routes were initiated in England and 
Denmark in the 2000s, in response to low cancer survival 
related to system delays.57,58 Similar rapid referral routes 
were introduced in Norway and Sweden in 2016, following 
the Danish experience. Although diagnostic delays are 
important factors in cancer care, the effect of these 
referral routes on cancer survival remains uncertain.
In Denmark, a nationwide screening programme with 
a monitoring database was introduced in 2014.59 The 
Norwegian Directorate of Health is planning to introduce 
a national colorectal cancer screening programme in 
Norway in 2019, offering a faecal immunochemical test 
or colonoscopy to individuals when they turn 55 years.60 
Similarly, a national colorectal cancer screening pro-
gramme is due to be implemented in Sweden in 2019, 
following regional screening programmes.61 In England, 
a one-off screening test with flexible sigmoidoscopy for 
people aged 55 years is being rolled out.62 With increases 
in diagnosis and treatment of asymptomatic disease, it is 
likely that survival and the proportion of patients treated 
for early stage disease will increase in the future.
Since 2013, surgeon-specific outcomes have been 
reported annually as quality measures in England.63 It is 
hoped that this increase in accountability will lead to 
improvements in patient care. However, these changes 
might also affect patient selection for surgery. The major 
reorganisation of the NHS in 2013,64 alongside sub stantial 
resource constraints in the NHS65 in the past decade, has 
had a potentially negative effect on cancer services. For 
instance, the 62-day treat ment waiting time target—the 
aim that a patient should wait no more than 2 months 
from the date that the hospital receives an urgent referral 
for suspected cancer to the start of their treatment—has 
been missed for several quarters running, showing that 
services are unable to meet the demands placed on them.66 
Given the ongoing financial pressures and austerity in the 
UK and the NHS, the future trends in survival for patients 
with cancer in England are uncertain.
Our findings have important policy implications, 
suggesting that the colorectal cancer survival deficit in 
England as compared with Denmark, Norway, and 
Sweden can be attributed partly to shortfalls in provision 
of surgical treatment. We showed that older patients in 
England, in particular, were less likely to receive re-
sectional surgery than patients with similar characteristics 
in the other countries in our study. We posit that increases 
in the proportion of patients receiving resectional surgery 
might translate into better longer-term outcomes in 
England, provided that adequate postoperative care is 
also available.
Improving the capture of information on patients 
with colorectal cancer in specialised clinical registries, 
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including data from individuals who are not eligible for 
surgery, would allow a more complete population-based 
comparison of colorectal cancer outcomes. Complete and 
comparable data on comorbidities, frailty, and additional 
therapies are required to improve understanding of 
international differences and inequalities in cancer 
outcomes.
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    Colon tumours     
  
Data received according to data 
specification 
Denmark England Norway Sweden   
  Records Patients Percentage Records Patients Percentage Records Patients Percentage Records Patients Percentage   
  8,856 
    
8,815  100.00 71,292 71,292 100.00 9,006 8,668 100.00 12,168 11,790 100.00   
   Ineligible morphology* 206 204 2.31 1,359 1,359 1.91 241 222 2.56 0 0 0.00   
   Ineligible topography** 0 0 0.00 0 0 0.00 0 0 0.00 0 0 0.00   
   Aged < 18 years 0 0 0.00 4 4 0.01 0 0 0.00 0 0 0.00   
   Aged 100+ years 2 2 0.02 0 0 0.00 2 2 0.02 1 1 0.01   
  Total ineligible 208 206 2.34 1,363 1,363 100.00 243 224 2.58 1 1 0.01   
                     
  Total eligible 8,648 8,609 100.00 69,929 69,929 100.00 8,763 8,444 100.00 12,167 11,789 100.00   
   Age-site mismatch 0 0 0.00 0 0 0.00 0 0 0.00 0 0 0.00   
   Age-site-morphology mismatch 3 3 0.03 3 3 0.00 1 1 0.01 1 1 0.01   
   Invalid dates 3 3 0.03 0 0 0.00 5 5 0.06 2 2 0.02   
   Death certificate only 36 36 0.42 0 0 0.00 99 99 1.17 0 0 0.00   
   Duplicate registration*** 0 0 0.00 0 0 0.00 0 0 0.00 0 0 0.00   
   Synchronous tumour*** 0 0 0.00 0 0 0.00 4 2 0.02 193 95 0.81   
   Multiple primary same site*** 77 38 0.44 0 0 0.00 607 290 3.43 539 259 2.20   
  Total exclusions 81 42 0.49 3 3 0.00 424 105 1.24 381 3 0.03   
  Included in analysis 8,567 8,567  69,926 69,926   8,339 8,339  11,786 11,786    
                  
  
*: Specific non-adenocarcinoma ICD-O-3 morphological codes; **: Topographical codes C21.X (anal tumours). ***: Total exclusions do not include patients in this 
row because one record is kept for each. 
  
  Appendix Table 1. Data quality control (ineligible and excluded records) by country - Colon cancer diagnoses 2010-2012.   







                                
    Rectal tumours     
  
Data received according to data 
specification 
Denmark England Norway Sweden   
  Records Patients Percentage Records Patients Percentage Records Patients Percentage Records Patients Percentage   
  4,476 4,474 100.00 28,650 28,650 100.00 3,453 3,438 100.00 5,832 5,800 100.00   
   Ineligible morphology* 72 70 1.56 948 948 3.31 291 288 8.38 0 0 0.00   
   Ineligible topography** 0 0 0.00 103 103 0.36 17 17 0.49 0 0 0.00   
   Aged < 18 years 1 1 0.02 0 0 0.00 0 0 0.00 1 1 0.02   
   Aged 100+ years 1 1 0.02 0 0 0.00 1 1 0.03 1 1 0.02   
  Total ineligible 74 72 1.61 1,051 1,051 100.00 309 306 8.90 2 2 0.03   
                     
  Total eligible 4,402 4,402 100.00 27,599 27,599 100 3,144 3,132 100.00 5,830 5,798 100.00   
   Age-site mismatch 0 0 0.00 0 0 0.00 0 0 0.00 1 1 0.02   
   Age-site-morphology mismatch 0 0 0.00 0 0 0.00 0 0 0.00 0 0 0.00   
   Invalid dates 7 7 0.16 0 0 0.00 4 4 0.13 0 0 0.00   
   Death certificate only 4 4 0.09 0 0 0.00 17 17 0.54 0 0 0.00   
   Duplicate registration*** 0 0 0.00 0 0 0.00 0 0 0.00 0 0 0.00   
   Synchronous tumour*** 0 0 0.00 0 0 0.00 2 1 0.03 56 28 0.48   
   Multiple primary same site*** 0 0 0.00 0 0 0.00 22 11 0.35 8 4 0.07   
  Total exclusions 11 11 0.25 0 0 0.00 33 21 0.67 33 1 0.02   
  Included in analysis 4,391 4,391  27,599 27,599   3,111 3,111  5,797 5,797    
                  
  
*: Specific non-adenocarcinoma ICD-O-3 morphological codes; **: Topographical codes C21.X (anal tumours). ***: Total exclusions do not include patients in this 
row because one record is kept for each. 
  
  Appendix Table 2. Data quality control (ineligible and excluded records) by country - Rectal cancer diagnoses 2010-2012.   












                          
    Colon tumours  Rectal tumours   
    Denmark England Norway Sweden  Denmark England Norway Sweden   
    n (%) n (%) n (%) n (%)  n (%) n (%) n (%) n (%)   
  Age             
   15-54 463 (70.2) 4,237 (74.3) 495 (75.5) 712 (82.5)  371 (77.1) 2,065 (66.4) 248 (71.7) 465 (74.3)   
   55-64 1,091 (73.7) 8,956 (75.7) 990 (73.6) 1,442 (80.3)  705 (75.4) 4,083 (68.8) 499 (73.5) 860 (78.0)   
   65-74 2,077 (73.1) 15,554 (76.2) 1,844 (75.5) 2,999 (82.1)  1,072 (71.4) 5,733 (68.6) 664 (70.2) 1,439 (75.7)   
   75-84 1,818 (70.8) 14,855 (67.6) 1,974 (73.9) 3,255 (83.3)  698 (63.1) 3,962 (54.4) 510 (63.0) 1,090 (69.0)   
   84-99 468 (62.8) 3,386 (48.3) 553 (62.2) 915 (77.2)  118 (44.5) 593 (28.9) 124 (52.3) 208 (47.4)   
               
  Sex             
   Male 2,875 (70.7) 25,362 (70.0) 2,869 (72.1) 4,614 (80.5)  1,837 (69.6) 10,772 (62.1) 1,232 (68.2) 2,410 (71.5)   
   Female 3,042 (72.0) 21,626 (70.5) 2,987 (74.3) 4,709 (83.0)  1,127 (68.3) 5,664 (60.2) 813 (67.2) 1,652 (72.6)   
               
  Stage at diagnosis            
   I 741 (89.7) 6,860 (93.9) 816 (86.3) 1,299 (91.0)  739 (93.5) 5,058 (90.6) 599 (85.9) 1,106 (90.5)   
   II 2,463 (93.0) 16,040 (94.4) 2,115 (88.3) 3,434 (97.3)  922 (90.2) 3,927 (80.0) 551 (84.8) 1,134 (91.4)   
   III 1,816 (90.9) 15,280 (91.0) 1,637 (88.0) 3,184 (95.8)  892 (85.4) 5,269 (71.2) 534 (84.1) 1,344 (88.3)   
   IV 870 (39.7) 6,185 (41.0) 1,139 (56.9) 1,334 (51.2)  305 (33.3) 1,287 (26.3) 328 (48.2) 376 (29.6)   
   Unknown 27 (4.3) 2,623 (24.4) 149 (18.7) 72 (13.9)  106 (20.5) 895 (22.6) 33 (9.3) 102 (26.1)   
               
  Total  5,917 (71.3) 46,988 (70.2) 5,856 (73.2) 9,323 (81.7)  2,964 (69.1) 16,436 (61.5) 2,045 (67.8) 4,062 (71.9)   
               
 
Resectional surgery: Surgery removing the primary tumour, within nine months of diagnosis, excluding diagnostic, and palliative 
procedures.  
  
Appendix Table 3. Proportion of surgically-treated patients below age 90 years by age, sex and stage at diagnosis, colorectal 
adenocarcinoma diagnoses, 2010-2012.   







                
    Life expectancy in years   
   Age Denmark England Norway Sweden   
          
  Females       
   70 15.8 16.3 16.8 16.8   
   75 12.3 12.7 13.0 13.0   
   80 9.2 9.5 9.6 9.6   
   85 6.6 6.7 6.8 6.8   
   90 4.4 4.5 4.4 4.4   
          
  Males       
   70 13.3 14.0 14.0 14.3   
   75 10.2 10.7 10.6 10.9   
   80 7.5 7.9 7.7 7.9   
   85 5.3 5.6 5.4 5.5   
   90 3.6 3.8 3.6 3.6   
          
  Based on population-based life tables produced by the 
London School of Hygiene & Tropical Medicine.1  
  
    
  
Appendix Table 4. Life expectancy in people aged 70+ 
years in the general population, 2010.   






                          
    Colon tumours  Rectal tumours   
    Denmark England Norway Sweden  Denmark England Norway Sweden   
    n (%) n (%) n (%) n (%)  n (%) n (%) n (%) n (%)   
  Stage I            
   Radiotherapy 2 (0.2) 132 (1.8) 2 (0.2) 2 (0.1)  218 (27.5) 1,934 (34.1) 260 (36.9) 613 (49.2)   
   Chemotherapy 36 (4.3) 137 (1.8) 12 (1.2) 21 (1.4)  207 (26.1) 649 (11.4) 162 (23.0) 118 (9.5)   
               
  Stage II            
   Radiotherapy 21 (0.8) 389 (2.2) 19 (0.8) 23 (0.6)  282 (27.3) 2,414 (48.1) 344 (52.2) 817 (64.6)   
   Chemotherapy 527 (19.4) 2,798 (16.0) 115 (4.6) 417 (11.4)  371 (35.9) 1,369 (27.3) 241 (36.6) 266 (21.0)   
               
  Stage III            
   Radiotherapy 20 (1.0) 662 (3.8) 19 (1.0) 11 (0.3)  303 (28.5) 4,084 (54.3) 305 (47.3) 991 (63.9)   
   Chemotherapy 1,254 (61.6) 8,143 (47.2) 827 (42.8) 1,774 (51.6)  720 (67.8) 3,488 (46.4) 233 (36.1) 741 (47.8)   
               
  Stage IV            
   Radiotherapy 81 (3.6) 564 (3.6) 54 (2.6) 14 (0.5)  217 (23.2) 1,776 (35.3) 286 (40.9) 390 (30.1)   
   Chemotherapy 1,361 (60.3) 6,426 (41.0) 672 (32.3) 298 (11.2)  624 (66.7) 2,516 (50.1) 271 (38.8) 205 (15.8)   
               
  Missing stage            
   Radiotherapy 10 (1.4) 350 (2.9) 15 (1.7) 4 (0.7)  162 (28.5) 1,091 (25.0) 126 (31.3) 124 (28.1)   
   Chemotherapy 94 (13.2) 1,136 (9.5) 28 (3.2) 15 (2.6)  138 (24.3) 462 (10.6) 24 (6.0) 74 (16.8)   
               
  Notes: Missing data on chemotherapy (all countries), and radiotherapy (Denmark and England) mean that the figures 
presented are not fully comparable. Cautious interpretation is advised.  
  
    
  
Appendix Table 5. Proportion of patients with evidence of receiving radiotherapy and chemotherapy by stage, 
colorectal adenocarcinoma diagnoses 2010-2012.   






Appendix Figure 1a: Proportion of patients younger than 90 years with evidence of receiving resectional surgery for colon 
adenocarcinoma, by stage at diagnosis and age group, diagnoses 2010-2012. 
To be compared with Figure 2a; Resectional surgery: Surgery removing the primary tumour, within nine months of diagnosis, 
excluding diagnostic and palliative procedures. For Norway and Sweden, we had information on surgical status for all patients. 
Information on surgery was missing for some patients in Denmark and for a tiny proportion of patients in England. The dark shaded 
areas at the top of the bars for Denmark and (less visible) for England represent the proportion of patients with unknown surgical 
status, by stage and age-group. The overall height of the bars represents the proportion we would observe if all of the patients with 





Appendix Figure 1b: Proportion of patients younger than 90 years with evidence of receiving resectional surgery for rectal 
adenocarcinoma, by stage at diagnosis and age group, diagnoses 2010-2012. 
To be compared with Figure 2b; Resectional surgery: Surgery removing the primary tumour, within nine months of diagnosis, 
excluding diagnostic and palliative procedures. For Norway and Sweden, we had information on surgical status for all patients. 
Information on surgery was missing for some patients in Denmark and for a tiny proportion of patients in England. The dark shaded 
areas at the top of the bars for Denmark and (less visible) for England represent the proportion of patients with unknown surgical 
status, by stage and age-group. The overall height of the bars represents the proportion we would observe if all of the patients with 
missing treatment data had received surgery. 
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3.3 Exploring the role of comorbidity in explaining differences in stage-specific 
treatment of rectal cancer between Denmark and England  
3.3.1 Background 
The work presented in the previous section showed that in comparison with Norway and 
Sweden, England still lags behind in colon and rectal cancer survival, overall and in the stage-
specific analysis. In contrast, CRC survival in Denmark is close to that of Norway and Sweden, 
especially for rectal cancer. This finding is consistent with another recent international 
comparison of cancer survival.156 We also show that the proportion of patients receiving 
resectional surgery for colorectal cancer was lower in England than in the other countries, 
especially in the older age groups and/or with stage IV disease. In the paper, we argue that 
the suboptimal management of older patients in England could help explain international 
differences in cancer survival.128 A plausible alternative explanation of this finding is that 
older cancer patients in England have a higher degree of concomitant chronic conditions 
than patients of similar age and disease extension in the other countries, so the higher risk 
of perioperative mortality and morbidity affects negatively their eligibility for surgery.83,157 
This is unlikely to be the case in the general population of these countries because life 
expectancy is highly comparable in the older age groups.158 The prevalence of comorbidity 
in cancer patients may, however, differ from the one in the general population, as some 
chronic conditions may share risk factors with the cancer in question; for instance, obesity is 
a risk factor for both ischaemic heart disease and colorectal cancer.159  
To account for the effect of comorbidity in determining receipt of treatment, in this follow-
up analysis, I examined the distribution of resectional surgery by stage, age and comorbidity 
level in patients with non-metastatic rectal cancer in Denmark and England, for which we 
had information on comorbidity, addressing objective 3 of this research degree project. I 
focus on patients with non-metastatic disease because these tumours should be amenable 
to surgical resection, in the absence of other contraindications for surgery. 
3.3.2 Materials and methods 
Data sources and variable definitions 
Patients with non-metastatic (stage I-III) rectal adenocarcinoma diagnosed during 2010-2012 
in Denmark and England were included in the analysis. Information on patients diagnosed in 
Denmark was obtained from National Cancer Registry records linked to the Danish Colorectal 
Cancer Group (DCCG.dk) database. Information on patients diagnosed in England was 
obtained from National Cancer Registry records linked to the National Bowel Cancer Audit 
(NBOCA) data, and to the Hospital Episode Statistics (HES) database. 
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‘Resectional surgery’ was defined as the procedure to remove the primary tumour, 
regardless of the intent and outcome of the surgery, performed within nine months of 
diagnosis. Procedures to derive TNM stage and resectional surgery were described 
previously.126,128 
For Danish patients, diagnoses recorded up to 10 years before their cancer contributed to 
the Charlson Comorbidity Index (CCI), derived by Danish Colorectal Cancer Group Database 
(DCCG.dk) staff; for English patients, CCI was calculated using diagnoses recorded in 
secondary care records (Hospital Episode Statistics, HES) up to 9 years before the cancer 
diagnosis, using an algorithm previously described.124 For all patients, diagnoses made in the 
3 months previous to the cancer diagnosis were excluded. Individual chronic conditions 
included in the CCI and their associated scores are listed in Table 3.1. For analyses, the CCI 
was then categorised into 3 levels: no record of comorbidity (CCI 0), mild comorbidity (CCI 1-
2), and moderate to severe comorbidity (CCI 3 and above).  
          
  Individual diagnoses CCI score   
       
   Myocardial infarction 1   
   Congestive heart failure 1   
   Peripheral vascular disease 1   
   Cerebrovascular disease 1   
   Dementia 1   
   Chronic pulmonary disease 1   
   Rheumatic disease 1   
   Peptic ulcer disease 1   
   Mild liver disease 1   
   Diabetes without chronic complication 1   
   Diabetes with chronic complication 2   
   Hemiplegia or paraplegia 2   
   Renal disease 2   
   Previous malignancy 2   
   Moderate or severe liver disease 3   
   Metastatic solid tumour 6   
   AIDS/HIV 6   
          
Table 3.1: Chronic conditions included in the Charlson Comorbidity Index (CCI) 
 
Statistical analyses 
First, I compared the proportion of patients with rectal adenocarcinoma receiving resectional 
surgery by age and disease stage by country, focusing on patients without record of 
comorbidity. I then carried out a sensitivity analysis to examine whether the age gradient 
could be explained by misclassification of the comorbidity status in an important proportion 
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of patients in England. If this were the case, a share of patients in England did not undergo 
surgery because they had comorbidity that contraindicated it, but they were incorrectly 
classified as having no comorbidity due to lack of this information in secondary care records. 
The sensitivity analysis entailed randomly changing the comorbidity status of approximately 
half of patients in England without record of resectional surgery, and no comorbidity. This 
was done by assigning each relevant patient a value of a uniformly distributed random 
variable (with values between 0 and 1), and changing the comorbidity status of the lowest 
half. Effectively, these patients were excluded from the sub-analysis focusing on those 
without comorbidity, increasing the proportion of patients treated in England. The 
procedure was performed 1000 times. Results from individual iterations were averaged to 
obtain the proportion treated, and were also used to obtain standard errors and 95% 
confidence intervals. 
Finally, I used a multivariate logistic regression model to predict the probability of receiving 
resectional surgery by country, age, sex, stage and comorbidity status. The initial model 
included the main effects of country, age, sex, stage, and comorbidity level and all potential 
interactions. Main effects were kept a priori in the final model, plus relevant interactions 
based on the likelihood ratio test. The non-linear effect of age was modelled using restricted 
cubic spline variables. After predicting the probability of receiving potentially curative 
surgery, I compared the instantaneous rate of change in (or, the first derivative of) the 
probability of receiving resectional surgery by age between the countries for each 
combination of sex, stage and comorbidity level. 
3.3.3 Results 
Proportion of patients without comorbidity undergoing resectional surgery 
Comorbidity information was available for 97.2% (out of 2,887) and 99.9% (out of 18,208) of 
eligible patients in Denmark and England, respectively. Patients without a DCCG.dk record in 
Denmark (2.8%), and those with neither NBOCA nor HES record in England (0.1%) were 
classified as having no record of comorbidity. In Denmark, 31.4% of patients with non-
metastatic rectal adenocarcinoma had a record of comorbidity, while in England, 22.3% of 
such patients had a record of comorbidity. In both countries, the prevalence of comorbidity 
increased with age (from 9.3% in the 18-55 age group to 43.0% in the 85+ in Denmark; and 
from 8.2% in the 18-55 age group to 34.4% in the 85+ in England).  
As in our previous paper,128 the proportion of patients receiving resectional surgery for rectal 
adenocarcinoma decreased with increasing age in both countries, and the age decline was 
substantially steeper in England than in Denmark at each stage of disease (Figure 3.1). There 
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was no significant difference in the proportion of patients treated for stage I disease (Figure 
3.1), though it tended to be lower in England in patients aged 85 years or older. The 
proportion of patients receiving resectional surgery for stage II and III rectal cancer was 
substantially lower in England than in Denmark in those aged 75 years or older without a 
record of comorbidity. 
 
Figure 3.1: Percentage of patients with evidence of resectional surgery for rectal cancer, 
2010-2012, excluding patients with comorbidity  
Error bars are 95% CI. Resectional surgery: surgery to remove the primary tumour within 9 months of diagnosis, 
excluding diagnostic and palliative procedures. Light grey areas represent the proportion of patients with 
unknown surgical status by stage and age group; overall height of the bars shows the proportion of patients that 
would receive surgery if all patients with missing treatment data had surgical treatment. 
 
The proportion of patients with neither evidence of comorbidity nor of resectional surgery 
was substantially larger in England (14.7%, or 2,677 patients) than in Denmark (7.4%, or 214 
patients), as was the overall prevalence of comorbidity (reported above). Because of the 
lower prevalence of comorbidity in England, I carried out a sensitivity analysis to assess 
whether potential misclassification of the comorbidity status of patients without surgery in 
England could explain why the proportion of older patients surgically treated was lower in 
England than in Denmark. Of patients diagnosed in Denmark, 1970 (68.5%) were included in 
the sensitivity analysis. The exact number English patients included varied slightly between 
the 1000 iterations of the sub-analysis, and ranged between 12,597 (69.2%) and 12,782 
(70.2%), with an average of 12,686 (69.7%) patients.  
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The proportion of patients surgically treated in England increased in comparison with the 
results including patients with no record of comorbidity (irrespective of their treatment 
status), in all combinations of stage and age group, due to the exclusion of an important 
proportion of English patients with neither evidence of comorbidity nor of surgery (Figure 
3.2). After this additional exclusion, the proportion treated for patients aged younger than 
85 years was similar between the countries. In contrast, the pattern of a lower proportion of 
older patients receiving resectional surgery in England was still obvious in stage II and III rectal 
cancer patients, though less marked than in the previous analysis. 
 
Figure 3.2: Percentage of patients with evidence of resectional surgery for rectal cancer, 
2010-2012, excluding those with comorbidity and approximately half of patients in England 
without surgery and without comorbidity 
Error bars are 95% CI. Resectional surgery: surgery to remove the primary tumour within 9 months of diagnosis, 
excluding diagnostic and palliative procedures. Light grey areas represent the proportion of patients with 
unknown surgical status by stage and age group; overall height of the bars shows the proportion of patients that 
would receive surgery if all patients with missing treatment data had surgical treatment. 
 
Probability of receiving resectional surgery by age and comorbidity 
The final logistic regression model to predict receipt of resectional surgery included the 
effects of country, stage, comorbidity level, three restricted cubic spline variables for age, 
and all relevant interactions. The effect of age on the probability of having resectional 
surgery varied by country, stage, comorbidity level, and sex. Similarly, the effect of 
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comorbidity on the outcome varied by country, stage, age, and sex. The effect of stage also 
varied by country and by comorbidity status and age. 
Figures 3.3a and 3.3b show the predicted probability of receiving treatment by age in each 
strata of stage and comorbidity level in Denmark and England for women and men, 
respectively. Because ‘sex’ was one of the variables included in the logistic regression 
models, the predictions from these models are presented by sex, even if the results are 
largely comparable between women and men. In both countries the probability of receiving 
treatment decreased in older ages, usually after 70 years of age. In each combination of 
stage, comorbidity level and sex, the predicted probability of receiving resectional surgery 
was consistently lower in England than in Denmark. The probability of receiving surgery 
tended to be similar between the countries for younger patients, for whom there was more 
uncertainty around the estimates than for older patients, thus wider 95% confidence 
intervals. In general, the difference in the probability of receiving resectional surgery 
between Denmark and England increased with increasing stage, comorbidity level, and age. 
In patients with stage I disease without comorbidity, the probability of receiving treatment 
was similar between the countries. In stage I patients with comorbidity, the predicted 
probability of treatment was lower in England than in Denmark at each age of diagnosis; and 
it tended to be larger with increasing age and level of comorbidity. For instance, the 
predicted probability of receiving resectional surgery in men aged 60 years, without 
comorbidity, and stage I rectal cancer was 96.5% (95% confidence interval 95.0-97.5) in 
Denmark and 94.9% (93.9-95.7) in England; while at age 85 years the predicted probability 
of resectional surgery was 82.8% (77.5-87.1) in Denmark and 79.8% (77.0-82.4) in England. 
In men with stage I disease and CCI score 1-2, the predicted probability of receiving surgery 
at age 60 was 97.8% (96.4-98.6) in Denmark and 94.4% (92.7-95.7) in England; in the same 
subgroup, the predicted probability of receiving surgery at age 85 years was 85.5% (79.7-
89.8) in Denmark and 73.2% (68.8-77.1) in England.  
In patients with stage II disease, the probability of receiving surgery was lower in England 
than in Denmark in each level of comorbidity, and significantly so (judged by the lack of 
overlap of 95% confidence intervals) from around age 50 years and older. The predicted 
probability of receiving surgery in women without comorbidity and with stage II disease at 
age 60 years was 94.0% (92.1-95.4) in Denmark and 87.0% (85.1-88.6) in England; while at 
age 85, it was 79.3% (74.9-83.1) in Denmark and 66.3% (63.1-69.3) in England. In women 
with stage II disease and CCI score 1-2, the probability of receiving surgery at age 60 years 
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was 95.0% (92.6-96.6) in Denmark and 82.2% (78.0-85.7) in England; and at age 85, it was 
78.1% (71.5-83.5) in Denmark and 50.9% (45.7-56.0) in England. 
Patients with stage III disease in Denmark were also more likely to receive resectional surgery 
than those in England at all ages, and significantly so for patients aged 50 years and older. 
For instance, the predicted probability of receiving surgery in women without comorbidity 
and with stage III disease at age 60 years was 90.2% (87.9-92.2) in Denmark and 79.4% (77.4-
81.2) in England; at age 85, it was 69.0% (64.2-73.4) in Denmark and 52.6% (49.6-55.6) in 
England. In women with stage III disease and CCI score 1-2, the probability of receiving 
surgery at age 60 years was 92.0% (88.7-94.3) in Denmark and 72.9% (68.5-76.9) in England; 
and at age 85, it was 67.8% (60.3-74.4) in Denmark and 37.2% (32.8-41.8) in England. The 
trends were similar between women and men. 
 
Figure 3.3a: Predicted probability of receiving radical surgery by age, comorbidity, and 
country in women diagnosed with rectal cancer, 2010-2012 
Predicted from a logistic regression model including country, three restricted cubic spline variables for age, stage, 
comorbidity level, sex, and relevant interactions between these factors. Resectional surgery was defined as 
surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and palliative 
procedures. Categories of comorbidity represent levels of the Charlson Comorbidity Index score. Area around 





Figure 3.3b: Predicted probability of receiving resectional surgery by age and country in men 
diagnosed with rectal cancer, 2010-2012 
Predicted from a logistic regression model including country, three restricted cubic spline variables for age, stage, 
comorbidity level, sex, and relevant interactions between these factors. Resectional surgery was defined as 
surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and palliative 
procedures. Categories of comorbidity represent levels of the Charlson Comorbidity Index score. Area around 
prediction lines represent 95% confidence intervals. 
 
In both countries, the probability of receiving resectional surgery decreased with increasing 
age, however, this decline started at an earlier age, and at a faster rate in England than in 
Denmark. To explore this further, I compared the first derivative of the probability, or, the 
rate of change in the probability with a very small increment in age. This rate of change is 
positive when the probability increases with age and negative when the probability of surgery 
is decreasing with age. Results for each strata of stage, comorbidity level are presented in 
Figure 3.4a and 3.4b for women and men, respectively (as per the predictions in Figures 3.3a 
and 3.3b).  
In general, in both countries, the rate of change in the probability of receiving resectional 
surgery was positive (increasing probability with increasing age) until around age 65 years, 
after which it became negative (decreasing probability with increasing age), in each strata of 
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stage and comorbidity level. However, in each strata, the rate of decrease in the probability 
of receiving resectional surgery with age appeared steeper in England than in Denmark. To 
evaluate this, I compared the age at which the rate started to decrease considerably 
(arbitrarily defined as the point at which the probability of receiving treatment decreased by 
more than 2% with a very small increase in age, by approximately one third of a day, or 
1/1000 year). This rate of change in the probability of treatment was observed in all strata in 
both countries, and systematically occurred at an earlier age in England than in Denmark. For 
instance, in men with stage II rectal cancer and no comorbidity, the probability of receiving 
resectional surgery decreased by more than 2% from age 81 years in England and from 85 
years in Denmark. In both countries the rate of change in the probability remained negative 
in older ages, though the rate of decrease was less marked (closer to zero) in oldest ages, as 







Figure 3.4a: Instantaneous rate of change in the probability of receiving resectional surgery 
in women diagnosed with rectal cancer, 2010-2012 
Instantaneous rate of change was defined as the change in the probability of receiving resectional surgery with a 
very small increase in age of approximately one third of a day, or 1/1000 year. A positive value represents an 
increase in the probability, and vice versa. An increasing but negative rate (increase towards 0) represents a 
decrease in the probability at a slower rate than at the previous age. Predicted from a logistic regression model 
including country, three restricted cubic spline variables for age, stage, comorbidity level, sex, and relevant 
interactions between these factors. Resectional surgery defined as surgery to remove the primary tumour within 




Figure 3.4b: Instantaneous rate of change in the probability of receiving resectional surgery 
in men diagnosed with rectal cancer, 2010-2012 
Instantaneous rate of change was defined as the change in the probability of receiving resectional surgery with a 
very small increase in age of approximately one third of a day, or 1/1000 year. A positive value represents an 
increase in the probability, and vice versa. An increasing but negative rate (increase towards 0) represents a 
decrease in the probability at a slower rate than the previous age. Predicted from a logistic regression model 
including country, three restricted cubic spline variables for age, stage, comorbidity level, sex, and relevant 
interactions between these factors. Resectional surgery defined as surgery to remove the primary tumour within 
9 months of diagnosis, excluding diagnostic and palliative procedures. 
 
3.3.4 Discussion 
After accounting for comorbidity, patients in England, especially older ones, were less likely 
to undergo resectional surgery for non-metastatic rectal cancer than patients with similar 
disease stage and age in Denmark. The difference in the probability of receiving potentially 
curative surgical treatment between the countries increased with increasing comorbidity 
level, disease stage and age. These findings suggest that although comorbidity is an 
important determinant of treatment, it does not fully explain the differences in the 




Comorbidity is an important determinant of cancer outcomes through different mechanisms. 
Patients who have frequent contact with the healthcare system to control their chronic 
condition(s) may be monitored more closely and have their cancer diagnosed at an earlier 
stage than patients with no regular contact with healthcare.160,161 In contrast, certain chronic 
conditions, such as diabetes, renal disease, and dementia, may hinder early cancer diagnosis 
by masking some of its associated symptoms.160,162 Furthermore, serious concomitant 
chronic conditions may contraindicate procedures to diagnose, stage and treat cancer. 
Several studies have found that comorbidity affects cancer outcomes, potentially in relation 
to lower probability or receiving potentially curative treatment.59,83,124,160 
As expected, in the analysis, comorbidity, age, and stage at diagnosis were important 
determinants of receiving resectional surgery for rectal cancer in Denmark and in England, 
however, the magnitude of the effect of these factors varied between the countries, shown 
by the significant interactions (judged using the likelihood ratio test) between these factors 
(comorbidity, age and stage) and the variable ‘country’. For each stage and age, the predicted 
probability of receiving treatment in Denmark between patients with no record of 
comorbidity and those with a low CCI score (1-2) was similar. In contrast, the predicted 
probability of receiving surgery for patients in England was substantially lower in patients 
with low CCI score (1-2) than those without comorbidity, even in patients with stage I 
disease. The decline in the probability of receiving surgery with increasing comorbidity in 
England was especially pronounced for older patients.  
There have not been many population-based studies examining the role of comorbidity in 
explaining cancer treatment and survival, because this information is not traditionally 
collected in national cancer registration, and potentially because of comparability issues. A 
recent ICBP study examined the role of comorbidity in explaining differences in lung cancer 
survival between nine jurisdictions in Australia, Canada, Norway and the UK using national 
cancer registry data linked to secondary care records. They compared three measures of 
comorbidity (Charlson, Elixhauser, and the total number of in-patient days), focusing on the 
first six diagnostic codes made in the 4-36 months previous to the cancer diagnosis. Overall, 
they found these comorbidity measures to have  good “face validity” (“degree to which the 
indicators evaluated  the construct of comorbidity they purported to measure”),163 however, 
they had little predictive validity in 1-year survival models. They judged the reliability of the 
indices (“the extent to which the indices measured a stable phenomenon across 
populations”),163 by comparing age-standardised prevalence rates of the indexed conditions, 
which they found to vary substantially between jurisdictions. Researchers concluded that 
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they were not able to quantify the level of comparability of these indices between 
jurisdictions due to differences in coding practices, and called for further efforts in 
standardising data collection practices.163 Although it is not entirely clear which comorbidity 
measure is ideal for international comparisons of population-based cancer outcomes, the 
CCI is a frequently used measure in epidemiological research, as it can be feasibly and reliably 
derived from secondary care records.83,124,163 
The Charlson Comorbidity Index was proposed in 1987 as a method to predict mortality risk 
in longitudinal studies.61 The CCI scores common chronic conditions based on their 
associated age-standardised relative risks of death at one year (obtained from a cohort of 
hospitalised patients in 1984 in the US); the scores are then added to obtain a composite 
index.61 The CCI has the major advantage of being easily applicable to routinely collected, 
administrative hospital data, thus it is frequently used because of its simplicity and 
reproducibility.124,164 However, the simplicity of the CCI is also a source of criticism because 
its additive nature assumes that there is no synergy or interactions between the different 
chronic conditions included. Another critique of the CCI is that some of the conditions 
included have improved prognosis since the index was developed.  A particular concern is 
that HIV/AIDS is given the same score (6) as a metastatic solid tumour, although the 
prognosis of treated HIV is much better than what it was in the 1980s, and better than most 
metastatic solid tumours.  
In a 2010 study, researchers adapted the CCI to the largest longitudinal primary care 
database, the UK-based General Practice Research Database (GPRD; nowadays called Clinical 
Practice Research Datalink, CPRD) to examine its relationship with mortality. They found a 
significant association between the derived CCI and 5-year mortality, and concluded that  the 
CCI was a good discriminator of mortality.165 Authors argued that the issue of HIV having 
better prognosis was unlikely to affect their results because of the low prevalence of the 
disease in the data (8 HIV cases in a sample of over 145,000 individual patient records).165 
Their findings are consistent with another study comparing the performance of the CCI 
between English primary and secondary care records (from CPRD and HES, respectively), 
which found that with either source of information, the CCI had ‘excellent performance’ in 
predicting mortality at one and five years of follow-up.166 In a different discussion on the 
weight of HIV for the CCI, researchers argued that inaccurate results are more likely in 
populations with a high prevalence of HIV/AIDS, and suggested the HIV weight for the CCI 
should be reassessed in such cases.167 In the CRC population included in this analysis, there 
were 3 HIV cases in England (out of 18,208 patients, and out of 45 with a CCI ≥6). The 
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corresponding figure for Denmark is not available as I had access to the composite CCI score 
rather than to individual diagnoses, but judging by the proportion of patients with a CCI ≥6 
(29 out of 2,887), it is sensible to conclude that HIV prevalence in this population was also 
very low. Therefore, despite the known issue with the weight of HIV/AIDS, it is likely that the 
CCI is a valid discriminator of mortality risk in the study population.  
Alternative measures of disease severity may be better predictors of mortality than the CCI. 
For instance, the Acute Physiology and Chronic Health Evaluation (APACHE) II, generally used 
in critical care, is  a better discriminator of in-hospital mortality than the CCI, as it uses twelve 
physiological measurements (including arterial pH, heart and respiratory rate, serum sodium 
and potassium, among others), rather than individual chronic diagnoses.164 The additional 
resources needed to derive physiology-based scores, however, prevent its use in population-
based research,164 making the CCI the best, and frequently the only, measure of comorbidity 
available for research.  
The prevalence of comorbidity was lower in England than in Denmark overall and in each age 
group, and under-ascertainment of diagnoses from secondary care records cannot be 
excluded. To minimise the issue of comparability of different degrees of comorbidity, and of 
potential under-ascertainment of comorbidity diagnoses, the first part of the analysis was 
restricted to patients with no evidence of comorbidity. Then, I carried out a sensitivity 
analysis for misclassification of the comorbidity status in patients in England who did not 
receive surgery. The findings were robust even to the quite extreme scenario I used in the 
sensitivity analysis, suggesting that there is indeed a difference in the proportion treated, 
after accounting for comorbidity differences. Furthermore, the higher prevalence of 
comorbidity (including some conditions which are affected by similar risk factors as 
colorectal cancer) is consistent with the higher incidence of colorectal cancer in Denmark 
than in England and the UK. 
Norway and Sweden were also included in our Lancet Oncology paper (Section 3.2), but I was 
not able to include them in the analysis adjusting for comorbidity because comorbidity 
information was not available in their respective specialised registries without additional 
linkage to secondary care records (impossible within the timeframe of this study). 
Nonetheless, the comparison between Denmark and England is particularly relevant. 
Historically, both countries have had poorer cancer outcomes than Norway and Sweden.3 
Recent reports have shown that cancer survival in Denmark is now closer to that in Norway 
and Sweden; whereas cancer survival in England, though improved, still lags behind.1,156 The 
paper presented in Section 3.2 included both colon and rectal cancer patients, however 
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these subsequent analyses by comorbidity status did not include colon cancer patients 
because of the high proportion of patients without a DCCG.dk record and therefore with 
missing information on comorbidity and surgical status (more than twice as many as rectal 
cancer patients). This missing information would have added substantial uncertainty around 
the estimates, precluding a fair comparison of treatment status by age, stage and 
comorbidity. 
In England, surgical specialties have periodically reported outcomes for individual 
consultants and hospitals since 2013. The clinical outcome publications include case 
numbers and 90-day mortality for patients undergoing elective colorectal cancer surgery by 
surgeon and hospital. Additional surgical outcomes are reported in specific annual reports, 
for instance, unplanned 30-day readmissions in the 2016 report, and positive circumferential 
rectal resection margin rate in the 2018 report. None of these measures/targets, however, 
monitor that patients eligible for potentially curative treatment are actually receiving it. 
Moreover, there is some debate on whether the publication of surgeon-specific outcomes 
encourages risk-adverse behaviour from surgeons, even while they may facilitate informed 
decision-making for patients.168  A recent examination at the potential issue of “gaming of 
clinical data” found no evidence of decrease in the overall proportion undergoing bowel 
resection, nor in the 90-day mortality rates (adjusted for patient characteristics) after the 
public reporting of surgeon-specific outcomes.168 Results were not shown by substrata of 
patients, and although the overall figures remain constant, it is possible that high-risk 
patients (e.g. older, and with multiple morbidity) may be affected by risk-adverse behaviour 
prompted by such reporting. Concerns exist about the challenging task of correctly 
identifying poor performance at surgeon level when the numbers of specific procedures per 
surgeon are low, and so would be the statistical power to detect outliers; hence, the lack of 
evidence of poor performance would not necessarily indicate good performance.169 Others 
have pointed out how the (over-)emphasis on the role of individual surgeons on patient 
outcomes disregards the importance of the complex interaction between several factors, 
including the organisational culture,170 perioperative care, support from other health 
professionals, and the communication between them.171,172 
Wider health system factors may be particularly important for older cancer patients: even 
with best intentions, clinicians may be reluctant to indicate aggressive treatment to patients 
if adequate postoperative care and social support are unavailable.  
Anastomotic leakage, the most severe complication following colorectal resectional surgery, 
is associated with high morbidity and mortality.173-175 Reported risk factors include malignant 
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disease, emergency surgery, high ASA score, and old age, among others.176 Prevention of this 
complication is somewhat elusive, but its early detection is key to minimise its negative 
consequences.174,175 Close follow-up in the immediate postoperative period is thus essential 
to detect anastomotic leakage in the pre-clinical phase, for instance by observation of 
changes in the drainage fluid, biochemical parameters of systemic reactions (such as C-
reactive protein) and by prompt access to radiographic tests.174,176,177 A close follow-up in the 
postoperative period is also key to ensure hemodynamic stability, and to avoid medical 
complications following abdominal surgery.178   
A national, population-based study of postoperative mortality after colorectal cancer surgery 
in England found a decrease in postoperative mortality from 6.8% to 5.8% between 1998 and 
2006 (5.8% after elective surgery, and 14.9% after emergency surgery during the whole study 
period), and significant variation between NHS hospitals, after accounting for different 
patient and tumour characteristics.179 A single-centre study of postoperative mortality in 
patients undergoing emergency laparotomy in Bath found that patients admitted to critical 
care and high dependency units had lower short-term mortality than those sent to the 
standard post-anaesthesia unit.180 The study authors note that there was no lack of critical 
care beds in their institution during the study period, and that the decision on postoperative 
care was made solely on clinical grounds (though often based on incomplete patient 
history).180 In England, however, the (lack of) availability of critical care beds for non-cardiac 
surgery has been highlighted as a problem affecting surgical outcomes.181-183 A 2011 
investigation on short-term mortality in patients aged 75 years and older after colon cancer 
surgery in England found wide variation in adjusted 30-day mortality between NHS Trusts.184  
They reported increased odds of early mortality with increasing age (after adjusting for 
comorbidity, sex and surgical approach); and decreased odds of early mortality with the 
laparoscopic approach.184  Although authors did not investigative the effect of postoperative 
care directly, they argued that institutional differences in the use of intensive care and 
geriatric services could be behind the differences in early mortality between Trusts.184 A 2006 
study using data from the Intensive Care National Audit & Research Centre database in the 
UK found that less than 15% of ‘high risk’ surgical patients (mainly older, with coexisting 
chronic conditions) had been admitted to intensive care units following surgery, and 
accounted for 80% of the deaths, though represented only 12.5% of the surgical 
population.183  
In recognition of unsatisfactory levels of care after emergency surgical admissions, the 
Emergency Laparotomy Network and audit (NELA) was established in 2010 in England.178 In 
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its first report, authors acknowledged that surgical mortality is influenced by the hospital’s 
ability to recognise and manage complications, and that this likely to be better done in a 
critical care unit than in a standard ward.178 Authors also found that when requested, a 
critical care bed was available most of the times, however, the rate of referral appeared 
“inappropriately low”, given the high postoperative mortality.178  
Postoperative mortality in Denmark has been reported to be higher than in Norway and 
Sweden, and more similar to that in England.185 Between 2001 and 2011 Denmark saw an 
important decrease in postoperative mortality following elective colorectal cancer surgery 
from 7.3% to 2.8%186 (a larger decrease than the one reported for England between 1998 
and 2006).179 The laparoscopic surgical approach has been associated with the reduction in 
mortality following colon cancer surgery (it was used in over 65% of colon cancer surgery in 
2015).186,187 A study of CRC diagnoses in Denmark during 2001-2004 found a wide variation 
in 30-day postoperative mortality (3.5-44.1%), with the odds of death 4.6 times higher in 
emergency patients, and 5.8 times higher in patients with high ASA score; authors argued 
that the hospitals’ ability to manage these patients were behind the institutional variation in 
postoperative mortality.188 A 2014 study found that mortality following an emergency 
surgery remained high (18.5%).189 A failure to recognise complications early, and inadequate 
level of care (admission to standard ward followed or not by critical care unit admission) 
were found as determinants of postoperative mortality.189 A more recent analysis of 
postoperative mortality in Denmark (2005-2015) reported further decreases in 90-day 
postoperative mortality during the study period (from 31% to 24%).190 Proposed 
explanations of reductions in postoperative mortality following CRC surgery in Denmark 
include improvements in the organisational structures (such as centralisation of surgery in 
specialised centres), perioperative optimisation and use of laparoscopic surgery.71,186 
A 2010 review of the global burden critical illness in adults reported a lower number of ICU 
beds per 100,000 population in the UK (3.5) than any of the other European countries 
included (such as Sweden, 8.7; Spain, 8.2; and Germany, 24.6), and lower than other  
developed countries such as Australia (8.0) and Canada (13.5).191 After non-cardiac surgery, 
patients are generally admitted to a standard post-anaesthesia unit, then transferred to 
critical care units if complications develop.189,192 However, access to critical care may well 
vary (within and) between countries. In England, there is extreme variation in the planned 
used of critical care following colorectal surgery (from 0 to 97% of patients undergoing 
colorectal surgery after an emergency admission) between CCGs.193 Access to ICU following 
colorectal cancer surgery in the English NHS varies by institution (personal communication 
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with colorectal surgeon Michael Machesney). Furthermore, access to critical care beds for 
colorectal cancer patients may depend not only on the number of beds available but also on 
the overall number of patients undergoing non-cardiac surgery at a given institution. In 
Denmark, on the other hand, specialised centres in which elective colorectal cancer surgery 
is performed generally have access to ICU when deemed necessary (personal communication 
with colorectal surgeon Professor Lene H. Iversen). 
It is possible the unavailability of adequate postoperative care for older colorectal cancer 
patients is more of a problem in England than in the Scandinavian countries, and that this 
may help explain why older patients in England, and those with comorbidities are less likely 
to receive resectional surgery than those in Scandinavian countries. 
It is also possible that, although clinical guidelines generally recommend surgery, older 
patients receive other treatment modalities instead of surgery (chemotherapy and/or 
radiotherapy, and palliative care) to avoid operative risk and minimise complications, 
especially in those with multimorbidity. The data on chemotherapy and radiotherapy was 
not sufficiently complete in all the datasets to allow a fair comparison between countries.128 
More recently, there have been efforts to improve the registering of those data in the 
specialised CRC registries, and/or dedicated datasets for these treatment modalities, like the 
Radiotherapy Dataset194 and the Systemic Anti-Cancer Therapy Dataset195 in England. Future 
research should exploit these additional data sources to explore further this issue and 
compare stage-specific outcomes across age groups by treatment modality.  
Along with health system factors, negative perceptions of ageing influence patients’ health 
behaviour, their expectations of care, and potentially, the clinical decision-making. So-called 
‘therapeutic nihilism’, where clinicians and/or patients believe that treatment is of little 
value, may be more prevalent when evaluating older cancer patients, whose life expectancy 
is (often wrongly) considered to be short.196 Negative perceptions of old age are likely 
perpetuated by the findings of poor operative outcomes in older patients (partly, a result of 
inadequate postoperative care), thus potentially creating a vicious cycle that results in older 
patients not receiving surgery, and having poor cancer outcomes.  
Provided that adequate postoperative care is available, cancer outcomes may be improved 
by increasing access to – and the proportion of patients receiving – potentially curative 
treatment, which for many cancers including colorectal tumours, is surgery. In England, 
improved patient outcomes though improved access to surgery has already been 
documented for lung cancer.197 Analyses of the National Lung Cancer Audit data have shown 
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a wide variation (by socioeconomic status, geographic location and age) in resection rates 
and lung cancer survival in England.198,199  
Potential explanations of the age inequalities in cancer management in England, such as 
frailty, the availability and use of adequate perioperative care, and attitudinal factors 
deserve closer examination. Recent data streams such as clinical audits and patient-reported 
outcomes offer the possibility to explore some of these issues further. 
3.4 Study implications and link to Chapter 4 
Surgery is the cornerstone of colorectal cancer management both for curative and palliative 
purposes. There are however differences in the proportion of patients receiving resectional 
surgery in each stage of disease, with a sharp decline in the proportion treated with 
increasing age in England, the country with poorest colorectal cancer survival in comparison 
with Denmark, Norway and Sweden. The sharp decline in the proportion of patients receiving 
resectional surgery with increasing age was not as marked in the comparator countries. So, 
why are older cancer patients in England less likely to receive resectional surgery than those 
in Denmark, Norway and Sweden? Despite some differences in clinical guidelines, indications 
for surgery are highly comparable between the countries, and in none of these is 
chronological age a contraindication for surgical treatment. A plausible explanation of the 
differences found is varying levels of comorbidity, and its associated risk of perioperative 
mortality, between the countries. However, the differences in the proportion of patients 
treated (between Denmark and England) were still evident even after excluding patients with 
comorbidity. Residual confounding due to misclassification of comorbidity status is possible, 
however, after a sensitivity analysis for misclassification of comorbidity, the difference in the 
proportion treated in the older age groups was still evident. Furthermore, the predicted 
probability of receiving resectional surgery in England was lower than in Denmark at 
comparable levels of comorbidity, especially in the older ages. The findings suggest that, 
although important, comorbidity alone does not explain the deficit in the proportion treated 
in England in comparison with Denmark. Differences in the postoperative care may explain 
some of the differences in the management of colorectal cancer in older patients.  
Further research should look into the role of additional treatment modalities in explaining 
the lower proportion of older patients in England receiving resectional surgery. Although 
chemotherapy and/or radiotherapy are generally indicated along with rather than instead of 
surgery, it is possible that these treatments are being indicated to replace surgery in order 
to minimise complications and mortality risk. Additional datasets from England would 
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provide more detailed information on radiotherapy (National Radiotherapy Dataset, RTDS)194 
and on chemotherapy (Systemic Anti-Cancer Therapy Dataset, SACT).195  
Potential follow-up work should include closer examination and comparison of 
postoperative care, early mortality, postoperative complications and failure to rescue, by 
different characteristics including age, comorbidity, and urgency of admission. Such 
comparison may shed light into understanding whether and how perioperative care may be 
improved to improve cancer outcomes. 
The findings presented in this chapter justify closer examination of the age disparities in 
cancer management within England because the underlying causes of under-management 
of cancer in older patients are not obvious. Comorbidity and its associated risk of 
perioperative mortality and complications may be a mechanism by which older patients are 
less likely to have optimal management than their younger counterparts in England, and 
elsewhere. Moreover, older cancer patients and those with multimorbidity are more likely 
to be diagnosed following an emergency admission. Colorectal cancer patients who present 
to secondary care as emergencies (because of bowel obstruction, bleeding, and/or 
perforation, for instance) have worse outcomes than patients diagnosed through elective 
routes. They are frequently in a poor acute health status, which may impede them to 
undergo optimal investigation and treatment. The following chapter focuses on exploring 
these factors – comorbidity and the diagnostic route – and their contribution as mechanisms 
behind the age difference in the likelihood of having an incomplete diagnostic investigation 
and potentially curative surgery for colorectal cancer in England, after accounting for 
differences by sex and socioeconomic status.  
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Chapter 4: Exploring health status and emergency presentation 
as mechanisms behind the age inequalities in colorectal cancer 
management in England 
4.1 Introduction 
In Chapter 3 of this thesis, I showed that the age differences in the receipt of surgical 
treatment were not as evident in Denmark, Norway and Sweden, as they were in England, 
and that these differences were unlikely to be explained by differences in the prevalence of 
comorbidity, at least between Denmark and England. I argued that these differences in 
management may explain partly the “survival gap” between England and the Scandinavian 
countries. 
In this chapter, I explore in more detail the age differences in the probability of receiving 
adequate management of colorectal cancer within England. According to current clinical 
guidelines, diagnostic and staging investigations should be offered to all colorectal cancer 
patients, unless procedures are contraindicated by ‘major comorbidity’.41 If true, the age 
differential in the completeness of staging investigation should be mostly explained by age 
differences in prevalence of comorbidity. Major comorbidity may contraindicate surgical 
treatment due to increased perioperative risk. The diagnostic route may also influence cancer 
care and outcomes. Patients diagnosed with cancer through an emergency admission usually 
have a poor acute health status at diagnosis, and are less likely to be fully investigated and 
treated. 37,38 
In the work presented in this chapter, I use causal mediation analysis to examine and 
disentangle some of the underlying mechanisms underpinning age differences in the 
management of colorectal cancer patients in England. The paper presented in the next 
section (4.2) examines age inequalities in the completeness of diagnostic and staging 
investigation, and the extent to which these age differences are explained by comorbidity 
and the diagnostic route (emergency presentation or not). The following section (4.3) focuses 
on the age inequalities in the receipt of potentially curative surgery for stage I-III colorectal 





4.2 Age variation in the completeness of diagnostic and staging investigation 
for colorectal cancer 
This section addresses objective 4 of this research degree project, which is to examine the 
effect of age on receiving a complete diagnostic and staging investigation for colorectal 
cancer and to explore how this relationship is mediated by comorbidity and the diagnostic 
route in England. The research for this section has been reported in the paper entitled 
“Exploring age variation in colorectal cancer diagnostic and staging investigation in England 
using mediation analysis”, which was submitted for peer-review to the European Journal of 
Epidemiology in March 2019. 
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Older cancer patients often have fewer staging investigations and inferior treatment compared to 
younger patients. This suboptimal cancer management is commonly attributed to the increased 
likelihood of an emergency presentation, and to comorbidity, which is more prevalent in older patients 
and may contraindicate some medical interventions. We aim to quantify how far the age disparities in 
completeness of diagnostic and staging investigations for colorectal cancer (CRC) are explained by 
patients’ health status and their diagnostic route (emergency or not). 
Methods 
We obtained information on colon and rectal cancer patients diagnosed in England during 2010-2012 
from population-based cancer registry records. Staging investigations and comorbidities in the six years 
before the cancer diagnosis were derived from the National Bowel Cancer Audit and Hospital Episodes 
Statistics datasets. A counterfactual-based mediation analysis, allowing for multiple mediators, was 
used to quantify the proportion of the age effect on staging investigations mediated by health status or 
diagnosis route. A novel sensitivity analysis technique for multiple mediators was developed to assess 
the robustness of the findings against unmeasured confounding. 
Results 
Around half of patients had complete staging investigations. For colon cancer, there was a J-shaped 
association with patients aged 60-69 years being the least likely to have an incomplete DSI. The risk of 
an incomplete DSI in rectal cancer patients increased linearly with age. The age-investigation 
association was barely mediated by health status, but was partly mediated by being diagnosed through 
an emergency route. Overall, an important proportion of the age differential was not mediated by these 
factors, particularly in older patients. These findings were robust to strong degrees of unmeasured 
confounding of the relationship between the diagnostic route and having complete staging 
investigations. 
Discussion 
Colorectal cancer patients’ health status and diagnostic route did not fully explain the age differential 
in the completeness of staging investigations, contradicting prevailing beliefs. Findings suggest the 
important role of decision-making based on chronological age in investigation completeness. Age-
related inequalities in cancer management seem to occur as early as at the diagnostic and staging 
investigations phases. Clearer recommendations should be included in the clinical guidelines for the 




Cancer is an important contributor to disease burden in older people [1]. It is estimated that by 2030, 
76% of cancers in men and 70% in women will occur in people over the age of 65 years [2]. Nonetheless, 
older cancer patients are known to have fewer diagnostic and staging procedures, less evidence-based 
treatment, and worse cancer outcomes than younger patients [1].  
Colorectal cancer (CRC) is generally diagnosed through referral from primary care, screening, or after 
an emergency admission. In England, a cancer-specific referral route (two-week wait route, TWW) was 
introduced in the 2000s to hasten referral for suspected cancer to secondary care and avoid delays in 
diagnosis [3]. The National Bowel Screening Programme, rolled-out in 2006, offered biennial faecal 
occult blood testing (FOBT) to people aged 60-69 years, and was extended up to age 74 years in 2009 
[4, 5]. Despite its national coverage, uptake is reportedly low [6]. Patients diagnosed through emergency 
admissions (about a third and a sixth of colon and rectal cancer patient populations, respectively)  
frequently have poorer health at the time of diagnosis, are less likely to receive potentially curative 
treatment, and generally have poorer survival than patients diagnosed through other routes [7, 8, 9]. 
Once in secondary care, patients are investigated to exclude or confirm a CRC diagnosis, usually with 
colonoscopy or flexible sigmoidoscopy [10]. If the CRC diagnosis is confirmed, patients undergo further 
investigations to determine the extent of disease, described by TNM (tumour/node/metastases) stage, 
and to plan for optimal management. TNM stage is a combination of clinical stage, determined by 
physical examination and imaging procedures, and pathological stage of the primary tumour and 
regional lymph nodes, usually established during (generally therapeutic) surgery. Figure 1 summarises 
the patient pathway to CRC diagnosis and staging. 
Suboptimal cancer management and poorer outcomes in older cancer patients are often presumed to 
relate to their comorbidity and/or frailty (‘biological age’), and how this affects their options for effective 
treatment and their recovery from it [11, 12]. There are concerns, however, that the age differential in 
patient care and outcomes may be partly due to clinical decision-making based primarily on 
chronological age [13]. 
A complete investigation is essential for determining optimal treatment. According to current English 
clinical guidelines, diagnostic and staging investigations should be offered to all CRC patients, unless 
procedures are contraindicated, usually by ‘major comorbidity’ [10]. If this is true, the age differential 
in the completeness of staging investigation should be mostly explained by differences in comorbidity, 
and potentially, the diagnostic route (emergency or non-emergency), between age groups. Disentangling 
these underlying mechanisms is crucial to improve cancer management and outcomes.  
In this study we aim to examine the mechanisms behind age differences in the completeness of 
diagnostic and staging investigations in England, and to explore the role of patients’ health status and 
route to diagnosis using counterfactual-based mediation analysis. 
Materials and methods 
Data sources and variables 
All colorectal cancer patients aged 15-99 years diagnosed in England during 2010-2012 and recorded 
in the national cancer registry were included. Individual tumour records were linked to the National 
Bowel Cancer Audit (NBOCA) data [14], Hospital Episodes Statistics (HES) [15], and the Routes to 
Diagnosis monitoring dataset (RtD) for additional clinical information [8]. A binary variable was used 
to classify patients as having been diagnosed through an emergency presentation (EP) or not. Age was 
categorised into six groups: 15-49, 50-59, 60-69, 70-79, 80-89 and 90-99 years. We used the 60-69 age 
category as the reference for analysis, as this would include people eligible for CRC screening.  
We developed an algorithm to obtain information on diagnostic and staging investigations (DSI) 
performed within three months of the cancer diagnosis from NBOCA and HES records. The HES dataset 
contains information on in-patient, out-patient, and Accident & Emergency (A&E) diagnoses, and 
medical procedures performed within the English National Health Service (NHS). It uses the OPCS 
Classification of Interventions and Procedures 4.7 [16], an NHS Fundamental Information Standard for 
the classification of interventions and procedures performed in NHS hospitals in England. Codes for 
DSI procedures were identified. In cases of multiple codes for the same procedure in a single patient, 
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priority was given to those considered more precise (for instance ‘Diagnostic endoscopic examination 
of lower bowel and biopsy of lesion of lower bowel using fibreoptic sigmoidoscope’ was preferred to 
‘Unspecified endoscopic examination of lower bowel using fibreoptic sigmoidoscope’), and those 
performed closest to the cancer diagnosis date. Information on procedures was summarised into several 
categories: chest tomography, abdominal tomography, pelvic tomography, pelvic magnetic resonance 
imaging, colonoscopy, and CT colonography [10].  Information derived from HES was then 
complemented with data from NBOCA. This information was summarised into a binary indicator 
showing whether or not a ‘complete’ staging investigation was conducted, following definitions from 
NICE guidelines for CRC management [10]. For colon cancers, ‘complete’ was defined as having a 
colonoscopy or barium enema or CT colonograph, and CT scans of chest, abdomen and pelvis. Pelvic 
MRI was added to the definition for rectal tumours. 
Information on TNM stage at diagnosis was derived from NBOCA and National Cancer Registry 
records using an algorithm previously described [17]. Information on comorbidity was extracted from 
HES records using an algorithm developed by Maringe et al [18]. Chronic conditions diagnosed or 
treated within the secondary care setting up to six years before and up to the date of the CRC diagnosis 
were included. Individual conditions included ischaemic heart disease, heart failure, stroke, peripheral 
vascular disease, peptic ulcer, chronic kidney disease, chronic obstructive pulmonary disease, chronic 
liver disease, diabetes mellitus, dementia, para/hemiplegia, human immunodeficiency virus infection, 
obesity and previous cancer. The information was used to derive the Charlson Comorbidity Index (CCI) 
[19]. Information on metastatic disease (stage IV) and comorbidity were summarised into a binary 
variable ‘health status’ (good: no comorbidity, non-metastatic CRC; poor: Any comorbidity and/or 
metastatic CRC). 
Socioeconomic status of patients at the time of the CRC diagnosis was represented by the income 
domain of the Index of Multiple Deprivation of the Lower Layer Super Output Area (LSOA) of 
residence, categorised into five categories of deprivation according to the quintiles of the national 
distribution of the LSOA-level deprivation scores.  
Statistical analysis 
Mediation analysis was used to examine and disentangle the underlying mechanisms of the relationship 
between age (X) and the completeness of diagnostic and staging investigations (Y). It consists of 
splitting the total effect of the main exposure on the outcome into direct (not mediated) and indirect 
(mediated) effects through one or several mediating variables (mediators).  
Health status and EP are considered as potential mediators of the effect of age on having an incomplete 
DSI, with health status also potentially mediating the relationship between age and EP. The causal 
diagram of Figure 2 shows the assumed causal relationships between relevant factors. 
We used causal mediation analysis to decompose total effects into indirect and direct effects in the 
presence of interactions and non-linearities [20], which are common in complex scenarios like this one. 
Direct and indirect effects were defined as average contrasts between the outcomes of the study 
participants in different age groups under different hypothetical interventions on the mediator(s), as 
explained below. 
In the counterfactual-based mediation analysis below, we decompose the average difference in DSI 
between study participants in a given age group and participants with the same distribution of sex and 
deprivation in the reference age group (60-69). We refer to this as a total effect (TE), and decompose it 
into a direct and indirect effect. We define the direct effect (DE) of age on the outcome as the average 
risk difference of seeing the outcome between a given age group and the reference (60-69) if, for all 
patients, the health status and emergency presentation status were set at a fixed subject-specific level, 
randomly drawn from the distribution of these variables for reference patients of the same sex and 
deprivation status. 
The indirect effect (IE) of age on the outcome is defined as the change in risk of seeing the outcome in 
the given age group if, for all patients in that group, the distribution of health status and emergency 
presentation status are shifted from how it is in reference patients to how it is from patients of the same 
gender and deprivation status in the considered age group. 
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We further decompose the IE into “path-specific” effects through each of the mediators (health status - 
Ma, and EP - Mb). The path-specific effect via health status represents the effect that may arise when 
age influences health status, which may then in turn affect the outcome (either directly, or by influencing 
EP). It is denoted IEa. The path-specific effect via Mb represents the effect that may arise when age 
directly influences the risk of emergency presentation (and not mediated via health status), which may 
then in turn affect the outcome. It will be denoted IEb. These effects, which add up to the IE, were 
estimated along with the DE using a parametric g-computation procedure, as described by Daniel et al 
[21]. To do this, we first modelled each of the mediators and the outcome using multivariate logistic 
regression: 
- Health status was modelled as a function of age, deprivation quintile, sex and any interaction(s) 
that were significant at the 10% level. 
- EP status was modelled as a function of health status, age, deprivation quintile, sex and any 
interaction(s) that were significant at the 10% level. 
- Completeness of diagnostic and staging investigation was modelled as a function of 
emergency presentation status, health status, age, deprivation quintile, sex and any 
interaction(s) that were significant at the 10% level. 
Using the resulting models, we simulated the outcomes for each one of the hypothetical scenarios 
compared in the definitions of the IE, DE and TE, as well as the definitions of the path-specific effects, 
in temporal order. For instance, to estimate IEb, we used the above models to simulate for each subject 
what the health status, emergency presentation status and outcome would be if that subject had a 
particular age different from the reference level (age 60-69). We next simulated for each subject what 
the emergency presentation status would be if that subject’s age were at the reference level, but their 
health status was as simulated before. We then simulated what the outcome would be for that subject if 
they had the particular age (different from the reference level), the health status that was previously 
simulated, and the emergency presentation status that was newly simulated. The average contrast 
between these two simulated outcomes for each subject then represents IEb. Standard error and 
confidence intervals were estimated using 10,000 non-parametric bootstrap samples. Results from 
iterations were averaged to obtain point estimates. 
Like all mediation analyses, the above estimation procedure relies on untestable assumptions. These 
are unavoidable because we conceptualise the effect on an outcome of shifting the distributions of health 
status and emergency presentation, and these effects may be confounded [20]. 
In particular, the assumptions that we invoked, are: 
- Positivity: each health status and emergency presentation status can be observed at every level 
of the confounders. This is required to avoid having subgroups of the study population where 
everyone has the same health status or emergency presentation status, in which case the data 
carry no information about the effects of mediator on outcome [22]. 
- No interference: A patient’s DSI status is not affected by the health status or emergency 
presentation status of other patients. 
- An additional assumption of no unmeasured confounding between mediators and outcome 
(Um-y), shown in the causal diagram of Figure 2, is needed to identify the partitioned (or path-
specific) effects. 
Missing data on health status and emergency presentation status were handled using single stochastic 
imputation with chained equations, and compared against results from the complete-case analysis. A 
single imputation was sufficient, since the imputation procedure was also evaluated as part of the 
bootstrap procedure. Imputation models for health status and EP included the variables and interactions 
in the prediction models listed earlier, plus the outcome (DSI status) and the Nelson-Aalen estimator of 
the cumulative hazard rate function, evaluated at the observed event time. All analyses were carried out 
using Stata version 15 [23].  
Sensitivity analysis for unmeasured confounding 
The assumption of no unmeasured confounding (Um-y) between the mediator(s) and the outcome may 
well be violated [24]: Um-y may induce bias in the estimate of the DE since adjusting for the mediator 
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then introduces a spurious association between age and Um-y (and thus also the outcome) and results in 
what is called collider bias. 
In view of this, we developed a novel sensitivity analysis technique that can be used in combination 
with the g-computation strategy, even with multiple mediators. We used it to test the robustness of the 
findings against unmeasured confounding of the relationship between the mediator(s) and the outcome. 
We focus the sensitivity analysis on the relationship between the second mediator (EP) and the outcome, 
because we expect stronger confounding of the association between the cancer diagnostic route and 
investigations than between patients’ health status and the cancer investigations. Nevertheless, this 
technique can be extended to multiple mediators. In our analysis, we expect there is unmeasured 
confounding by one or several quality measures of cancer services in secondary care (U), which may 
determine both the diagnostic route (EP) and having a complete investigation (Y). For instance, 
hospitals without sufficient resources to meet demand may be incapable of offering adequate and timely 
staging investigations to diagnosed CRC patients; and may also be unable to offer timely outpatient 
appointments for suspected cancer, leading to more diagnoses being initiated through emergency 
admissions. 
The sensitivity analysis invokes three unknown sensitivity parameters that express the strength of the 
association between U and the relevant mediator (parameters λ0 and λ1), and between U and Y 
(parameter β). Assuming different strengths of associations between U, M and Y, we compared the 
findings with the original ones assuming no unmeasured confounding.  
The hypothetical variable U may be a vector of quality measures of secondary care, with higher U 
meaning better quality of care. Without loss of generality, we let U have mean zero. We moreover let 
U have variance of 1, conditional on X (age group), Mb (emergency presentation), and C (deprivation 
group, sex, and health status), in order to fix the scale (and thereby the meaning of the sensitivity 
parameters). We further assume that U is independent of X and C.  
We performed the analyses under different scenarios, with varying strengths of association between U 
and Mb (parameters λ0 and λ1), and between U and Y (parameter β), where: 
- β represents the strength of association between U and the outcome, on the log-odds ratio scale. 
- λ0 represents the risk difference of U between non-emergency presenters (Mb=0) and 
emergency presenters (Mb=1) in the reference age group (60-69 years). 
- λ0 + λ1 represents the difference in the probability in being treated in a hospital with good 
quality of care between non-emergency and emergency presenters, in the other age categories. 
We foresee that a larger probability of being treated in a ‘good’ hospital (U) is associated with a lower 
probability of having an incomplete investigation (Y). On the β scale, that means that we would expect 
β to be lower than 0, which would correspond to an odds ratio for the association between U and 
outcome below 1. In other words, we would expect patients in ‘good’ hospitals to be less likely to have 
incomplete investigations. The further away β is from 0, the stronger the association between U and Y. 
A β value of 0 implies that U is not associated with Y and that there is hence no unmeasured 
confounding. 
Because they are defined on the risk difference scale, both λ0 and λ0 + λ1 lie between -1 and 1, though 
it is unlikely that they would take these extreme values. Following the same logic as for β, λ0 and λ0 + 
λ1 are likely positive, as we can assume that non-emergency presenters are more likely to be managed 
in ‘good quality’ hospitals than emergency presenters. Given that likely positive direction of 
association, the most extreme difference would be that non-emergency presenters are all managed in 
‘good’ hospitals while all emergency presenters are managed in ‘bad’ hospitals in the unexposed, that 
is λ0=1.  
We would expect λ0 to be somewhat larger than λ0 + λ1, assuming that the main exposure (age) might, 
although not necessarily, have played a larger role in the latter. A λ1 value of zero would mean that the 
risk difference of U between non-emergency presenters and emergency presenters was the same in all 
age groups.   
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In summary, some combinations of the sensitivity parameters that would reflect a very strong 
confounding effect of U on the association between Mb and Y are:  
- β = -0.5: People treated in a good quality hospital had a 39.9% smaller odds of having an 
incomplete DSI than people treated in a bad quality hospital. 
- λ0 = 0.5: Non-emergency presenters are 50% more likely to be managed in a ‘good’ hospital 
than emergency presenters, in the unexposed. 
-  λ1 = -0.1: Non-emergency presenters are 40% more likely to be managed in ‘good’ hospital 
than emergency presenters, in the exposed (λ0 + λ1).  
Results 
Descriptive results 
There were 64,509 colon cancer patients and 35,433 rectal cancer patients diagnosed in England during 
2010-2012. Mean age at diagnosis was slightly lower in rectal cancer patients (70.0 vs 72.2 years in 
colon cancer patients). Approximately 47.5% of colon and 37.3% of rectal cancers were diagnosed in 
women (Table 1). 
There was a known diagnosis route for 93.5% of colon and 92.8% of rectal cancer patients. The most 
frequent diagnosis route for colon cancer was EP (27.9%), followed by the two-week wait pathway 
(TWW, 23.5%). For rectal cancer, the most frequent route to diagnosis was TWW (36.1%), followed 
by standard General Practitioner (GP) referral (25.4%). 9.5% of colon and 10.1% of rectal cancer 
patients were diagnosed through screening. After imputation of missing values of health status and EP 
status the distribution of these variables was comparable to that in the complete-case sample (Table 1). 
Stage at diagnosis was known for 67.8% of colon and 71.7% of rectal cancer patients. Among patients 
with known stage, 32.9% of colon cancer and 26.5% of rectal cancer patients had evidence of metastatic 
disease (TNM stage IV).  
39.4% of colon and 31.2% of rectal cancer patients had evidence of at least one of the chronic conditions 
indexed in the Charlson comorbidity index in the six years prior to their CRC diagnosis. Approximately 
53.1% of colon and 44.5% rectal cancer patients had evidence of either a pre-existing chronic condition 
and/or metastatic disease at the time of diagnosis, which we classified as having a ‘poor’ health status.  
Around a third (37.0%) of colon cancer patients and half (52.1%) of rectal cancer patients had what we 
defined as an incomplete DSI. The proportion of patients with an incomplete investigation increased 
with age: patients in the oldest age group (90-99 years) had a higher proportion of incomplete DSI 
(62.1% for colon and 81.3% for rectal cancer) than patients aged 60-69 years (31.6% for colon and 
48.0% for rectal cancer). Colon cancer patients in the youngest age group (15-49) were more likely to 
have an incomplete DSI than patients aged 60-69 years (45.0% vs 31.6%). This J-shaped relationship 
between the main exposure and the outcome was not seen in rectal cancer (Table 2). 
The proportion of patients with an incomplete DSI was higher in patients with ‘poor health status’: 
38.7% and 55.7% of colon and rectal cancer, respectively, in comparison with 21.2% and 35.3% of 
colon and rectal cancer patients without evidence of comorbidity or metastatic disease.  
Patients who were diagnosed through an EP were more likely to have an incomplete DSI (54.4% of 
colon and 73.9% of rectal cancer patients) than those diagnosed through other routes (21.2% of colon 
and 35.3% of rectal cancer patients). Those with unknown route to diagnosis were the most likely to 
have an incomplete investigation (71.9% of colon and 83.8% of rectal cancer patients).  
Mediation analysis 
Colon Cancer 
The total effect (TE) measured the risk difference (RD) of having an incomplete DSI between each age 
group and the baseline (60-69 years). For colon cancer, there was a J-shaped association with patients 
aged 60-69 years being the least likely to have an incomplete DSI (Table 3, Figure 3a). Patients in the 
youngest age group (15-49 years) had 8% additional risk of incomplete DSI, while the oldest (90-99 
years) had 20% additional risk of incomplete DSI. 
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Separating the TE into mediated and non-mediated effects, the first mediator, health status, explained 
very little of the age differential, and tended to be protective of the outcome (negative IE mediated by 
health status) consistently in all age groups (RD ranged between -0.001 in the 15-49 to -0.008 in the 
90-90 age group).  
In all age groups, the second mediator, emergency presentation, mediated an important part of the age 
differences in the completeness of DSI: in absolute terms a harmful effect of EP was similar among all 
age groups (RD range: 0.031 in the 90-99 to 0.050 in the 15-49 age group), but the proportion mediated 
varied between them, with the smallest proportion mediated being in the oldest age group.  
The effect of age that was not mediated by either of these two mechanisms (DE) varied considerably 
by age group: it was somewhat protective in the age groups adjacent to the reference category (RD: -
0.011 in the 50-59; and -0.028 in the 70-79 age group) but harmful in the youngest (RD: 0.033) and 
particularly in the oldest (RD: 0.173). Patients in the oldest age group had 17.3% additional risk of 
having an incomplete DSI that was not explained by their health or EP status. 
In terms of proportions, emergency presentation seemed to explain most of the age variation in the 
outcome - in all age groups except for the oldest, for which the RD remained largely unexplained by 
either health status or EP. 
Rectal Cancer 
The risk of an incomplete DSI in rectal cancer patients increased with age. In comparison with those 
aged 60-69 years, rectal cancer patients in the 15-49, 50-59 and 70-79 age categories had lower risk of 
having an incomplete DSI (TE range -0.028 -0.022) (Table 3, Figure 3b). Patients in the oldest age 
groups had considerably higher risk of the outcome (TE 0.053 in the 80-89; and 0.241 in the 90-99 age 
group). 
The first mediator, health status, did not explain much of the age differential, and tended to be protective 
of the outcome in all age groups (range -0.011 -0.003). Similarly, the mediated effect by emergency 
presentation in the completeness of DSI was relatively small, though harmful, in all age groups (RD 
range: 0.004-0.010).  
The DE, or effect of age that was not mediated by either of these two mechanisms, was protective in 
patients aged 15-59 and 70-79 in comparison with patients aged 60-69 years; but was harmful in the 
80-89 (RD 0.052) and 90-99 (RD 0.248) age groups. In other words, patients in the oldest age group 
had an additional 24.8% risk of having an incomplete investigation in comparison with patients aged 
60-69 years that was not explained by differences in health status, and emergency presentation. Most 
of the TE of age was therefore not mediated in the older age groups. 
Results of the sensitivity analysis 
Results from the sensitivity analysis show that the stronger the association between U (quality of 
hospital) and the outcome, and between U and Mb (emergency presentation), the higher the proportion 
of the TE that is explained by Mb, while the non-mediated effects move away from being harmful, in 
all age groups. However, the changes were insufficient for Mb to explain all the age differences in 
having an incomplete DSI, or to change the general interpretation of the original results, especially in 
the oldest and in the youngest age categories. The total and partitioned effects remained largely 
consistent with the original results (Figure 3). 
Discussion 
Age is associated with the completeness of diagnostic and staging investigations of CRC patients: we 
found a J-shaped association between age and the risk of an incomplete DSI in colon cancer patients, 
and a consistently increasing risk of an incomplete DSI with age for rectal cancer. Both older colon and 
rectal cancer patients (80+ years) have the highest risk of having incomplete investigations. We used 
mediation analysis to examine health status and emergency presentation as mechanisms to explain this 
age differential in DSI. 
Health status (a combination of the effect pre-existing chronic conditions and metastatic CRC disease 
at the time of diagnosis) did not explain the age differences in investigations. For colon cancer, 
emergency presentation explained most of the age differences in DSI, except among the oldest age 
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group (90-99 years). The higher risk of incomplete DSI in rectal cancer patients aged 80 years and older 
(compared to those aged 60-69) remained largely unexplained by differences in health status and 
emergency presentation. Our findings suggest that suboptimal management of older cancer patients 
begins in the diagnostic and staging investigation stage.  
Less intensive cancer management in older patients may be reasonable in some cases, however, there 
are concerns in England that age-related disparities in cancer care and outcomes partly arise because of 
clinical decision-making based primarily on chronological age rather than also considering biological 
age [13, 25, 26, 27, 28]. A recent study of non-small cell lung cancer patients in England found a 
dramatic decrease in the probability of receiving major surgery after age 75 years, even in patients with 
early stage disease and no reported comorbidity [29]. Another study found that chronologic age was an 
important determinant of clinical decision-making in a patient-scenario exercise, even if clinicians did 
not explicitly recognise it as such [26]. In a recent international comparison, older CRC patients in 
England were less likely to receive potentially curative surgery than patients with a similar extent of 
disease and age in Denmark, Norway and Sweden [30]. Life expectancy at 65 and 85 years are similar 
between these countries [31], so it is unlikely that comorbidity explains the international differences in 
receipt of treatment. 
Suboptimal management of older patients has been extensively described for different chronic 
conditions including cancer [10, 12, 32, 33]. The higher prevalence of comorbidity in older age 
increases the likelihood of adverse events, which can outweigh the potential benefits of cancer-directed 
treatment as recommended by clinical guidelines [11, 33]. Additionally, older patients may be 
disadvantaged by contemporary health research, policy, and clinical guidelines which largely focus on 
single illnesses [34]. Specialised services allow the development and delivery of improved treatments 
of individual conditions, but may not be as beneficial for older patients who often have more complex 
clinical profiles. Despite the need for scientific evidence to justify clinical interventions in older cancer 
patients, they are generally excluded from clinical trials, and are underrepresented in research [1, 32, 
35]. This is usually justified by the variable levels of comorbidity in older patients, which may 
compromise the generalisability of the findings. However, clinicians lack sufficiently detailed guidance 
to provide adequate cancer care to the elderly, and may tend as a result to err on the side of caution 
when deciding whether to recommend invasive tests and procedures. Similarly, patients and carers may 
benefit from more information about the implications of undergoing or refusing clinical interventions. 
Despite the uncertainty around cancer management in older patients, ‘old age’ is not a contraindication 
for investigation and treatment according to clinical guidelines [10]. 
A recent study found that the probability of dying within 90 days of a colon cancer diagnosis increased 
with age, even in patients with early stage disease and without comorbidity [36, 37]. Postoperative 
mortality also increases with age, and is higher in patients with comorbidity and in those who undergo 
emergency procedures [38]. Differences in early mortality may explain some of the age differences in 
DSI completeness: some patients, likely older, may have died before being fully investigated. Other 
patients, however, may have died early as a consequence of suboptimal management. Conscious of this 
potential reverse-causality, we reran the analyses in a subsample of patients who survived at least 90 
days after diagnosis. Selecting patients who survived at least 90 days likely causes an underestimation 
of the true age differences, as some patients who were excluded may have died early as a result of 
suboptimal management in relation to age. However, although the risk differences in the older age 
groups decreased in comparison with the original results, especially for colon cancer, the finding that 
age differences in the completeness of CRC investigations were not fully explained by comorbidity and 
the diagnostic route remained valid (Web-Appendix Figure 2). Thus the differences in early mortality 
are unlikely to explain the findings. 
Our finding of suboptimal management in the pre-treatment stage is important because without a 
complete investigation, a fully informed decision about treatment options simply cannot be made. 
Study limitations 
To our knowledge, this is the first time that information on diagnostic investigations has been derived 
from multiple data sources and used to assess the adequacy or completeness of those investigations 
based on current clinical guidelines in England. Until recently, such detailed clinical information was 
not routinely collected, and despite best efforts, it may still be incomplete. 
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HES contains information on medical procedures for administrative and financial purposes. Expensive 
procedures and/or those that are performed during a hospital admission are more likely to be included 
than less expensive diagnostic tests done in outpatient settings [personal communication: Sean McPhail, 
Public Health England]. Investigations performed in the private health sector are generally missing from 
HES. Since we are not able to differentiate people who underwent investigations but have missing 
information, from patients who did not undergo those procedures, our results may suffer from 
misclassification bias. However, we believe that purely administrative determinants of missing data are 
likely to affect all age groups alike. Missing information on diagnostic procedures performed in the 
private sector, is likely to be more prevalent in younger patients of working age, and/or patients of higher 
socioeconomic level, implying that a misclassification would only serve to underestimate the extent to 
which DSI is incomplete in older patients. 
Similarly, we relied on secondary care health records for obtaining information on comorbidity. It is 
possible that some patients with no record of comorbidity, actually had undiagnosed and/or unmanaged 
chronic conditions. Furthermore, our comorbidity measure may well lack diagnoses made and managed 
solely in primary care. Such misclassification, if present, may particularly affect patients with certain 
characteristics (e.g. more deprived, or institutionalised), who may also tend to be older. The vast 
majority of patients (99.3%), however, had a secondary care record, therefore, we believe that major 
comorbidities would have been recorded if present. If managed exclusively in primary care, these 
conditions are unlikely to be major comorbidities that would contraindicate the staging procedures 
explored in this analysis. 
Additional clinical information would have helped to characterise the overall health status of CRC 
patients. For instance, performance status scales are generally used in clinical settings to assess the 
degree of independence of cancer patients, and help determine eligibility for specific treatments [39, 
40]. Some authors argue, however, that these scales are not ideal for older cancer patients, especially 
those with multiple comorbidities [41].Older patients have higher prevalence of cognitive impairment, 
depression, decreased mobility and may also lack social support [34, 42]. Although comprehensive 
geriatric assessment tools have been proposed and validated [41, 43], these are not commonly used in 
practice. Moreover, indicators of frailty (increased vulnerability resulting from decreased reserves from 
multiple physiologic systems [44]), such as cognitive impairment, malnutrition, and decreased mobility 
are rarely documented formally for older cancer patients [1].  
Our measure of health status combined information on comorbidity with information on metastatic CRC 
to provide a richer measure than comorbidity alone. Nevertheless, this measure may still not capture the 
full extent to which frailty affects the clinical decision-making process. We tried several regroupings of 
the comorbidity information (e.g. cardiovascular risk, disability-related, minor/major comorbidity, CCI 
score categories), yet, none was an important predictor of the outcome in our data. Future research on 
the topic of age inequalities in cancer management would certainly benefit from improved measures of 
frailty in older patients, and documentation of those measures in electronic health records. A better 
understanding of the role of social support as a determinant of cancer management and outcomes would 
also potentially be useful to develop targeted interventions. 
Another limitation of this study is the missing information on the mediators, especially on stage 
information used for the health status variable. Additionally, we lacked information to characterise the 
healthcare provider and other health system factors that may impact the mediator(s) and outcome. We 
carried out imputation of missing information, and a sensitivity analysis for unmeasured confounding 
to address these issues. These techniques, however, come with assumptions and thus our findings would 
have been stronger had the relevant data been available. 
We have used counterfactual-based causal inference methods to examine age differences in CRC 
management.  We have however refrained from calling the direct effect of age ‘causal’ because age is 
a “non-manipulable exposure” [45, 46]. We recognise that it is not a person’s age per se that is a causal 
determinant of their cancer management. The direct effect of age represents the inequality that would 
remain if the distribution of health status and EP were equal between age groups. It reflects the effect 
of other factors strongly associated with age (for instance, social isolation and attitudes towards old 




Our study shows that clinical decision-making for colorectal cancer patients in England is affected by 
their age at diagnosis, even though chronological age does not contraindicate investigation or treatment 
interventions according to current clinical guidelines. The suboptimal management of older CRC 
patients in England starts before treatment options become clear, during the diagnostic and staging 
phases.  
These age differences in the likelihood of having incomplete diagnostic and staging investigations were 
not explained by comorbidity, and only partially by the diagnostic route, contradicting prevailing 
beliefs. The role of other potential mechanisms which may help or hinder the undertaking of these 
investigations, such as frailty and social support, should be examined further.  
Having a full investigation is essential for having optimal treatment and for improving cancer outcomes. 
Although clinical guidelines and health policy do not exclude older patients, targeted efforts that 
specifically address their needs are needed to improve evidence-based management and cancer 
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Table 1: Characteristics of colon and rectal cancer patients, England 2010-2012 
Notes: *: Health status is 0 when there was no record of comorbidity or metastatic disease, 1 when there 
was record of comorbidity and/or metastatic disease, and Unknown when there was no record of 
comorbidity and unknown stage. GP: General practitioner.  
N (%) After imputation N (%) After imputation
 Age group
15-49 3,432 (5.3) 2,148 (6.1)
50-59 5,828 (9.0) 4,722 (13.3)
60-69 15,913 (24.7) 10,066 (28.4)
70-79 20,352 (31.5) 10,494 (29.6)
80-89 16,200 (25.1) 6,912 (19.5)
90-99 2,784 (4.3) 1,091 (3.1)
 Female 30,649 (47.5) 13,198 (37.2)
 Stage at diagnosis
I 5,391 (12.3) 5,725 (22.5)
II 12,374 (28.3) 5,328 (21.0)
III 11,594 (26.5) 7,623 (30.0)
IV 14,384 (32.9) 6,728 (26.5)
[Unknown] 20,766 (32.2) 10,029 (28.3)
 Comorbidity 25,389 (39.4) 11,065 (31.2)
 Health status*
0 18,313 (34.8) 22,920 (35.5) 13,216 (45.6) 16,214 (45.8)
1 34,260 (65.2) 41,589 (64.5) 15,761 (54.4) 19,219 (54.2)
[Unknown] 11,936 (18.5) 6,456 (18.2)
 Route to diagnosis
Non Emergency routes 42,332 (65.6) 44,990 (69.7) 28,554 (80.6) 30,722 (86.7)
Screening 6,145 (10.2) 3,566 (10.8)
Two-week-wait 15,174 (25.2) 12,772 (38.9)
Standard GP 14,060 (23.3) 9,015 (27.4)
Other 6,953 (11.5) 3,201 (9.7)
Emergency presentation 17,964 (29.8) 19,519 (30.3) 4,320 (13.1) 4,711 (13.3)
[Unknown] 4,213 (6.5) 2,559 (7.2)
 Staging investigation
Incomplete 23,848 (37.0) 18,444 (52.1)





Table 2: Distribution of the outcome, incomplete diagnostic and staging investigation, by cancer by 
age group, stage, comorbidity and emergency presentation status 
Notes: *: Health status is 0 when there was no record of comorbidity or metastatic disease, 1 when there 
was record of comorbidity and/or metastatic disease, and Unknown when there was no record of 
comorbidity and unknown stage. 








15-49 1,546 (45.0) 1,037 (48.3)
50-59 2,070 (35.5) 2,247 (47.6)
60-69 5,024 (31.6) 4,827 (48.0)
70-79 6,637 (32.6) 5,221 (49.8)
80-89 6,841 (42.2) 4,225 (61.1)
90-99 1,730 (62.1) 887 (81.3)
 Stage at diagnosis
I 1,050 (19.5) 2,067 (36.1)
II 2,695 (21.8) 2,051 (38.5)
III 2,757 (23.8) 2,791 (36.6)
IV 5,628 (39.1) 3,660 (54.4)
[Unknown] 11,718 (56.4) 7,875 (78.5)
 Comorbidity
No 13,921 (35.6) 12,083 (49.6)
Yes 9,927 (39.1) 6,361 (57.5)
 Health status*
0 3,878 (21.2) 5,964 (26.0) 4,665 (35.3) 6,756 (41.7)
1 13,262 (38.7) 17,884 (43.0) 8,780 (55.7) 11,688 (60.8)
[Unknown] 6,708 (56.2) 4,999 (77.4)
 Emergency diagnosis status
0 11,046 (26.1) 12,781 (28.4) 13,108 (45.9) 14,893 (48.5)
1 9,771 (54.4) 11,067 (56.7) 3,191 (73.9) 3,551 (75.4)
[Unknown] 3,031 (71.9) 2,145 (83.8)




Table 3: Risk difference of having an incomplete staging investigation by age group in comparison with patients aged 60-69 years. Colon and 
rectal cancer diagnoses, England, 2010-2012 
Notes: TE: Total effects; DE:  Direct Effects (not mediated); IEa:  Indirect effects mediated through health status; IEb: Indirect effects mediated 
through emergency presentation; Positive numbers indicate higher risk of having an incomplete staging investigation in comparison with the 
reference age group (60-69 years) and vice versa.
TE DE IEa IEb
 Age group
15-49 0.082 (0.063 0.101) 0.033 (0.014 0.053) -0.001 (-0.003 0.001) 0.050 (0.048 0.052)
50-59 0.027 (0.012 0.043) -0.011 (-0.026 0.003) -0.001 (-0.003 0.001) 0.040 (0.038 0.041)
60-69
70-79 0.016 (0.005 0.027) -0.028 (-0.037 -0.020) -0.003 (-0.004 -0.001) 0.047 (0.045 0.049)
80-89 0.065 (0.054 0.077) 0.026 (0.016 0.036) -0.005 (-0.007 -0.002) 0.044 (0.042 0.047)
90-99 0.196 (0.173 0.218) 0.173 (0.149 0.198) -0.008 (-0.012 -0.004) 0.031 (0.027 0.035)
TE DE IEa IEb
 Age group
15-49 -0.028 (-0.053 -0.004) -0.030 (-0.055 -0.004) -0.004 (-0.008 -0.001) 0.006 (0.003 0.009)
50-59 -0.029 (-0.047 -0.011) -0.036 (-0.054 -0.018) -0.003 (-0.006 -0.001) 0.010 (0.008 0.013)
60-69
70-79 -0.022 (-0.037 -0.008) -0.027 (-0.041 -0.012) -0.005 (-0.008 -0.002) 0.009 (0.007 0.012)
80-89 0.053 (0.036 0.071) 0.052 (0.035 0.069) -0.007 (-0.011 -0.003) 0.009 (0.005 0.013)









Figure 1: Pathways to diagnosis and staging investigation (DSI) of colorectal tumours (used to 
defined ‘complete DSI’ in this study) 






Figure 2: Hypothesised causal relations between age at presentation and different characteristics of 
colon and rectal cancer patients 
Note: X: main exposure, age at presentation; C: measured confounders; Ma: First mediator; Mb: 
Second mediator; Y: outcome; Um-y: Unmeasured confounding of the relationship between the 
second mediator and the outcome; Solid line: measured. Dashed line: Unmeasured. Black arrows: 






Figure 3a: Differences in the risk of having an incomplete diagnostic and staging investigation 
(DSI) for colon cancer, in comparison with patients aged 60-60 years.  
Results from original mediation analysis (scenario 1), and sensitivity scenarios (scenarios 2-5, 
lighter colours) for unmeasured confounding of the relationship between emergency presentation 
and the DSI.  
Sensitivity parameters: Scenario 2: β=-0.2, λ0=0.5;  Scenario 3: β=-0.2, λ0=1;  Scenario 4: β=-0.5, 
λ0=0.5;  Scenario 5: β=-0.5, λ0=1. λ1=0 in all sensitivity analysis scenarios (2-4). 
Interpretation: β = -0.5: people treated in a good quality hospital had a 39.9% smaller odds of having 
an incomplete DSI than people treated in a bad quality hospital; λ0  = 0.5: Emergency presenters are 
50%  more likely to be managed in a good hospital in comparison with emergency presenters, in the 
unexposed; λ1 = 0: Emergency presenters are 50%  more likely to be managed in a good hospital in 





Figure 3b: Differences in the risk of having an incomplete diagnostic and staging investigation 
(DSI) for rectal cancer, in comparison with patients aged 60-60 years.  
Results from original mediation analysis (scenario 1), and sensitivity scenarios (scenarios 2-5, 
lighter colours) for unmeasured confounding of the relationship between emergency presentation 
and the DSI.  
Sensitivity parameters: Scenario 2: β=-0.2, λ0=0.5;  Scenario 3: β=-0.2, λ0=1;  Scenario 4: β=-0.5, 
λ0=0.5;  Scenario 5: β=-0.5, λ0=1. λ1=0 in all sensitivity analysis scenarios (2-4). 
Interpretation: β = -0.5: people treated in a good quality hospital had a 39.9% smaller odds of having 
an incomplete DSI than people treated in a bad quality hospital; λ0  = 0.5: Emergency presenters are 
50%  more likely to be managed in a good hospital in comparison with emergency presenters, in the 
unexposed; λ1 = 0: Emergency presenters are 50%  more likely to be managed in a good hospital in 







Appendix Figure 1a: Differences in the risk of having an incomplete diagnostic and staging 
investigation (DSI) for colon cancer, in comparison with patients aged 60-60 years. Results from 
mediation analysis, colon cancer (Λ1= -0.1) 
Notes: Sensitivity parameters: Scenario 2: β=-0.2, λ0=0.5; Scenario 3: β=-0.2, λ0=1; Scenario 4: β=-
0.5, λ0=0.5; Scenario 5: β=-0.5, λ0=1. λ1=0 in all sensitivity analysis scenarios (2-4). 
Interpretation: β = -0.5: people treated in a good quality hospital had a 39.9% smaller odds of having 
an incomplete DSI than people treated in a bad quality hospital; λ0  = 0.5: Emergency presenters are 
50%  more likely to be managed in a good hospital in comparison with emergency presenters, in the 
unexposed; λ1 = 0: Emergency presenters are 50%  more likely to be managed in a good hospital in 





Appendix Figure 1b: Differences in the risk of having an incomplete diagnostic and staging 
investigation (DSI) for rectal cancer, in comparison with patients aged 60-60 years. Results from 
mediation analysis, rectal cancer (Λ1= -0.1) 
Notes: Sensitivity parameters: Scenario 2: β=-0.2, λ0=0.5; Scenario 3: β=-0.2, λ0=1; Scenario 4: β=-
0.5, λ0=0.5; Scenario 5: β=-0.5, λ0=1. λ1=0 in all sensitivity analysis scenarios (2-4). 
Interpretation: β = -0.5: people treated in a good quality hospital had a 39.9% smaller odds of having 
an incomplete DSI than people treated in a bad quality hospital; λ0  = 0.5: Emergency presenters are 
50%  more likely to be managed in a good hospital in comparison with emergency presenters, in the 
unexposed; λ1 = 0: Emergency presenters are 50%  more likely to be managed in a good hospital in 







Appendix Figure 2: Differences in the risk of having an incomplete diagnostic and staging 
investigation (DSI) for colon (a) and rectal (b) cancer, in comparison with patients aged 60-60 years, 




4.3 Age variation in the receipt of potentially curative surgery for colorectal 
cancer in England  
4.3.1 Background 
Older patients are less likely to receive optimal care, and frequently have poorer health 
outcomes than younger patients. This pattern has been described for several chronic 
conditions, including cardiovascular disease and cancer.12,200 The age gap in patient care 
appears to be particularly true for conditions that require surgical interventions, such as hip 
replacement for osteoarthritis, coronary artery bypass graft surgery for coronary heart 
disease, and bowel excision for colorectal cancer, even if these conditions are most prevalent 
in later life. Although the suboptimal management of chronic conditions in older patients is 
an important issue in other countries, it seems to be particularly critical in England.13 
Increasing evidence indicates that in England, older colorectal cancer patients are less likely 
to receive surgical management than younger patients.201,202 It is essential to understand 
what factors give rise to inequalities in cancer care in order to design and implement targeted 
interventions to improve cancer outcomes.  
In our paper in section 4.2, we showed that within England, older colorectal cancer patients 
were less likely to have a complete diagnostic and staging investigation than younger 
patients. Exploring the underlying mechanisms, it seemed that the difference in the 
proportion of patients who were diagnosed through an emergency presentation between 
age groups partly explained the age difference in investigations, especially for colon cancer. 
However, differences in the prevalence of comorbidity did not explain the difference in the 
completeness of diagnostic and staging investigation between patients aged 60-69 years and 
those 70 years and older. In older patients, most of the age difference in investigation 
remained ‘non-mediated’ by these factors. 
Moving forward in the cancer patient management pathway, in this section, I explore the 
age differences in the likelihood of having resectional surgery for non-metastatic colon and 
rectal cancer in England, addressing objective 5 of this research degree project. I focus on 
non-metastatic disease because according to clinical guidelines, stage I-III colorectal tumours 
should be amenable to surgical resection, provided there are no contraindications for 
surgery. I use causal mediation analysis to examine how much comorbidity, the diagnostic 
route, and having a complete investigation explain the difference in the likelihood of having 




4.3.2 Materials and methods 
Data sources and variable definitions 
Patients aged 15-99 years and diagnosed with non-metastatic colon and rectal 
adenocarcinoma in England during 2010-2012 were included. Patients with metastatic 
disease (TNM stage IV; 21.2% of all diagnoses), those with unknown stage (30.2% of all 
diagnoses) were excluded from this analysis, to ensure that all patients included were eligible 
for resectional surgery based on the extension of the disease (in other words, they were ‘at 
risk’ of having the outcome). As in the analyses presented in Section 4.2, individual tumour 
records from the National Cancer Registry were linked to the National Bowel Cancer Audit 
(NBOCA) data, Hospital Episodes Statistics (HES), and the Routes to Diagnosis monitoring 
dataset (RtD).  
The exposure of interest was age, which was categorised into six groups: 15-49, 50-59, 60-
69, 70-79, 80-89 and 90-99 years. The 60-69 age category was used as the baseline for 
analysis.  
Information on comorbidity was derived from HES, as described using the algorithm 
developed by Maringe et al.124 A binary indicator was used to flag the presence of any major 
comorbidity, including one or more of the following diagnoses: heart failure, cerebrovascular 
disease, chronic obstructive pulmonary disease, dementia, severe renal disease, severe liver 
disease, hemi/paraplegia, human immunodeficiency virus infection, and morbid obesity. 
A binary variable was used to classify patients as having been diagnosed through an 
emergency presentation (EP) or not, using information from the RtD dataset.  
Binary indicators for the completeness of diagnostic and staging investigation, and for 
resectional surgery status were derived from HES and NBOCA data using the algorithms 
described in Chapter 2.  
Deprivation quintile of patients at the time of the CRC diagnosis was represented by the 
income domain of the Index of Multiple Deprivation of the Lower Layer Super Output Area 
(LSOA) of residence at the time of diagnosis. 
Statistical Analyses 
As in the analysis presented in the paper in Section 4.2, counterfactual-based mediation 
analysis was used to decompose the effect of age on the outcome, which is the likelihood of 
not receiving resectional surgery for stage I-III colorectal cancer. I chose to present the 
outcome in its negative form (not having surgery), so the direction of the associations are 
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comparable with the results presented in Section 4.2, where the outcome was having an 
incomplete diagnostic and staging investigation. 
These analyses are a sequential progression of those presented in Section 4.2, which 
examined the effect of age (main exposure), health status (first mediator) and emergency 
presentation status (second mediator) on having a complete diagnostic and staging 
investigation (outcome). The present analysis focuses on the effect of age on having 
resectional surgery (outcome), using the investigation status as a third mediator, following 
comorbidity and emergency presentation. Figure 4.1 shows the directed acyclic graph with 
the causal assumptions made in this analysis. 
 
Figure 4.1: Assumed causal relationships between the relevant variables 
The pink arrow represents the direct effect of age on the outcome (likelihood of not undergoing resectional 
surgery for colorectal cancer). The blue pathway represents the effect of age on the outcome that is mediated 
through comorbidity.  The green pathway represents the effect of age on the outcome that is mediated by the 
diagnostic route, that is, being diagnosed following an emergency presentation.  The orange pathway represents 
the effect of age on the outcome that is mediated through having a complete diagnostic and staging investigation.  
Because the mediators are ordered sequentially, a part of the effect of ‘upstream’ mediators is mediated by 
‘downstream ‘mediator(s). 
 
I denominate as the ‘total effect (TE) of age’ the average difference in the outcome (not 
having resectional surgery) between patients in a given age group and patients in the 
reference category (age 60-69 years), with the same distribution of deprivation and gender. 
The TE is decomposed into ‘mediated’ (or direct) and ‘non-mediated’ (indirect effects).  
In a single mediator setting, the direct effect (DE) expresses the effect of the exposure on an 
outcome, comparing two counterfactual scenarios with different levels of the exposure 
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variable, while fixing the level of the mediator (in both scenarios) to a specific value drawn 
from the distribution of that variable in the unexposed, given the covariates, 203 or 
DE = E [ Y(1, M(0) – Y(0, M(0)) ] 
Applied to this research question, the direct effect of age on the outcome (not having 
resectional surgery) is the average risk difference of seeing the outcome between a given 
age group and the reference (60-69) if, for all patients, their comorbidity status, emergency 
presentation status (EP), and the diagnostic and staging investigation status (DSI) were set 
at a fixed level, randomly drawn from the distribution of these variables for patients in the 
reference age group, of the same gender and deprivation status. 
In a single mediator setting, the indirect effect (IE) captures the average change in the 
outcome that would be seen if, for all patients, different levels of the mediator are 
contrasted (a specific level, randomly drawn from the distribution of this variable in the 
exposed versus another specific level, randomly drawn from the distribution of this variable 
in the unexposed, given the confounders), while fixing the main exposure to the reference 
level, or: 
IE = E [ Y (1, M(1)) – Y(1, M(0)) ] 
Applied to the research question, the IE is the average risk difference in the outcome that 
would be seen contrasting two counterfactual scenarios in which all patients are in the 
reference age category (60-69 years), with contrasting levels of the mediators (comorbidity, 
EP, and DSI): the first being a fixed level, randomly drawn from the distribution of these 
variables for a given age category, and the second one being a fixed level, randomly drawn 
from the distribution of these variables for the reference age category, of the same gender 
and deprivation status.  
The IE are further decomposed into “path-specific” effects through each of the mediators 
(comorbidity status [Ma], EP [Mb] and DSI [Mc]). The path-specific effect via health status 
represents the effect that may arise when age influences comorbidity status, which may then 
in turn affect the outcome (either directly, or by influencing EP and DSI). It will be denoted 
IEa. The path-specific effect via Mb represents the effect that may arise when age influences 
the risk of being diagnosed through an emergency presentation (but not mediated by 
comorbidity), which may then in turn affect the outcome. It will be denoted IEb. Finally, the 
path-specific effect via Mc represents the effect that may arise when age directly influences 
the risk of having an incomplete diagnostic and staging investigation (not mediated through 
comorbidity and/or EP), which may then in turn affect the outcome. These effects (Ma, Mb, 
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and Mc), which add up to the IE, as well as the DE, were estimated using a parametric g-
computation procedure.148  The first step in g-computation is to model each of the mediators 
and the outcome, in this case using multivariate logistic regression: 
- Comorbidity status was modelled as a function of age, deprivation quintile, 
sex and any interaction(s) that were significant (at 10% level). 
- EP status was modelled as a function of comorbidity status, age, deprivation 
quintile, sex and any significant interaction(s). 
- Completeness of diagnostic and staging investigation was modelled as a 
function of emergency presentation status, comorbidity status, age, deprivation 
quintile, sex and any significant interaction(s). 
- Resectional surgery status was modelled as a function of diagnostic and 
staging investigation status, emergency presentation status, comorbidity status, age, 
deprivation quintile, sex and any significant interaction(s). 
The resulting models were then used to simulate the outcomes for each one of the 
hypothetical scenarios compared in the definitions of the IE, DE and TE, as well as the 
definitions of the path-specific effects, in temporal order. As in the previous analyses, 
standard error and confidence intervals were estimated using 10,000 non-parametric 
bootstrap samples. Results from iterations were averaged to obtain point estimates. 
4.3.3 Results 
Descriptive analysis 
Out of the 64,509 colon cancer patients and 35,433 rectal cancer patients diagnosed during 
2010-2012 in England, 28,971 and 18,336 had non-metastatic adenocarcinoma, respectively. 
Mean age at diagnosis was slightly lower in rectal (69.4 years) than in colon cancer patients 
(72.0 years) (Table 4.1). 
The proportion of patients with stage I disease was lower in patients with colon cancer 
(18.1%) than in those with rectal cancer (30.6%).  
There was a known diagnosis route for 97.8% of colon and 97.1% of rectal cancer patients. 
The most frequent diagnosis route was the two-week wait in both colon (28.8% of those with 
known route) and rectal (42.2%) cancer patients. Emergency presentation was the diagnostic 
route for 21.3% of colon and 7.3% of rectal cancer patients with a known route. After 
imputation of missing values of EP status, its distribution was comparable to that in the 
complete-case sample (Table 4.1). 
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Approximately 37.8% of colon and 29.2% of rectal cancer patients had evidence of at least 
one of the chronic conditions indexed in the CCI in the six years prior to their CRC diagnosis. 
The prevalence of comorbidity increased with age, from 11.7% in patients aged 15-50 years 
to 44.0% in those aged 90 years and older. 
Around a fifth (21.5%) of colon cancer patients and a third (36.6%) of rectal cancer patients 
had what we defined as an incomplete DSI. The proportion of patients with an incomplete 
investigation increased with age: patients in the oldest age group (90-99 years) had a higher 
proportion of incomplete DSI (34.9% for colon and 44.5% for rectal cancer) than patients aged 
60-69 years (17.9% for colon and 33.9% for rectal cancer). Colon cancer patients in the 
youngest age group (15-49) were more likely to have an incomplete DSI than patients aged 
60-69 years (21.2% vs 17.9%). For rectal cancer, the proportion of patients with an 
incomplete DSI increased with increasing age. 
Around a third (37.0%) of colon and half (52.1%) of rectal cancer patients with non-metastatic 
disease did not have evidence of undergoing resectional surgery. The oldest age group (90-
99 years) had the highest proportion of patients not undergoing resectional surgery (62.1% 
and 81.3% of colon and rectal cancer, respectively). Colon cancer patients in the 60-69 age 
group and rectal cancer patients in the 50-59 age group were the most likely to undergo 
resectional surgery (68.4% and 52.0%, respectively). 
The proportion of patients without evidence of undergoing resectional surgery was higher 
for patients with later stage at diagnosis. It was also higher in patients diagnosed after an 
emergency presentation (54.4% of colon and 73.9% of rectal cancer patients) than in patients 
diagnosed through other routes (26.1% of colon and 45.9% of rectal cancer patients). The 
proportion of patients not undergoing surgery was slightly higher in patients with 
comorbidity than in those without evidence of comorbidity. Among patients with an 
unknown route to diagnosis, 71.9% of colon and 83.8% of rectal cancer patients had no 






Table 4.1: Characteristics of patients diagnosed with non-metastatic colon and rectal cancer 
in England, 2010-2012 
Resectional surgery defined as surgical procedure to remove primary tumour and surrounding tissues, excluding 








15-49 1,295 (4.5) 1,045 (5.7)
50-59 2,573 (8.9) 2,477 (13.5)
60-69 7,621 (26.3) 5,611 (30.6)
70-79 9,879 (34.1) 5,684 (31.0)
80-89 6,784 (23.4) 3,185 (17.4)
90-99 819 (2.8) 334 (1.8)
 Female 13,659 (47.1) 6,530 (35.6)
 Stage at diagnosis
I 5,246 (18.1) 5,616 (30.6)
II 12,256 (42.3) 5,261 (28.7)
III 11,469 (39.6) 7,459 (40.7)
 Comorbidity 10,937 (37.8) 5,353 (29.2)
 Route to diagnosis
Non Emergency routes 22,279 (78.7) 24,192 (78.9) 16,500 (92.7) 18,551 (92.6)
Screening 3,830 (13.5) 2,420 (13.6)
Two-week-wait 8,165 (28.8) 7,514 (42.2)
Standard GP 6,918 (24.4) 4,939 (27.7)
Other 3,366 (11.9) 1,627 (9.1)
Emergency presentation 6,042 (21.3) 6,479 (21.1) 1,304 (7.3) 1,485 (7.4)
[Unknown] 650 (2.2) 532 (2.9)
 Diagnostic and staging investigation
Incomplete 6,240 (21.5) 18,336 (36.6)
Resectional surgery
No surgery 2,164 (7.5) 3,554 (19.4)





Table 4.2: Absence of resectional surgery: Number and proportion of patients with no 
evidence of resectional surgery for colon and rectal cancer by age group, stage, comorbidity 
and emergency presentation status. England, 2010-2012 
Resectional surgery defined as surgical procedure to remove primary tumour and surrounding tissues, excluding 
diagnostic and palliative non-resectional procedures. *: Not treated: number and percentage of patients with no 
evidence of undergoing resectional surgery. 
 
Mediation analysis 
In the logistic regression model for the outcome, the main exposure (age) and the three 
mediators were significantly predictive of the outcome. However, none of the mediators 
explained the age differences in treatment receipt (Figure 4.2 and Table 4.3). This means that 
the difference in the prevalence of these factors in oldest and youngest age groups – in 
comparison with the reference age category (60-69) – do not explain the difference between 
age groups in the likelihood of undergoing resectional surgery. 
Patients diagnosed with colon cancer at age 90-99 years had 28.6% (22.6-34.6) additional 
risk of not undergoing resectional surgery compared with those aged 60-69 years, and most 
of this additional risk was not mediated by any of the three mechanisms explored. Patients 
Colon 
N (%) not 
treated*





patients  per 
category
N (%) not 
treated*





patients  per 
category
 Age group
15-49 55 (4.2) 1,295 168 (16.1) 1,045
50-59 115 (4.5) 2,573 343 (13.8) 2,477
60-69 234 (3.1) 7,621 698 (12.4) 5,611
70-79 532 (5.4) 9,879 959 (16.9) 5,684
80-89 915 (13.5) 6,784 1,152 (36.2) 3,185
90-99 313 (38.2) 819 234 (70.1) 334
 Stage at diagnosis
I 323 (6.2) 5,246 491 (8.7) 5,616
II 748 (6.1) 12,256 1,042 (19.8) 5,261
III 1,093 (9.5) 11,469 2,021 (27.1) 7,459
 Comorbidity
No 1,042 (5.8) 18,034 2,109 (16.2) 12,983
Yes 1,122 (10.3) 10,937 1,445 (27.0) 5,353
 Emergency presentation (EP) status
Non- EP 1,295 (5.8) 1,530 (6.3) 22,279 2,855 (17.3) 3,370 (18.2) 16,500
EP 688 (11.4) 791 (12.2) 6,042 527 (40.4) 655 (44.1) 1,304
[Unknown] 181 (27.8) 650 172 (32.3) 532
Diagnostic and staging investigation status
Complete 1,326 (5.8) 22,731 2,049 (17.6) 11,624
Incomplete 838 (13.4) 6,240 1,505 (22.4) 6,712




aged 80-89 had 9.9% (7.1-11.5) additional risk of not undergoing surgery. The risk in the 
younger age categories (59 years and younger and 70-79 years) was not significantly 
different to that of the reference category, 60-69 years. 
Patients diagnosed with rectal cancer at age 90-99 years had 53.2% (48.3-58.0) additional 
risk of not undergoing resectional surgery than those aged 60-69 years, and most of it was 
not mediated by any of the three mechanisms explored. Patients aged 80-89 had 18.7% 
(16.0-21.5) additional risk of not undergoing surgery. The risk in the youngest age category 
(1549 years) was slightly higher (2.8%, 0.7-4.9) than in the reference category. Patients aged 
70-79 years had the same risk of the outcome as in the reference category. 
 
Figure 4.2: Risk difference in having resectional surgery for colon and rectal adenocarcinoma 
in comparison with patients diagnosed at age 60-69 years, England, 2010-2012 
Non-mediated effects or direct effect of age; *: being diagnosed through an emergency presentation; **: having 







Table 4.3: Risk difference of not undergoing resectional surgery by age group in comparison with patients aged 60-69 
years. Colon and rectal non-metastatic adenocarcinoma diagnoses, England, 2010-2012 
Total effect: total risk difference in comparison with that of reference groups (age 60-69 years); Direct effects: of age, or non-mediated effect; Indirect 
effect a: mediated through comorbidity; Indirect effect b: mediated through emergency presentation; Indirect effect c: mediated through diagnostic 
and staging investigation; Positive numbers indicate higher risk of not undergoing resectional surgery in comparison with the reference age group 
(60-69 years) and vice versa. 
 
Total effect Direct effect Indirect effect a Indirect effect b Indirect effect c
15-49 0.002 (-0.009 0.012) 0.006 (-0.006 0.017) -0.004 (-0.008 0.000) -0.001 (-0.005 0.002) 0.001 (-0.003 0.006)
50-59 0.009 (-0.001 0.020) 0.017 (0.004 0.030) -0.004 (-0.012 0.004) -0.004 (-0.007 0.000) 0.000 (-0.003 0.004)
60-69
70-79 0.017 (0.008 0.025) 0.022 (0.013 0.031) -0.006 (-0.010 -0.003) 0.001 (-0.001 0.004) 0.000 (-0.002 0.003)
80-89 0.093 (0.071 0.115) 0.094 (0.074 0.114) -0.012 (-0.018 -0.007) 0.012 (0.006 0.018) -0.001 (-0.003 0.001)
90-99 0.286 (0.226 0.346) 0.289 (0.231 0.347) -0.015 (-0.025 -0.004) 0.012 (0.001 0.023) -0.001 (-0.007 0.006)
Total effect Direct effect Indirect effect a Indirect effect b Indirect effect c
15-49 0.028 (0.007 0.049) 0.037 (0.015 0.059) -0.010 (-0.017 -0.003) 0.002 (-0.002 0.006) -0.002 (-0.006 0.003)
50-59 0.004 (-0.011 0.019) 0.012 (-0.006 0.030) -0.009 (-0.020 0.001) 0.003 (-0.001 0.007) -0.001 (-0.004 0.002)
60-69
70-79 0.029 (0.015 0.044) 0.035 (0.022 0.049) -0.010 (-0.015 -0.004) 0.003 (-0.001 0.008) 0.000 (-0.001 0.001)
80-89 0.187 (0.160 0.215) 0.201 (0.174 0.228) -0.019 (-0.027 -0.010) 0.005 (-0.001 0.010) 0.000 (-0.001 0.002)













This study shows that older patients are less likely to have surgical treatment for colorectal 
cancer, even in the subgroup of patients with non-metastatic disease. I examined the role of 
comorbidity, the diagnostic route (being diagnosed through an emergency presentation or 
not), and the completeness of staging investigation in explaining these age differences within 
England. Although these factors were important determinants of treatment receipt, they 
explained very little of the differences in the receipt of resectional surgery for non-metastatic 
colon and rectal adenocarcinoma between age groups. 
These findings are consistent with those presented in Chapter 3. Comorbidity did not explain 
the differences in the probability of receiving resectional surgery for rectal cancer between 
Denmark and England; and it did not explain the age differences in the probability of 
receiving a full investigation, or resectional surgery within England.  The findings are however 
somewhat contrasting to the ones presented in Section 4.2, with regards to the role of 
emergency presentation as a mediating factor. Emergency presentation seemed to be an 
important mechanism for the age differences in investigation but not for surgical treatment. 
There are two potential explanations of this finding. First, patients diagnosed through an EP 
may still receive some sort of resectional surgery, regardless of the investigation. This is 
plausible because in case of an acute event, such as an obstruction, surgery is still indicated, 
though the intent (curative or palliative) may be different than an elective procedure. Intent 
or outcome of the surgical procedure was not considered in the definition of treatment used 
in the analysis, so variation in the intent could not examined. Second, excluding patients with 
unknown stage and metastatic disease may have caused the exclusion of an important 
proportion of patients diagnosed through an emergency route and unlikely to have surgery 
because of their acute condition. Selecting patients for whom surgery should be indicated, 
as I have done, likely highlights the age differences that remain unexplained by biological 
factors such as comorbidity, advanced stage, and emergency presentation. The finding of 
age inequalities in cancer management in this selected group are important precisely 
because they point the attention away from these biological factors, and suggest that 
alternative explanations should be sought.  
As in the studies presented previously in this thesis, it is possible that the measure of 
comorbidity used in this analysis does not capture fully the overall health status of patients 
at the time of diagnosis. I used a binary indicator to flag patients with ‘major conditions’ that 
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might have contraindicated surgery because of increased risk of postoperative mortality and 
complications, such as heart failure, cerebrovascular disease and dementia. A binary 
indicator, however, oversimplifies the wide spectrum of health status, thus potentially 
leading to residual confounding. I considered different categorisation of the comorbidity 
information that was available, including several categories of the Charlson Comorbidity 
Index with increasing severity, flags for conditions with potential disability associated, and/or 
markers for increased cardiovascular risk. None of these variables improved the prediction 
of the outcome in the logistic regression model, suggesting that the binary indicator used 
was not worse than the other ways of categorising the comorbidity information.  
Another limitation of the indicator of health status used is that it may not fully capture 
‘frailty’, or the increased vulnerability resulting from decreased reserves from multiple 
physiologic systems.79 Frailty is likely considered in the decision to treat because it is 
associated with poor outcomes. However, the concept of frailty as a clinical syndrome is fairly 
new;80 and although several operational definitions have been proposed,81,82 none is widely 
used in practice to assess frailty objectively. The working definition of frailty is therefore 
likely to vary. Improving the assessment of the health status of patients (including frailty), 
and its monitoring through clinical audit and registration, would allow a better 
understanding of the operative risks of patients, and better monitoring and comparison  of 
cancer outcomes. 
The age disparities in the likelihood of receiving resectional surgery (as well as having a full 
investigation) were larger for rectal than for colon cancer. The colon and rectum have 
different location, blood supply, venous drainage, and thus treatment.19 Because its location 
is closer to the anal canal and sphincter, a permanent stoma is more frequently required 
after rectal cancer surgery than after colon cancer surgery. A permanent stoma has 
implications for patient lifestyle and quality of life,204 and may be more difficult to manage 
for patients who are less independent and/or lack social support. A recent study of social 
support in surgically treated CRC patients found poorer health-related quality of life 
outcomes in those who reported low levels of social support.205 The prospect of life-changing 
consequences following surgery may be preventing older patients from receiving surgery, 
potentially more so for rectal cancer patients than for colon cancer patients. 
In comparison with colon cancer surgery, rectal cancer surgery is more frequently followed 
by surgical complications, such as anastomotic leakage.19,175 Although surgical complications 
are less frequent in colon cancer patients, they are reported to be more likely to die from 
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them, than rectal cancer patients.206 Medical postoperative complications, such as 
pneumonia and cardiovascular events, are more frequent in colon cancer patients – who are 
older on average – than in rectal cancer patients.19,175  Several studies have found that 
increasing age is an independent predictor of short-term mortality and postoperative 
medical complications.206-208 Iversen and colleagues found that postoperative medical 
complications, but not surgical ones, were a strong predictor of short-term mortality 
following emergency surgery for colon cancer.207 Marusch and colleagues found that 
pneumonia and cardiovascular complications resulted in a high postoperative morbidity and 
mortality in older colorectal cancer patients.208 Arguably, it is difficult to differentiate surgical 
from medical complications, as these may arise from interrelated events. However, all this 
evidence highlights the importance of close observation for surgical and non-surgical 
complications in the postoperative period, especially in older patients and those at higher 
risk of complications, to improve surgical outcomes.  
In general, the anticipated risk of operative mortality influences the decision to offer surgical 
treatment, and it might be a particularly important consideration in older patients. 
Multimorbidity, frailty and disability are known risk factors for postoperative mortality, but 
are not the only determinants. As discussed in the previous chapter, perioperative care is 
also an important determinant of cancer outcomes. In comparison to other European 
countries, the availability of critical beds per hospital population is lower in England.191 
Furthermore, access to high-dependency and intensive care varies between hospitals, 
especially for patients undergoing non-cardiac surgery. It is possible that limited access to 
adequate postoperative care is affecting the prospects of older patients getting surgical 
treatment, because they are more likely to develop postoperative complications, and need 
admission to ICU for organ support.209 
Given the limited health resources, it is probable that chronological age is being used in 
England as a criterion to ration and prioritise the allocation of health resources (such as 
intensive care beds) consequently affecting older patients’ prospects of undergoing 
aggressive cancer treatment. Rationing of resources means denying potentially beneficial 
medical care to a particular group of patients in order to conserve and use those resources 
for a different type of patients.210 Rationing of health resources based on age is not explicit 
policy in the UK, however, it may occur.211 There are arguments for and against it. Some 
people think it is fair to give priority to younger patients over older ones for scarce potentially 
life-saving resources, because the old have already lived more years, whereas the young 
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should have the same opportunity to live as many years.211,212 The counterargument to this 
is that all lives are equally valuable, regardless of age, sex, race, and any other 
characteristic.213,214 Resource rationing may happen at the micro level (at individual level), 
macro level (by health authorities or institutions), and even at societal level.215 Age-based 
rationing is obvious in screening programmes, for instance, where the age eligibility criterion 
is justified based on targeting the population at highest risk. Age-based rationing at the 
individual level in the clinical setting  is more difficult to assess because the clinical judgement 
is supposed to involve a comprehensive assessment of the patient’s needs.215 In 1998, Kapp 
argued that age-based rationing of medical treatment (dialysis, access to coronary care and 
cancer treatment) in the UK had been justified “under the linguistic guise of medical 
“indications””.210 In the current context, these claims may no longer apply to the same 
extent, as several measures have been introduced to avoid age discrimination since 
then.216,217 However, clinicians will inevitably need to make decisions at the individual level, 
and it is arguably unfair that they bear the responsibility to deny resources to some patients 
when resources are constrained. 
In conclusion, to improve cancer outcomes, the finding of poorer surgical outcomes in older 
colorectal cancer patients should not justify them not receiving surgery, but rather 
encourage further efforts to improve patient safety in the perioperative period. Several 
measures to optimise patients’ condition preoperatively (such as incentive spirometer and 
chlorhexidine for oral care),206,218 to evaluate their surgical risk, and to plan their 
postoperative care68,69,77,78 have been proposed in order to avoid or minimise postoperative 
complications, and to predict the risk of complications preoperatively. Without taking sides 
pro/against age-based rationing of health resources (which will come in Chapter 5), it is clear 
that any such decision needs to follow a wider discussion and agreement at a societal level, 





Chapter 5: Discussion  
5.1 Contributions of this work  
In this study, I examined the impact of increasing age on the likelihood of having optimal 
management of colorectal cancer, and its role in explaining international differences in 
cancer survival. To do this, first, I carried out an international comparison of CRC 
management and survival between Denmark, England, Norway and Sweden. I found that 
that for each disease stage, age-standardised net survival up to three years after a colon or 
rectal cancer diagnosis was poorer in England than in Norway, Sweden, and Denmark (rectal 
cancer only). In all countries, survival of patients with missing stage was between that of 
patients with stage III and stage IV disease. The proportion of patients with missing stage 
was substantially larger in England than in the other countries, suggesting an 
underestimation of the differences found in the stage-specific analysis. The pattern of 
Denmark substantially reducing the survival deficit in comparison with Norway and Sweden 
over time, while England showed a smaller survival improvement, is consistent with another 
recent population-based survival comparison from the CONCORD programme.156 
The findings from the first International Cancer Benchmarking Partnership (ICBP) study had 
shown that, during 1995-2007, the survival deficit in the UK and Denmark was particularly 
large for colorectal cancer patients aged 65 years and older.3 Authors suggested that the 
survival trends were consistent with later diagnoses or differences in treatment. Subsequent 
ICBP analyses focusing on CRC found that an adverse stage distribution was contributing to 
the lower survival in Denmark; while the UK jurisdictions included had considerably lower 
stage-specific survival, suggesting unequal access to optimal treatment.5 This ICBP study did 
not include all CRC patients diagnosed in the UK because at the time stage data was not 
widely available. The availability of stage data has improved considerably since then, and 
even more when applying the algorithm to derive stage from different data sources 
described in Chapter 2.126 As a result, I was able to conduct a more recent population-based 
comparison of CRC stage-specific survival using national data for Denmark, England, Norway 
and Sweden. The finding of lower stage-specific survival in England presented in Chapter 3 
of this thesis is consistent with that reported in the ICBP 2013 publication.5  
To explore the role of cancer management in explaining the international differences in 
survival, I compared between Denmark, England, Norway and Sweden, the proportion of 
patients receiving resectional surgery for each stage of disease in different age groups (and 
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separately for colon and rectal tumours). Older patients in England were less likely to receive 
resectional surgery than patients of similar age and extension of disease in Denmark, Norway 
and Sweden. In patients younger than 75 years, comparing the distribution of resectional 
surgery receipt for each stage and age group between the countries, the proportion treated 
was generally comparable between the countries, and higher in England than in the other 
countries for stage I disease. In patients aged 75 years and older, the proportion treated was 
systematically lower in England than in the other countries, for each disease stage. In 
patients with rectal cancer, there was an age gradient (decrease in the proportion treated 
by age) in Denmark, England and Sweden, which was particularly pronounced in England; 
while in colon cancer patients, a clear age gradient in the proportion treated was only evident 
in England of the four countries compared. The patterns in treatment receipt by stage in the 
older age group mirror the survival findings, in that Norway and Sweden had both the highest 
survival and highest proportion of older patients treated, and England had the lowest survival 
and lowest proportion of older patients treated, of the countries compared. To my 
knowledge, this is the first international population-based comparison of CRC treatment 
receipt by stage and age between these countries.  
To account for the role of comorbidity in explaining the international differences in the 
proportion of patients receiving resectional surgery and in survival, I then carried out sub-
analyses of the proportion of patients treated for non-metastatic rectal adenocarcinoma in 
Denmark and England – the countries for which comorbidity information was readily 
available. The lower proportion of patients treated in the older age groups in England (in 
comparison with Denmark) was evident at different levels of comorbidity, with the exception 
of patients with stage I disease and no record of comorbidity. After adjusting for comorbidity, 
the probability of receiving resectional surgery for CRC was still lower in England than in 
Denmark, and the between-country difference in the probability to be treated tended to 
increase with increasing age, stage and level of comorbidity. The findings indicate that 
although comorbidity helps determines treatment eligibility, it does not fully explain the 
between-country differences in the proportion treated in the older age groups, at least 
between Denmark and England. 
To date, few studies have examined the role of potentially curative treatment in explaining 
population-based survival, as this information is rarely collected in population-based 
national cancer registries. The European Registration of Cancer Care (EURECCA) initiative of 
the European Society of Surgical Oncology (ESSO) and European Cancer Organisation (ECCO), 
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a multidisciplinary platform aiming to improve the quality of cancer care, has produced 
several publications focusing on colorectal cancer comparing clinical audit data, clinical 
practice and cancer outcomes across Europe.42,120 Recently, a EURECCA study examined 
treatment and survival of patients diagnosed with rectal cancer at age 80 years and older in 
Belgium, Denmark, The Netherlands, Norway and Sweden in 2001-2010.219 In patients with 
non-metastatic disease they found a higher proportion of patients undergoing surgery in 
Denmark (92.4% of those registered in the DDCG database) and Sweden (92.0%) than in 
Norway (77.3%), and higher cancer survival in Sweden than in the other countries. In those 
with stage IV disease, the proportion of patients undergoing surgery was higher in Norway 
(40.6%) than in Sweden (34.0%) and Denmark (22.2%), and 5-year survival was similar 
between the countries.219 They also report wide differences in the use of radiotherapy and 
chemotherapy. Their results on the proportion treated are comparable to those reported in 
Chapter 3, but because their focus was on patients aged 80 and older, they did not report 
fluctuations in the proportion treated by age group; and they did not include England in their 
analyses. Nonetheless, there has been increasing evidence that older cancer patients in 
England are less likely to receive treatment than patients of similar age in other countries, 
and compared with younger patients in England. A EURECCA Breast Cancer Group study 
examined the variation in treatment and survival of patients diagnosed with non-metastatic 
breast cancer at age 70 years and older in Belgium, England, Ireland, The Netherlands and 
Poland during 2000-2013. The proportion of patients without evidence of surgery (breast-
conserving or mastectomy) in England was lower than in the other countries for stage I and 
II, and second lowest (after Ireland) for stage III disease.220 Survival was also lowest in England 
for each stage of disease.220 Another recent population-based study of patients diagnosed 
with non-small cell lung cancer in England during 2009-2012 found that the predicted 
probability of receiving surgery decreased sharply after age 65 years, even in patients with 
stage I-II disease, good performance status and no evidence of comorbidity.199 
Several studies have found that comorbidity affects cancer outcomes, potentially in relation 
to lower probability of treatment with curative intent. However, until recently, there have 
not been many international population-based studies examining the role of comorbidity in 
explaining cancer treatment and survival, because this information is not routinely collected 
in national cancer registration. In the recent ICBP study examining the role of comorbidity in 
explaining differences in lung cancer survival between nine jurisdictions in Australia, Canada, 
Norway and the UK, authors concluded that they were not able to quantify the level of 
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comparability of these indices between jurisdictions due to differences in coding practices, 
and called for further efforts in standardising data collection practices.163 There is therefore 
no accepted standard for measuring comorbidity for international comparisons of 
population-based cancer survival. Still, the Charlson Comorbidity Index is frequently used as 
a measure of comorbidity in epidemiological research because can be feasibly and reliably 
derived from secondary care records.124 
To explore in more detail the age differences in CRC management within England, I assessed 
some of the potential underlying mechanisms behind the age differences in CRC 
management using mediation analysis methods. I started by examining the initial phase of 
cancer management, the diagnostic and staging investigation. I found that the proportion of 
patients receiving a full diagnostic and staging investigation for CRC was lower in patients 
aged 80 years and older than in younger patients. The diagnostic route partly explained some 
of the age differences, however, patients’ health status did not significantly explain the age 
differences. The results were robust to a sensitivity analysis for unmeasured confounding of 
the relationship between the diagnostic route and the likelihood of having an incomplete 
investigation. I then explored the role of having a major comorbidity (diagnosis of heart 
failure, cerebrovascular disease, dementia, diabetes with organ damage, severe renal or 
hepatic disease, or hemi/paraplegia) emergency presentation, and having a full investigation 
as sequential mechanisms that may explain the age differences in the likelihood of receiving 
resectional surgery for CRC in England. The results of this analysis are consistent with the 
previous ones (looking at the age differences in investigations), in that most of the age 
differences in the outcome remained ‘not mediated’ or unexplained by these mechanisms.  
The findings presented in this thesis add to the increasing evidence showing that older colon 
and rectal cancer patients in England are less likely to receive optimal treatment than 
younger patients, even after accounting for differences in known ‘risk factors’ for under-
management, namely, disease stage, comorbidity, and the diagnostic route (emergency or 
not).201,202,221  An analysis of data from rectal cancer patients diagnosed in England during 
2009-2014 found a substantial difference in the proportion of patients undergoing major 
resection, from 66.5% in patients younger than 70 years, to 31.7% in those aged 80 years 
and older.201 They also reported significant variation in resection rates in patients 80 years 
and older between NHS Trusts, after adjusting for sex, deprivation, year of diagnosis, 
Charlson comorbidity score, disease stage and diagnostic route.201 An analysis of regional 
data from the Northern and Yorkshire cancer registry including information on patients 
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diagnosed with colon cancer during 1999-2010 found that patients aged 60-69, 70-79, and 
80 years and older were significantly less likely to receive surgery and adjuvant 
chemotherapy than those younger than 60 years, after adjusting for sex, deprivation, stage, 
and period of diagnosis.202 Another cohort study looking at patterns of cancer care by age 
group in patients who died during 2005-2011 (and had their cancer registered in the 
Northern and Yorkshire cancer registry) found that patients aged 18-69 years had the highest 
likelihood of receiving chemotherapy, radiotherapy or surgery (68.7, 64.5 and 37.3%, 
respectively), while the aged 80 years and older had the lowest probability of receiving each 
type of treatment (27.1, 57.6, and 33.6%, respectively).221 Colorectal cancer was one of the 
cancer types included, among others, indicating that the issue of under-management of 
cancer in older patients is wider, and not specific to CRC. 
In the analyses presented in Chapter 4, I did not only ‘control for’ other potential explanatory 
factors of the differences in management by age group (comorbidity, the diagnostic route, 
and stage in the analysis examining surgical treatment), but also quantified the extent to 
which they explained the age differences. To do this, I used innovative analytic methods from 
the counterfactual-based causal inference framework, causal mediation analysis. To date, 
few studies have used causal mediation to understand inequalities in cancer outcomes. 
Valeri and colleagues used causal mediation analysis to examine the role of stage in 
explaining race differences in colorectal cancer survival in the US.222 Similarly, Li and 
colleagues used causal mediation methods to examine how much of the socioeconomic 
inequalities in breast cancer survival in Northern England were explained by disease stage 
and treatment.223 Both studies found that stage at diagnosis explained some of the racial and 
socioeconomic differences (respectively) in survival. To my knowledge, there have not been 
any published studies focusing on examining the underlying mechanisms behind age 
inequalities in cancer management and outcomes.  
All the findings presented in this thesis consistently indicate that there are age inequalities 
in the management of colorectal cancer patients in England in comparison with older 
patients in other countries (who also consistently perform better than England in terms of 
cancer survival), and in comparison with younger patients in England. These differences in 
cancer management are not fully explained by differences in biological factors such as 
disease stage or comorbidity, as it is frequently assumed. In the next section, I will explore 
other potential explanations of the age inequalities in cancer management. 
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5.2 On data harmonisation and comparability of results  
Several steps were taken to ensure the comparability of outcomes between specific groups 
of patients included in the analyses.  The inclusion criteria and variable definitions were 
based on the standard and widely used classifications, such as the third edition of the 
International Classification of Diseases for Oncology topographical and morphological codes 
and the Union for International Cancer Control TNM Classification of Malignant Tumours, 
adhered to by the four colorectal cancer registries contributing with data for the analyses. 
Despite the use of the same standard classification systems, registration practices may vary. 
For instance, registries may use different editions of the same classifications leading to 
inconsistent definitions.  
Section 2.3 covered variable definitions and presented different algorithms to derive clinical 
information. As discussed in Section 2.3.2, the ‘non-restrictive’ strategy to derive stage 
information addresses the main challenge in cancer registries using different editions of the 
TNM Classification: the handling of information on distant metastases.  
I collaborated with clinicians and registry staff in the four countries to ensure the inclusion 
criteria and definitions used in the analyses were as harmonised as possible. For instance, 
the Swedish ColoRectal Cancer Registry collects information on colon and rectal 
adenocarcinomas, and no other types of tumours (based on ICD-O-3 morphology codes). The 
other national colorectal cancer registries (in Denmark, Norway and England) do not have 
such eligibility criterion based on tumour morphology. Therefore, for the international 
comparison of treatment and survival of CRC between these countries, tumours of specific 
morphology other than adenocarcinoma were excluded from the analysis.  
Similarly, the definition of ‘resectional surgery’ took into account (only) information that was 
available in all relevant data sources. For example, reliable information on residual disease 
after removal of the primary tumour (and on the surgical intent) was not available in all 
datasets, therefore this information was not taken into account, even when available. 
Similarly, the time window for eligible surgical procedures was up to nine months after 
diagnosis took into account that some patients may have received neoadjuvant therapy with 
delayed surgery,134 and allowing additional time to account for delays between diagnosis and 
start of treatment. 
Despite best efforts, some differences in practices cannot be fully accounted for in the data 
preparation and harmonisation process. For instance, the handling of death certificate 
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initiated cancer diagnoses is known to vary between registries. This process entails tracing 
back additional clinical information from death certificates in a routine basis (if additional 
information is found, the case is classed as death certificate initiated, or DCI; if no additional 
information is found, the case is classified as death certificate only, or DCO). The proportion 
of DCO cases is frequently used to judge completeness of registry data (with a high 
proportion of DCOs indicating under-ascertainment of cases).224 DCO cases are generally 
excluded from survival analysis,225 including the survival analyses presented in this thesis. 
Both DCOs and DCIs have an important effect on the survival estimates. By definition DCO 
cases have 0 survival time, as they are diagnosed at the event time, and similarly, DCIs will 
likely have a short survival time. In Sweden, however, because of legal reasons, registries do 
not accept registration from death certificates.226 The underreporting of cases to the Swedish 
Cancer Register is however relatively small. A quality study using a 1998 sample estimated 
that the underreporting was 3.7%, with substantial variation between cancer sites (from 
“low to modest” for breast and digestive tumours to “substantial” for leukaemia and 
lymphoma).227 This may result in an overestimation of survival, especially short-term. A 2019 
study examined whether different registry practices between ICBP jurisdictions, such as the 
handling of death certificate cases and using different hierarchical rules for the incidence 
date, could have a potential effect on survival estimates. The study found that after tracing 
back DCI cases in Sweden and standardising incidence dates, 1-year survival from colorectal 
cancer decreased by around 3% in Norway and Sweden. These 1-year survival estimates, 
however, were still higher in Norway and Sweden than in England by around 5% at one year. 
It is thus unlikely that these differences in registration practice will explain all the differences 
in survival, especially in the longer term.   
Incidence rates of colorectal cancer vary between the countries, as reported in Section 1.2. 
Of the countries included in this thesis, CRC incidence is reportedly highest in Norway, 
followed by Denmark, and lowest in Sweden. It is unclear the extent to which these are true 
differences in incidence (and risk factors), or partly a reflection of differences in case-
ascertainment and/or coding. The lack of cancer registration from death certificates in 
Sweden may partly explain the lower incidence of CRC, however it is unlikely to completely 
explain the difference (for instance between 42.6 diagnoses per 100,000 in men in Norway 
in comparison with 32.2 diagnoses per 100,000 in men in Sweden). The proportion of DCO 
cases are around 1.0% in Norway, a country with diagnostic activity, cancer outcomes, and 
long-standing cancer registries comparable to those in Sweden. Thus, it is improbable that 
154 
 
the proportion of (unregistered) DCOs would be much higher in Sweden than in Norway. 
Another possibility is that countries with higher incidence of CRC are over-ascertaining cases, 
such as the registration of in situ tumours (carcinoma confined within the basement 
membrane of the bowel epithelium).228 Specialised CRC registries include only invasive 
tumours, however, there might be some inter-observer variability in the pathologic 
assessment of tumour tissue, especially of polyps and whether they are classified carcinoma 
in situ or intramucosal carcinoma (Tis in TNM classification of malignant tumours),43 or 
invasive adenocarcinoma (invading submucosa, T1 and higher in TNM classification of 
malignant tumours).43,228 If present, this inter-observer variability may affect the 
comparability of the results for the earliest stage category, and potentially more so in 
countries with relatively high proportion of diagnoses with asymptomatic disease.  
The four countries included in the analyses have 100% public health coverage. However, 
health financing and the role of the private health sector in providing services and reporting 
activities somewhat varies between the countries. Government compulsory and 
contributory schemes finance most of the health spending in the UK (83% of total health 
spending), Denmark, Norway and Sweden (84% of total health spending in each country) 
(2011 data).229 Private health financing includes out-of-pocket payments and different types 
of private health insurance complementing (cost-sharing after basic coverage), 
supplementing (adding further services) or replacing (provider faster access or wider choice 
of providers) public health services.230 Household out-of-pocket payments make a smaller 
proportion of health expenditure in the UK (10%) than in Denmark, Norway and Sweden 
(around 15%), while voluntary healthcare payment schemes make up a higher proportion of 
healthcare spending in the UK (around 8%) than in Denmark (2%), Norway and Sweden 
(<1%).229 The proportion of the population covered by private health insurance is however 
larger in Denmark (24% in 2011, mainly complementary and supplementary services) than in 
the UK (10.9% in 2011, mainly duplicate services).229 Reportedly, 98-99% of hospital activity 
in England is funded by the NHS.231,232 In England, NHS care providers are required to submit 
data to the National Cancer Registration Analysis System (NCRAS), including NHS-funded 
activities carried out in the private sector (and presumably privately-funded activity carried 
out in the NHS).232 Though private hospitals in England may voluntarily submit data to the 
registry, it is likely that diagnoses and/or procedures made entirely in the private sector are 
not fully captured in population-based datasets. Similarly, in Denmark, the DCCG.dk registers 
procedures carried out in public hospitals. The analyses presented in Section 3 account for 
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the uncertainty about the surgical status of patients not registered in the DCCG.dk. However, 
the under-ascertainment of cancer activity in the private sector may bias the results, 
especially in the demographic groups with relatively high use of private insurance services: 
least-deprived and those of working age.  
Previous research has found that most of the international differences in survival are found 
in the first year at diagnosis,233 and that differences decrease when conditioning five-year 
survival to surviving the first year after diagnosis.3,233 Conditioning 5-year survival to surviving 
the first year (‘five-year conditional survival’) may reduce the bias due to differences in 
registration practices, and also account for differences in late presentation when examining 
survival for all stages combined. Møller and colleagues examined the EUROCARE-4 findings 
from a UK perspective, comparing survival estimates between European countries and the 
European average. Overall, one-year survival estimates for England were below the 
European average, while conditional five-year survival was just above the European 
average.233 Still, five-year conditional survival for colorectal cancer patients in England was 
lower than those in Norway and Sweden, and higher than in Denmark.233 Stage-specific 
survival estimates, which account for the differences in late presentation and delayed 
diagnosis, were still lower in England than in Norway and Sweden in a previous international 
study.3 These findings are consistent to those presented in Section 3 of this thesis, except 
that CRC survival in Denmark is now closer to that in Norway and Sweden.128 
The survival analyses presented in this thesis are also stage-specific. Survival estimates are 
presented for the longest possible follow-up time in the available data, three-years after 
diagnosis, for which differences in registration have lower impact than for shorter follow-up. 
The under-ascertainment of cases and potential misclassification of surgical status in relation 
to the use of private health services will systematically affect more affluent patients and 
those of working age. Any comparison of treatment receipt between younger and older 
patients (and between deprived and affluent patients) will possibly underestimate the 
proportion treated in the younger (and affluent) group, thus underestimating the age (and 
socioeconomic) inequalities. 
5.3 Explaining the age inequalities in health outcomes 
There is a considerable amount of evidence that older patients with treatable conditions are 
not always receiving optimal care. Suboptimal management of older patients is not an issue 
specific to (colorectal) cancer. Inadequate management of older patients has been 
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extensively reported for other conditions such as cardiovascular disease, mental health 
conditions, and hip replacement for osteoarthritis, to name a few.12,200,234-236 Similarly, under-
management of older patients has been examined in other geographic settings, though 
mainly in developed countries.92,237-239  
There is debate as to whether the age differential in the management of chronic conditions 
is due to “age-differentiated behaviour” (justifiable reasons for under-treating older 
patients) or due to age discrimination resulting from ageism (unjustifiable on biological 
grounds).102,104 Distinguishing age-differentiated behaviour from age discrimination in the 
provision of health may be particularly challenging because clinical decision-making involves 
a comprehensive assessment of patients’ needs, and it is difficult to disentangle the influence 
of chronological age from the other factors considered for that decision.  
There are several ways of exploring the effect of discrimination on health inequalities. 
Because discrimination is not easy to measure, the most common way to examine it at a 
population level is ‘indirectly’ through a comparison of outcomes between age groups, while 
adjusting for the effect other risk factors (usually the biological and sociodemographic 
determinants of the outcome).240  Any residual difference in outcomes would then suggest 
that discrimination is a possible explanation, assuming that there is no unmeasured 
confounding. The analyses presented in this thesis have followed this indirect approach to 
explore age inequalities in CRC management. The findings of this work consistently show that 
after accounting for the biological determinants (stage, comorbidity and the diagnostic 
route), there are still residual differences the outcome (CRC management) by age group. The 
finding of age inequalities in CRC management after adjusting for biological factors is 
consistent with other recent studies.201,202,221 Age discrimination needs to be considered as a 
potential contributor to the remaining age differences in cancer management.  
The assumption of no unmeasured confounding (which indicate discrimination) is however 
a strong one. It could be argued against the evidence here presented that residual 
confounding due to frailty might explain the under-management of cancer in older patients, 
and their adverse health outcomes. Comorbidity, frailty, and disability are interrelated, but 
increasingly recognised as different processes.79,80 Frailty represents a state of vulnerability 
and limited capacity to tolerate and respond to stressors because of limited reserves and 
function of different physiologic systems. Although this formal definition is generally 
accepted, there is no standard way to diagnose frailty and measure its associated risk of 
adverse health outcomes in practice.80 As a result, although informative for clinical decision-
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making, frailty in practice is likely (at least partly) a subjective interpretation of the expected 
tolerance of patients to disease and intervention(s), and therefore, possibly informed by 
other factors including attitudes, beliefs, and the wider context. For instance, a clinician may 
be less likely to treat a frail patient, if that patient were also lacking social support or a good 
environment in which to recover from the intervention. The clinician making such decision 
would most probably be doing it in good faith. However, the result is still that the patient is 
not receiving optimal treatment.  
Ageist attitudes and age discrimination might negatively affect health outcomes at the 
individual level. There is however the issue with measuring discrimination at the individual 
level that it requires the individual to recognise that they are being discriminated against.240 
To recognise age discrimination directly in a clinical setting, therefore, it would require older 
patients or their carers to know how other, younger, patients would be treated. Age 
discrimination is thus likely to be under-recognised and under-reported. With this in 
consideration, it is not surprising that, evidence on the (direct) effect of age discrimination 
on health outcomes tends to focus on the effect of self-perception of ageing on mental 
health outcomes or health behaviour.240 For instance, studies have shown that patient 
‘preferences’ on treatment may be adversely influenced by negative views of ageing held by 
themselves and their carers.102 Patients with negative self-perception of ageing may have 
harmful health behaviours and may have low expectations of their care.241 Some studies have 
examined the effect of self-perception of ageing on more objective health outcomes, such 
as cardiovascular events and longevity, and found that people with negative perceptions of 
ageing had more acute cardiovascular events and shorter life span than those with positive 
views of age.242,243 Arguably, negative perceptions of ageing could be partly a consequence 
of personal experiences of poor health.  
The traditional biomedical and lifestyle frameworks used in epidemiological research favour 
measuring exposures and risk factors (biological, chemical or physical; and health 
behaviours, respectively) at the individual level to understand disease distribution in the 
population.244 Within these epidemiological frameworks, measuring exposure to 
‘discrimination’ and its effect on health outcomes is problematic. The study of health 
inequalities and social determinants of health can benefit from ‘alternative’ theoretical 
frameworks to guide epidemiological questions and analysis of inequalities.240 One of these 
alternatives is the ecosocial theoretical framework of disease distribution, first proposed by 
Nancy Krieger in 1994. This theoretical framework pays particular attention to the ecologic 
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and societal context, during the life course and historically, in which social inequalities arise, 
and how people express biologically (or ‘embody’)245 their experience through this context, 
thus creating population trends in health and disease.107,240,244 Taking from this theory, we 
can scrutinise in more detail the wider context to appreciate whether age discrimination is a 
plausible explanation of the age inequalities in health outcomes.    
Age discrimination is reportedly the most frequent type of discrimination,246 however, it has 
remained relatively under-studied.214,240 Empirical evidence of direct age discrimination in 
the clinical setting exists. For instance, studies have shown that clinicians are more reluctant 
to share diagnoses and prognoses with older patients, and that they spend less contact time 
with older than with younger patients.247-249 An analysis of the English Cancer Patient 
Experience Survey (CPES) found that older patients tended to be more satisfied with their 
care than younger patients; however, they were also less likely to report being given written 
information about their test that was easy to understand, and information about side 
effects.250 Older patients were also less likely to be given the name of the cancer nurse 
specialist in charge of their care, and less likely to be asked to participate in research.250 These 
findings are similar to previous NHS inpatient surveys, and suggest that patient satisfaction, 
as it is based on personal expectations, is not an ideal indicator of age discrimination.251 
Moreover, the findings of these surveys suggest that older patients could benefit from better 
support to navigate the health care system. 
The proportion of people with limiting long standing illness or disability increases with age.252 
Access to adequate social support is thus particularly important for the older population to 
enable them to function independently. Independent living refers to having control and 
choice over the support that one needs, rather than living alone and doing everything for 
oneself.85,253 Social care includes a wide range of non-medical services for people with 
different types and levels of needs because of physical or learning disabilities, mental health 
needs, among others. In England, publicly funded social care services are provided by local 
authorities after assessment of needs and financial means (income and assets).254 As in other 
countries, services for people aged 65 years and older are delivered through a generic service 
for older people, while younger adults use particular services according to their particular 
needs.85 This age difference in the organisation and delivery of the services suggests that 
there are different (and lower) standards and expectations for the care of older people.85 It 
has been reported that older people and those with mental health needs are likely to 
underestimate their needs, probably in relation to having low expectations of care, or denial 
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of their needs.255 Conversely, people with physical, sensory or learning disabilities tend to 
over-assess their needs; potentially in relation to a longer history of advocacy, campaigning, 
and awareness of their rights.255 A study of social care services in Norway (interviewing 
municipality managers in charge of allocation of social care services) found a tendency for 
preferential treatment of younger patients, possibly in relation to higher levels of 
expectations, advocacy and rights consciousness.256 In a setting of limited resources 
(availability of staff more than financial constraints in the Norwegian context), informants 
tended to prioritise the need of the young for getting ready to go to work or school, 
suggesting that the ambition of independence was not there for older patients.256 
The majority of social care in the UK is provided informally by family and social network or 
paid for privately.254 The expectation is that social care is an out-of-pocket expense for those 
who can afford it, and that public services are reserved for those with financial need (and is 
generally co-funded). However, austerity measures have meant that public spending on 
social care and social protection in the UK has fallen consistently in real terms and as a 
percentage of gross domestic product since 2009-2010,254,257 putting additional pressure on 
the services already under strain. It is likely that these cuts disproportionately affect older 
people, who in general have more complex needs, but lower expectations and advocacy for 
their rights, in comparison to other vulnerable groups. Given the current situation of social 
care services in the UK, it is unlikely that older people with care needs (even those who meet 
the financial need criteria) are being adequately supported to have choices in their social 
care. Furthermore, gaps in the provision of social care is associated with frequent use of 
acute health services.258-261 The fact that social care services in England (and the UK) are 
structurally disconnected from the healthcare system makes it particularly difficult for 
people who need to navigate both systems. Similarly, it makes it difficult for clinicians to 
assess the likely long-term effects of treatment on patients’ lives, and adequately plan their 
care. 
Comorbidity, frailty and disability are associated with a higher risk of complications and 
mortality following surgery. These factors are generally perceived as “biological” 
determinants of surgical treatment eligibility and receipt, especially in older people. 
However, the influence that these factors have on health outcomes is not deterministic, but 
largely influenced by the wider context. The availability of an adequate level of postoperative 
care is equally (if not more) important for short-term outcomes. It is likely that CRC patients 
in England do not have comparable access to intensive care after surgery as patients in other 
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countries do (See Section 3.3.4). The elevated risk of postoperative mortality in relation to 
inadequate postoperative care disproportionally affects the prospect of older patients 
receiving surgery, because they are more likely to need intensive care (because of 
multimorbidity or emergency surgery). Moreover, it is plausible that given the limited 
resources, younger patients are prioritised for treatment and post-operative care over older 
patients. Similarly, prioritisation of limited resources favouring younger over older patients 
is likely to be the case for publicly funded social care services. Disability is a potential 
endpoint of different types of chronic conditions and/or frailty, and is also determined by 
the physical environment, social expectations and availability of social support. It is therefore 
possible that age, comorbidity, (perceptions of) frailty and disability have a heavier weight in 
the clinical decision-making process in England than in the Scandinavian countries. The 
limited availability of adequate postoperative care and social care in England may help 
explain the lower proportion of older patients receiving surgical treatment for CRC in 
England, in comparison with Denmark, Norway and Sweden. 
Another frequently mentioned determinant of treatment receipt is “patient choice”. It is 
often believed that older patients tend to prefer less-aggressive treatment options than 
younger patients. This belief has been challenged, and there is now a good amount of 
evidence supporting the notion that most older cancer patients want to have optimal 
treatment of their cancer.102,262 Moreover, “preferences” are likely influenced by the amount 
of practical support patients require and have available at home, as well as the travel time 
to treatment centres.263,264 The CPES findings of older patients being the least likely to be 
given information about their treatment, and about secondary effects of treatment suggests 
that the treatment choice (even if it were a true choice) is less likely to be an informed one 
in older patients.250 Furthermore, the expectations of care are informed by personal (or 
close) experience with the healthcare system, which until recently had limited focus on the 
needs of older patients. 
The 2001 Department of Health’s National Service Framework for Older People was the first 
national strategy and action plan to improve health and social care services for older people 
in the UK. It recognised that services were not always meeting older people’s needs by 
“allowing organisational structures to become a barrier to proper assessment of need and 
access to care, and because best evidence-based practice is not in place across important 
clinical areas”.216 Tellingly, this strategy document also acknowledged that in the NHS, the 
‘one-size-fits-all’ post-war approach to health services had survived too long, and that the 
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financial commitment to older people in public services – around 40% of NHS budget,  and 
50% of social services budget in 1998-1999 – had not translated into an institutional and 
cultural focus on their needs.216 Several initiatives were set out, like the commitment to 
review the eligibility criteria for social care services to avoid age discrimination, the 
introduction of specialised stroke units in general hospitals, planned increments in 
intermediate care services to promote rehabilitation and avoid unplanned hospital 
admissions, among others.216 
After the introduction of the National Service Framework for Older People, the UK 
Department of Health reportedly carried out a series of audits of NHS policy to identify those 
which were explicitly ageist.251 Several years later, in the context of the Equality Bill 2009 
(later Equality Act 2010), which outlawed age discrimination in the provision of goods and 
services, and the related European legislation promoting non-discrimination and equal 
opportunities irrespective of religion or belief, disability, age or sexual orientation in the 
European Union (COM(2008) 426), the Department of Health commissioned a series of 
reviews of the evidence of ageism and age discrimination in several public services (primary 
and secondary care, and social services) in the UK. The review of ageism in secondary care 
found that instances of explicit policy-based age discrimination within the NHS were likely 
rare. It however found substantial evidence of indirect discrimination and ageist attitudes 
among NHS staff.251 Among the evidence presented in the review, is a University of Kent 
study on staff perceptions of ageist attitudes in the clinical setting, which reported that 32 
out of 57 respondents had “sometimes or often” witnessed older patients not being referred 
to specialist services when needed.265 The review also covers a 2003 survey to all staff of 
Wirral Hospital NHS Trust, which found that 13 out of 100 participant doctors replied ‘No’ to 
the question “Should older people have equal access to health care when compared with 
younger people?” as opposed to 5/100 trained nurses and 6/100 hospital managers.251,266 
Often, the reasoning included the important role of life expectancy in clinical decision-
making. After listing many accounts of under-investigation and under-treatment in cancer 
care, stroke and cardiology, the authors recognise that the evidence is so strong and 
widespread that, even taking into account polypharmacy and comorbidity, they “must 
conclude that ageist attitudes are having an effect on overall investigation and treatment 
levels”.251  The authors also conclude that anecdotal indications of indirect age discrimination 
are widespread and rightly wonder “How many anecdotes does it take to constitute 
evidence?”.251   
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Ageism and age discrimination in health and social care is much wider than one-to-one 
interactions. Global health policy and public health have been accused of being institutionally 
ageist for using and promoting the use of metrics such as potential years of life lost (YLL), 
disability-adjusted life years (DALY) and premature mortality (deaths occurring between ages 
15 to 70 years) for setting global health targets.213,214 YLLs and DALYs measure the burden of 
mortality according to the number of years between age at death and an arbitrary threshold 
around 70 years, after which death is given a null value. Though the meaning is not intended 
to be that life after the threshold is worthless, it sends a clear message about where priorities 
in global health ‘should’ be, and that treating older patients is likely of little value. The 
justifications for using these metrics (and this line of thought) include the “fair innings 
argument” which is the idea that there is a certain lifespan that can be reasonably expected 
for every member of a population, and that it is unfair if people cannot achieve that.267 This 
injustice would legitimate, using this argument, giving priority to a younger patient over an 
older one if only one of them could receive a certain treatment because of scarce resources, 
all other things being equal. The other justification is an economic one, based on the grounds 
of younger people (in working age) being more productive and contributing more to society 
than older people.213 In a provocative comment on the Journal of Medical of Ethics in 1994, 
AB Shaw (from the Bradford Royal Infirmary, West Yorkshire) argues that the case for ageism 
is moral (and economic) because health is a limited resource.268 Though intuitive, these 
arguments contradict the United Nations universal value of equal rights, the principle of 
health as a human right for all, and the NHS principle of providing a “universal service for all 
based on clinical need, not ability to pay”.216 They perpetuate stereotypes of older people 
being frail and dependent,214 when many people keep making substantial contributions to 
society in later life, and ignore that people in retirement have already made their societal 
contribution.213  
In the context of austerity after the 2008 economic recession, ‘efficiency savings’ have been 
a priority in the NHS.269-271 The push for savings has seen calls by NHS leading figures to keep 
“high-cost patients out of hospital”,272 and for community-based management of frail 
patients, likely older and/or with multimorbidity.273,274 Several geriatricians have 
recommended improving hospital services to meet older patients’ needs, rather than 
denying hospital management to those who most need it.274-276 The focus of recent health 
policy on enabling and supporting people to take responsibility for their health not only 
overlooks the effect of the wider context on “patient choice”,277 but is also unhelpful for 
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older people with complex needs who are not having sufficient options for their care.  A 
recent commitment to provide additional funding for the NHS, the NHS Long Term Plan 
published in early 2019, has acknowledged the need to “support people to age well”, and to 
help more people live independently for longer at home.278 The much-expected government 
plan (Green Paper) for social care funding and reform is however yet to be published, and it 
is currently not clear how the proposals to improve long-term care of older people will be 
delivered.279-281 
The context of austerity makes the argument of rationing of resources based on age 
particularly relevant, and potentially palatable, despite the increasing political disposition to 
assert the right to health and social care of older people in England and the UK. Several 
opinion pieces by respected scholars and health professionals were published in scientific 
journals – mainly in the 1900s – arguing in favour of age discrimination and age-based 
rationing of resources on economic grounds and the “fair innings” argument.268,282 The 
counterargument is, in my view, irrefutable. Age discrimination is unethical, and should be 
unacceptable in a society holding the principles of justice, equality and solidarity.283,284 It 
would surely be considered inappropriate in the current societal context to propose a 
resource-rationing measure explicitly based on and discriminating against any of the other 
characteristics protected characteristics by the Equality Act 2010, such as gender, race, 
religion, or sexual orientation. Somehow, we as a society remain largely insensitive to the 
needs and rights of older people. A part of the problem seems to be that age discrimination 
is often covert.  
Priorities in global health in general have remained focussed on diseases of the young, 
overlooking the needs of older people, and the increasing burden of non-communicable 
diseases.9 The global health priorities on non-communicable diseases remain on primary 
prevention rather than treatment,285 even if a large part of the potential to decrease the 
disease burden will likely come from secondary and tertiary prevention in older patients.9 
Recently, it was recognised that the original UN Millennium Development Goals, established 
after the Millennium Summit of the UN in 2000, were largely disconnected from the needs 
of the ageing population.286 The 2002 Madrid International Plan of Action on Ageing (MIPAA) 
was subsequently signed by UN members, agreeing for the first time to “link questions of 
ageing to other frameworks for social and economic development and human rights”. The 
document affirms older persons’ entitlement to full access to health care and services, and 
the needs of these services to include the necessary personnel training and facilities to meet 
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the needs of older people.287 It sets out a series of actions and objectives to address issues 
in relation to health promotion and well-being throughout life, universal and equal access to 
health-care services, HIV in older life, and training of care providers and health professionals 
to work with older persons.287 The MIPAA has been recognised as a step in the right direction 
for equal treatment of older persons.288,289 It was however criticised for failing to recognise 
the bias against older people in health metrics such as DALYs.214 More recently, the World 
Health Organization’s global strategy and action plan on ageing and health built on the 
MIPAA aligning the ageing agenda with the Sustainable Development Goals.289 It was 
adopted by UN Member States in 2016, highlighting the need for multidimensional action to 
address the needs of the older population. The strategy introduced the concept of Healthy 
Ageing as wider than the absence of disease, and recognises that combatting ageism is “a 
fundamental step in fostering Healthy Ageing”.290 The timing and focus of the new WHO 
strategy ‘campaigns’ to challenge ageism289 are telling. Ageism and age discrimination 
continues to be a pervasive issue. 
Negative attitudes to older age are widespread in society. Contemporary demographic 
changes mean that an increasing proportion of the population is in the older age bands. As 
a society, we are aware of the economic burden from the high costs for health and social 
care of older people, and the high costs of pensions.291 In the media, older people are often 
portrayed in a negative light, reflecting and shaping societal values.292 Moreover, older 
people living with cancer may be subject to double stigmatisation because of their age, and 
because of their cancer diagnosis.293 People with cancers associated with lifestyle risk factors 
(such as smoking and lung cancer; diet, physical inactivity and colorectal cancer) may be 
particularly stigmatised as it is perceived the cancer is a consequence of their lifestyle 
choices.96 Age discrimination may also synergise with discrimination based on other 
characteristics, such as gender and race. 
It is clear that evidence of a causal relationship between age discrimination and health 
outcomes will not come from a single study, nonetheless, considering the findings of this 
thesis in the wider context provides a better idea of the magnitude of the issue of age 
inequalities, and the potential determinants. Age discrimination is a widespread issue. 
Political commitments to address it, such as outlawing it and asserting the rights of older 
people is a step in the right direction, but they are not enough. Ageist attitudes and age 
discrimination are deeply rooted in society in general, and are magnified in the delivery of 
health and social care, especially in settings of limited resources. As with other types of 
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discrimination, acknowledging it exists, recognising it when it happens and its detrimental 
effects on individual and population health is necessary to tackle it. 
In view of the wider context, it is not only plausible but also likely that age discrimination has 
a role in explaining the age differences in colorectal cancer management found in the studies 
presented in this thesis, as well as ‘biological’ factors, such as comorbidity, frailty and 
disability. The interaction between attitudinal and biological factors is however complex, and 
greatly affected by the wider context. Healthcare services are generally arranged to manage 
single conditions, and largely overlook the complex needs frequently experienced by older 
patients.98 Additionally, financial cuts in health and social care are likely to translate into less 
adequate care that disproportionally affects older people. These wider factors are reflected 
in older people’s poorer health and larger dependence, ‘confirming’ perceptions of older 
people being frail and dependent, and validating age discrimination in healthcare, which in 
turn affect health outcomes. It is likely that this vicious cycle is reinforced by the current 
austerity context in England, more so than in the Scandinavian countries, resulting in 
comparatively worse health outcomes. Figure 5.1 summarises the proposed vicious cycle 
between contextual, biological and attitudinal factors behind the finding of under-
management of older CRC patients in England.   
5.2.1 Breaking the cycle 
Specialisation of care has allowed improvements in cancer outcomes, and it has contributed 
to the large focus of contemporary research and policy into developing and implementing 
unidisciplinary interventions.98 Isolated, unidisciplinary health services are however not 
helpful for older people with complex needs and may lead to inadequate care and 
unnecessary polypharmacy.294 In England, health services are currently disconnected from 
long-term and social care services, making it problematic to plan and secure adequate care, 
and return to independence after a hospital discharge.  
The WHO’s 2015 World Report on Ageing and Health suggests the implementation of an 
older-person-centred and integrated care approach to meet the complex needs of older 
people. Older-person-centred care focuses on the individual, their experience, needs, and 
preferences in their context as a part of a family and a community.294 An important feature 





Figure 5.1: Relationship between biological, attitudinal and contextual factors that determine 
under-management of cancer in older patients and other cancer outcomes. 
Notes: (1) from Schroyen et al, 2015.92 (2) is a quote from Williams (1997) opinion piece.282 (3) is a quote from 
Shaw (1994) opinion piece.268 (4) examples of ageist language in clinical settings, from Oliver (2012) opinion 
piece.292 
 
One of the first models of integrated care was established in Quebec, Canada in the late 
1900s. The Program of Research to Integrate the Services for the Maintenance of Autonomy 
(PRISMA) aimed to address the problem of discontinuity of care for older people with 
multiple chronic conditions.296 It involved coordination of services with shared information 
services, shared responsibility for patients, a single assessment tool (including ADL IADL, 
communication and mental abilities), and a single entry point for patients, who received 
individualised service plans. The services ranged from primary care, outpatient specialised 
care, emergency, inpatient, rehabilitation, personal care, home support, and pharmacy 
among others. The coordination was done through a ‘case manager’ (mostly social workers 
or nurses) who were in charge of managing all the services needed and communicates with 
the primary care physician, who was in charge of the medical management. Case managers 
were notified of any emergency admissions; and in the case of hospital admissions, the case 
manager helped with the discharge plan, to ensure that the needed community support was 
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available. Reassessment plans was performed based on needs. After four years, comparisons 
with the normal care system showed a significant reduction in the incidence and prevalence 
of functional decline, reduced number of emergency visits, and improved client satisfaction 
and empowerment. There was no significant change in cost, indicating that benefits were 
achieved without additional costs.296 Several of the PRISMA components were then 
implemented at the provincial level. 
Coordinated person-centred care is increasingly recognised as a particularly useful approach 
in the management of patients with complex needs. In England, The National Collaborative 
for Integrated Care and Support was established in 2013 aiming to promote a culture of 
cooperation and collaboration between different care sectors.295 Recently, there have been 
initiatives to improve the integration and coordination of services. The Better Care Fund was 
introduced in 2016 providing financial support for local authorities and NHS organisations to 
plan and deliver services jointly.297 New care models are being implemented in ‘vanguard’ 
sites, which can be later adapted in other local areas, including integrated primary and acute 
care, enhanced health at care homes, and multidisciplinary community health.298 If 
successful, some of these initiatives could be scaled-up to a national scale to avoid further 
inequalities. 
In cancer care, the role of the Clinical Nurse Specialist in cancer care (CNS) is to coordinate 
services and personalise the cancer care pathway to support patients and their carers.299 The 
benefit of CNS for cancer patient outcomes has already been recognised, as well as potential 
detrimental effect of gaps in access.300-302 It is likely that the needs of an older patient with 
cancer go beyond the “cancer pathway” which usually ends at discharge. For their care to be 
integrated, it needs to consider long-term care needs. The principles of care integration and 
coordination could be applied further to serve older patients (diagnosed with cancer or in 
general), as to consider in a holistic manner the treatment options, management of 
comorbidities, post-operative care, needs at home after discharge, follow-up and 
reintegration to normal life.  
Aligning social with primary and secondary health services to serve the needs of older people 
requires a clear understanding of the environment in which people live, to appreciate their 
specific barriers and opportunities to improve their health and well-being. Furthermore, 
integration and coordination of requires adequate funding for both social and health care. It 
remains to be seen whether the awaited government plan for funding and reform social care 
services stimulates the integration of long-term care and health care.  
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The WHO’s global strategy and action plan on ageing and health recognises that one of the 
most important barriers to effective policy on healthy ageing are the common negative 
attitudes and assumptions about older people.290 Ageist views influence policy, research, and 
practice. A key to combat age discrimination is to recognise ageing as a normal and valued 
part of life, and older adults as appreciated members of society. Legislation, communication 
and education (especially of health and social care workforce) are key to identify (especially 
covert) ageism and tackle it. 
More could be done to engage older patients in interventions to promote early diagnosis and 
optimal management of cancer. An ICBP study found that although symptoms awareness 
was not lower in the UK and Denmark than in Australia, Canada, Norway and Sweden, 
perceived barriers to symptomatic presentation, such as worries about wasting the doctor’s 
time were higher in the UK than in the other countries.303 The study also found that in 
comparison with the other countries, there was lower awareness of the increasing risk of 
cancer with age in UK participants.303 A subsequent ICBP study looking into attitudes towards 
cancer in the UK found that participants aged 70 years and older were slightly less positive 
about the value of early diagnosis for increasing the chances of survival and of the prospect 
of cure after a cancer diagnosis than those aged 50-59 years, after accounting for differences 
in marital status, sex, education, ethnicity, UK region, self-rated health and cancer 
experience.304 Increasing awareness and improving the general attitude towards cancer in 
old age, and towards the value of early detection and treatment of cancer in older patients 
and their carers may help improve cancer outcomes in this group.  Nonetheless, other studies 
have found that cancer awareness and recognition of cancer symptoms does not necessarily 
result in seeking medical help.305,306 Similarly, prompt help-seeking does not, on its own, lead 
to better cancer outcomes. A recent study showed that women were more likely to be 
diagnosed with colon cancer after an emergency presentation than men, despite being more 
frequent help seekers, probably because women more frequently present with low-risk or 
unspecific symptoms.305 The authors argue that innovations in diagnostic strategies are 
needed [alongside cancer awareness and prompt help-seeking] to improve early diagnosis 
and prevent emergency presentations.305  
Cancer screening programmes explicitly exclude older patients, with upper age limits at 74 
years (extended recently from 69) for colorectal and breast cancer, and 64 years for cervical 
cancer. A study on ageism in the NHS qualified the age limits of screening programmes as 
one of the “most explicit forms of age discrimination in the NHS”.251 A review of the evidence 
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for colorectal cancer screening in older people concluded that there is actually little evidence 
on screening for older people, as none of the studies reviewed examined the benefits and 
limitations of screening in people aged 70 years and older, and few gave recommendations 
for upper age limits.306 Several other national screening programmes offer screening to all 
people over 50 years of age, without an upper age limit.306 It is likely that screening in older 
patients can play an important role not only in early detection but in improving the likelihood 
of receiving optimal treatment.  
From the research perspective, much can be done to increase the evidence base of the effect 
of different interventions, such as screening and different treatment modalities on cancer 
outcomes in older patients. Research is needed to establish the benefit of screening in older 
patients, to inform or support any age limit or even the lack of one. With regards to 
treatment, there have been some recent efforts towards improving the evidence base for 
cancer treatment in older patients. The Medical Research Council (MRC)-funded FOCUS 
(Fluorouracil, Oxaliplatin, CPT11 (irinotecan): Use and Sequencing) trial on chemotherapy for 
advanced CRC had no upper age limits for inclusion with the intention of including more older 
patients, however median age was still 64 years (mainly because concerns about adverse 
effects in older patients). The subsequent FOCUS2 specifically targeted older patients with 
advanced CRC, who were eligible for surgery, but for whom the oncologist deemed full-dose 
regiments to be unsuitable.307 It was the first large trial to recruit frail, older patients with 
advanced CRC. Although there was no difference in the outcome (progression-free survival) 
between the treatment arms (four arms of single or combined chemotherapy agents), the 
trial was ground-breaking in that it showed that older, frail patients can participate in clinical 
trials for cancer treatment.307,308 In 2017, the US National Institutes of Health introduced a 
policy and guideline to promote the inclusion of individuals across the life span as 
participants in research supported by them.309 Such push from funders should foster the 
expectation to include older patients in research, and for different stakeholders (clinicians, 
patients and researchers) to demand the improvement of the evidence base for managing 
older patients. Observational research can also be beneficial to understand and monitor 
health outcomes in older patients. Qualitative work is additionally needed to understand 
how the wider context and attitudinal factors affect health outcomes, and how to tackle 
them. 
It is clear that a multidisciplinary approach is needed to improve cancer outcomes in older 
patients, involving policy-makers, clinicians, researchers, patients and their carers, and the 
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general public. More could be done to actively assert and defend older people’s entitlement 
to full access to health and social care, as well as to recognise and tackle age discrimination.  
Policy-makers should recognise the potential dangers of using health metrics that give lower 
value to health outcomes of older people. The lack of evidence to manage older patients in 
the clinical setting should be a motivation to create and increase that evidence base, instead 
of a justification for suboptimal care. Better communication and integration between health 
and social support services would certainly contribute to better serve older patients with 
complex needs. 
5.4 On methods to study health inequalities 
Randomised controlled trials (RCTs) are widely considered the gold-standard for establishing 
causal relationships.310,311 RCTs generally focus on a super-selected proportion of patients 
with a given condition (generally the ideal candidates for treatment, with no comorbidity), 
and are often criticised for their lack of external validity or real-world meaning. Population-
based research, on the other hand, includes all the eligible population (usually defined 
geographically, and by a specific diagnosis), however, it generally lacks information on all 
potential confounders. Still, population-based observational studies are commonly used to 
understand the real-life burden of diseases, their implication on population health and 
health policy. Traditionally, epidemiological research uses observational data to test statistic 
associations between two factors (exposure and outcome). When this association is 
substantial, after taking into account potential confounders (generally by stratification, 
standardisation or regression modelling),312 researchers usually make the case for the 
possibility of a causal link between the two factors, usually without the word “cause”.  
A great contribution to the study and understanding of causal inference and potential 
outcomes is attributed to Jerzy Neyman, who in 1923, used in the context of RCTs, potential 
outcome notation for the first time.313 The application of potential outcomes and 
counterfactual thinking to observational settings (introduced by Donald Rubin,314 and 
generalised by James Robins315) has arguably revolutionised the way we think about causal 
inference. The potential outcomes approach (where researchers ask what would have 
happened to the outcome, had the exposure been different) provides definitions and 
analytic methods that produce estimates, which under explicit assumptions, can be 
interpreted as causal effects.316 The potential outcomes approach thus encourages 
‘interventional’ thinking about the relationship between exposures and outcomes for 
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observational studies (or the ‘randomised experiment paradigm’),317 and urges researchers 
to clearly define exposures, outcomes, and potential well-defined intervention(s).318 
Although the potential outcomes is not unanimously accepted, it stimulated an important 
debate in epidemiology about association and causation, especially in the observational 
setting. Traditionally, it is accepted that observational studies give evidence of associations, 
while the word causation is mostly avoided. Miguel Hernán (an influential proponent of 
causal inference methods) noted that although researchers often refrain from using the term 
“causal”, and refer to estimates as associational, the goal of many observational studies is in 
fact causal.319 This may apply to a big part of observational studies, however, the most 
valuable lesson from this framework is that it encourages an open and transparent discussion 
about the assumptions that are made to give estimates a causal interpretation.316 
Assumptions have always been there, but more as competence of statisticians than of 
epidemiologists.  
The main quantitative findings presented in Chapters 3 and 4 of this dissertation fall within 
the biomedical and lifestyles frameworks of study of disease distributions. These analyses 
were greatly helped by the counterfactual-based causal inference thinking in several ways. 
It was particularly helpful for the analysis to represent visually the assumed causal 
relationships using DAGs. In this way, the assumed relationships that informed the 
quantitative analyses were explicit from the start. However, it is difficult, if not impossible, 
to summarise complex interactions between biological and social factors that influence 
health outcomes in a DAG, without it being an oversimplification of reality.320 The discussion 
in Chapter 5 therefore takes from the ecosocial epidemiological framework to add additional 
context to the findings of age inequalities. 
Another frequent criticism of causal methods is the limited value of their application to non-
manipulable exposures, such as age or race.321 The interventional approach to 
counterfactual-based causal inference, where a well-defined intervention is generally 
expected, is generally favoured because of its clarity, as it is relatively simple – for clinicians, 
epidemiologists and biostatisticians – to think of exposures as treatment arms in a 
randomised controlled trial, and of potential outcomes as results of potential interventions 
on the exposure. Results from such research potentially translatable into effective 
interventions. This approach, however, is not without its critics, because it arguably restricts 
the scope of epidemiological questions to those that may be subject to intervention,322,323 
when in reality there are many issues in population health, where an experimental approach 
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is simply not applicable. Social epidemiology and health disparity research focus on social 
determinants of health that are frequently non-manipulable because they cannot be 
modified (such as age or sex), or because they are complex social constructs (such as 
ethnicity and socioeconomic status) that are difficult to pinpoint. The fact that they are non-
manipulable does not mean that such factors should not be considered as ‘causes’ of health 
outcomes – provided that by causation we mean the capacity of some variables to respond 
to changes in others.322,324 
The interventional approach to assess causation is also criticised because a well-defined 
intervention is subject to what is humanly possible at one specific time.322 A well-defined 
intervention can potentially be stretched to hypothetical interventions that are feasible, but 
probably not practical to tackle the issue in question.323 Etiological causation (focusing on the 
reasons, as opposed to a potential intervention), on the other hand, may not lead 
researchers to feasible or practical interventions, but it can provide the justification to do 
something about the disparities in the outcome.323   
Specific to causal mediation methods, there is a debate on whether the decomposition of 
effects is relevant for inference in population health. This is because the identification of 
natural (in)direct effects requires the use of ‘composite cross-world counterfactuals’ 
(combination of hypothetical scenarios that are not logically compatible, nor observable in 
real life for any individual, even in experimental settings), and thus their relevance for health 
policy and real-life interventions is unclear.203,321 To address these limitations, instead of 
estimating ‘natural’ effects, I estimated ‘interventional’ effects, introduced by VanderWeele, 
Vansteelandt and Robins,325 and adapted and extended by Vansteelandt and Daniel to the 
multiple mediator setting.203 Interventional effects do not rely on cross-world 
counterfactuals and can be identified under weaker assumptions than natural effects.203 
Interventional effects differ from ‘controlled effects’ (preferred for public health 
questions)321 in that in the counterfactuals used, for each subject, the mediators are set at 
some value randomly drawn from their distribution, given the confounders, rather than at a 
specific values.326 Like controlled effects, interventional effects are considered to have more 
policy relevance than natural effects because they can inform specific interventions on the 
mediators (at population- and not necessarily at individual-level) to modify the outcome.203  
Methods from the framework of causal inference using counterfactuals have enabled me to 
conduct a closer examination of the mechanisms behind the age inequalities in CRC 
management. The added value is that these methods allowed me to quantify the 
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contribution of specific mediators in the presence of statistical interactions, while being 
explicit about my assumptions. This complex analysis would not have been possible with 
traditional regression approaches to mediation analysis.146,327 Clearly, an intervention on 
patients’ age to reduce inequalities in cancer care is not feasible. However, it is possible to 
envisage potential intervention(s) would aim to reduce the prevalence of comorbidity or 
emergency presentations as means to reduce the age inequalities in CRC management. Given 
the findings, however, an intervention to reduce the prevalence of comorbidity – although 
potentially feasible and beneficial in several ways – would probably not result in reducing 
age inequalities in CRC management; and an intervention to reduce EP would probably have 
a substantial effect on the age differences in investigations, but a negligible one on reducing 
age inequalities in treatment receipt. I have, however, refrained from calling the effect of 
age ‘causal’ in the analysis presented in Chapter 4, because it is irrelevant for my research 
question about age inequalities in cancer management. Whatever the approach, the findings 
are consistent throughout the analyses: that older patients in England are not receiving 
optimal cancer care. The take-home message from the findings is not that chronological age 
causes or determines cancer management, but that there are other factors in relation to age, 
beyond comorbidity and the diagnostic route, that influence patients’ likelihood of receiving 
optimal management. The findings highlight the need to explore other factors contributing 
to the age inequalities in cancer care and outcomes in order design targeted interventions 
to tackle them. 
5.5 Potential extensions of this work 
The work presented in this thesis could be extended in several ways. First, it would be useful 
to extend the application of the analyses of the age variation to other types of treatment for 
colorectal cancer (chemotherapy, radiotherapy with or without surgery). For the study 
period, information of chemotherapy and radiotherapy was not sufficiently complete or 
detailed in the English data sources, however newer databases, like the COloRECTal cancer 
data Repository (CORECT-R),201 as well as the Radiotherapy Dataset194 and the Systemic Anti-
Cancer Therapy Dataset,195 would allow a closer examination of additional therapies, as well 
as a more granular examination of the surgical treatment, and its variation by age. 
An important barrier to effective cancer management in older patients is that the evidence 
base supporting treatment is limited, because they are generally excluded from clinical trials. 
Important questions regarding the effectiveness of standard treatment in older patients 
remain. An extension of this research could examine the potential benefit of surgery, as well 
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as other treatment strategies in prolonging survival. Research should also look into how 
different treatment strategies compare, and into whether the average treatment effect 
changes in different settings. Detailed population-based data offer a unique opportunity to 
perform such comparisons as long as the relevant (complex) analytic methods are applied. 
The understanding of age inequalities in cancer management would benefit from a closer 
examination of the role of frailty in the clinical setting. First, it would be useful to compare 
the (variability of the) current operational definitions used in clinical settings, within England, 
and in comparison with other countries. Second, it would be interesting, in collaboration 
with clinicians, to find suitable measures (or proxies) of frailty from secondary care data 
sources, and to examine the predictive values of such measures for different patient 
outcomes (such as treatment receipt, complications, readmissions, morbidity, disability, 
quality of life, mortality and survival).  
A closer examination of postoperative care and postoperative mortality by age and their 
geographic variation would be beneficial to understand variations in care and outcomes. The 
role of the diagnostic route (emergency or not), the timing of surgery, and the role of 
palliative procedures could inform practice and potentially allocation of resources. 
Additional research on the influence of social support on cancer outcomes would improve 
the understanding of how to better support older cancer patients. For instance, because 
publicly-funded social services are delivered by local authorities (with geographically-defined 
target populations), it would be possible to conduct a natural experiment to assess the effect 
of one of the new care models recently introduced at a given local authority, and compare 
cancer outcomes with another local authority offering standard care. Similarly, proxy 
measures of social support (such as marital status, cohabitation) could be sought in 
secondary data sources, such as the Office for National Statistics’ Longitudinal Study,328 to 
compare cancer outcomes at different levels of social support. 
From a qualitative perspective, it would be beneficial to extend the research into attitudes 
to ageing and older age held by clinicians, patients and the general public. An international 
comparison of attitudinal factors in the clinical settings would help clarify whether ageism is 
more of an issue in England than in other countries, and it would raise awareness of ageism 
in health care. Furthermore, it would be interesting to compare self-reported measures of 
discrimination (from patient-reported outcome measures) against measure of unconscious 
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bias or prejudice (and objective measure of discrimination)240 in patients and healthcare 
staff. 
The application of a similar research question and methodology to a different cancer site 
would be extremely beneficial. Although I have focused on the study of colorectal cancer, 
the issue of under-management of older patients is likely to happen (at least to a certain 
extent) for other cancer sites, as the wider context issues will certainly apply. In the case of 
no or lower age inequalities in the management of a different cancer, it could be informative 
to understanding how to tackle inequalities in CRC management. 
5.6 Conclusion 
In the work included in this thesis, I have used information on colorectal cancer patients from 
several national population-based data sources linked to national cancer registry records to 
examine age variations in colorectal cancer management. This work offers additional 
understanding on how age inequalities may come about, and potential opportunities to 
address them.  
Older colorectal cancer patients in England are less likely to receive optimal management in 
comparison with patients of similar age in Denmark, Norway and Sweden, and in comparison 
with younger patients in England. The findings indicate that these differences in 
management are not fully explained by comorbidity, or stage at diagnosis (or the diagnostic 
route for the national comparison).  
The finding of under-management of older patients is likely a reflection of complex 
interactions between biological, contextual, and attitudinal factors. Many older patients 
have complex needs, and the current organisation of health and social care services is likely 
unfit to serve those needs. Systemic change is required to address the needs of the ageing 
population, including better coordination and integration of services, better evidence base 
for improving the health of older patients, and continuous monitoring of health outcomes in 
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